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Abstract 
 
Blood vessels play a vital role in cancer development and progression as tumours cannot grow beyond 
a small diameter in their absence. Blood vessels are abundant and intrinsically abnormal in 
glioblastoma multiforme (GBM), while current antiangiogenic therapies are disappointing as these 
tumours are either unresponsive or gradually develop resistance. Hence, characterisation of aberrant 
blood vessels in primary and recurrent GBM, and following radiotherapy could open new therapeutic 
avenues for GBM in the future. This study identified different blood vessel morphologies in patient-
derived glioblastoma samples. Patients presented with varying degrees of blood vessel abnormality 
which increased in recurrent tumours following surgery, radiotherapy and chemotherapy. High nestin 
positivity and large lumen size were key characteristics, particularly in recurrent tumours. Nestin 
positive cells were closely associated with the blood vessel endothelial lining but distinct to CD31 
positive endothelial cells. Nestin positive cells were negative for the glioblastoma stem-like cell (GSC) 
markers OLIG2 and SOX2, and astrocyte or immune cell markers, but positive for the pericyte marker 
PDGFRb and smooth muscle cell (SMC) marker alpha smooth muscle actin (a-SMA), suggesting they 
are distinct from GSCs. Nestin and SMA positive blood vessels were found in close proximity to tumour 
necrotic regions, but were associated with low hypoxia levels suggesting functionality. 
 
The effects of radiotherapy on blood vessel abundance, morphology and function are poorly 
characterised, as are the molecular mechanisms of glioblastoma blood vessel formation. DOCK4 is a 
guanine nucleotide exchange factor (GEF) for the small GTPase  Rac1, which is highly expressed in 
neuronal and endothelial cells, and regulates cellular protrusions, cell migration and blood vessel 
lumen size. Irradiation experiments were performed using the CT2A model of glioblastoma grown 
intracranially in syngeneic mice. While a decrease in vascularisation and lumen size were observed 
early after irradiation, the abundance and size of lumenised blood vessels increased at later stages. 
Using Dock4 heterozygous knockout mice to overcome early embryonic lethality of homozygous 
Dock4 deletion, it was shown that reduction of DOCK4 levels reverses the increase in blood vessel size 
in response to irradiation, however without observed concurrent changes in tumour growth, or 
survival. 
 
Invasion of cells into the normal brain parenchyma limits the efficacy of surgery and radiotherapy thus 
contributing to recurrence and poor prognosis of glioblastoma.  Glioblastoma invasion is known to 
take place along white matter tracts and alongside blood vessels. The role of DOCK4 in glioblastoma 
invasion was investigated in spheroid assays in collagen, using both established glioblastoma cell lines 
and patient-derived glioblastoma stem-like cells (GSCs). Lentiviral shRNA-mediated knockdown of 
 v 
DOCK4 reduced invasion into the surrounding matrix in spheroid assays. However, DOCK4 knockdown 
did not alter invasive capacity when glioblastoma cells were co-cultured with endothelial cells. On the 
other hand, co-culture with endothelial cells increased the sensitivity of some glioblastoma cell lines 
to irradiation.  
 
In summary, this study shows that aberrant pericyte/SMC blood vessel coverage and larger blood 
vessel size are prevalent in GBM and increase with recurrence. These aberrant blood vessels appear 
functional and may play an important role in glioblastoma resistance to chemo- and 
radioradiotherapy, and facilitate tumour recurrence. Radiotherapy promotes aberrant blood vessel 
morphology and size in experimental tumours. DOCK4 inhibition may normalise the glioblastoma 
vasculature, and concomitantly inhibit invasion of a subpopulation of glioblastoma cancer stem cells. 
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1.1 Glioblastoma multiforme (GBM) 
Glioblastoma multiforme (GBM) is the most prevalent malignant primary brain tumour. Over 12,000 
people are diagnosed with brain tumours in the UK each year (CRUK tumour incidence statistics) which 
accounts for approximately 3% of total cancer cases. Gliomas arise from the uncontrollable growth of 
glial cells, the cells forming connective tissue that surrounds and protects neuronal cells in the brain 
and the spinal cord. Glial cells include astrocytes, oligodendrocytes, ependymal cells and microglia. 
While low-grade gliomas, typically Grade I pilocytic astrocytoma and Grade II oligodendroglioma and 
oligoastrocytoma may be treated successfully or managed over several years, high-grade gliomas 
(Grades III and IV) are the malignant forms that are more refractory to treatment and account for 
most patient deaths. The 2007 World Health Organisation (WHO) classification of CNS tumours 
classifies GBM histologically as a Grade IV diffuse infiltrative astrocytoma with cytoplasmic and nuclear 
atypia, mitotic activity, and endothelial proliferation with or without necrosis (Louis et al. 2007). The 
2016 WHO classification considered both histological and molecular parameters to better define the 
CNS tumours, particularly astrocytoma and oligodendroglioma, and also specifically referred to 
tumours not described in the 2007 classification, namely epithelioid glioblastoma, giant cell 
glioblastoma and gliosarcoma (Louis et al. 2016). For instance, giant cell epithelioid glioblastoma is 
classified under IDH wild-type GBM with large eccentric nuclei, eosinophilic cytoplasm and rhabdoid 
cell type.  While it is characterised by its demarcated superficial cerebral location on MRI with 50% of 
them possessing BRAF V600E mutation, epithelioid glioblastoma lacks EGFR amplification unlike the 
IDH wild-type group. 
 
1.1.1 GBM molecular subtypes 
GBM is highly heterogenous, and different molecular subtypes appear to respond differently to 
therapy (Verhaak et al. 2010). According to the 2016 WHO classification, GBM is categorised into two 
major groups: Isocitrate dehydrogenase 1 (IDH1) wild-type and IDH mutant. IDH1 is a gene which 
encodes an enzyme isocitrate dehydrogenase and mutation of this gene leads to abnormal function 
of cellular metabolism and tumorigenesis (Yang et al. 2012). IDH-wild-type GBM is the most common 
type accounting for 90% of all GBM cases, is of de novo origin (primary tumours) and affects elderly 
patients. IDH-mutant GBM is less common accounting for 10% of all GBM cases, and are secondary 
tumours (progressing from WHO low grade tumours) which are usually diagnosed in younger 
individuals (Louis et al. 2016). The abnormal cell metabolism and production of 2-hydroxyglutarate (2-
HG) makes IDH mutant patients sensitive to chemotherapy such as temozolomide (TMZ), and as a 
result patients with IDH mutation have better survival when treated with TMZ (Lu et al. 2017). In 
addition to their IDH status, GBM tumours are also classified based on their O-6-methylguanine-DNA 
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methyltransferase (MGMT) status: MGMT methylated and MGMT unmethylated (Verhaak et al. 
2010). The MGMT gene encodes for a DNA repair enzyme which protects cells, including cancer cells, 
from apoptosis by removing alkyl adducts from 06 guanine position. However, when MGMT promoter 
is methylated, DNA repair is impaired and alkylating agents like TMZ induces cell death (Thon, Kreth, 
and Kreth 2013). Hence, a positive link has been identified between MGMT methylation and patient 
response to chemotherapy. Hegi and co-workers found that GBM patients with methylated MGMT 
promoter tumour status have a two-fold survival benefit over patients with non-methylated tumours 
(Hegi et al. 2005). However, patient survival depends on multiple factors including tumour grade, 
location, proliferation indices, genetic alterations, patient age and neurological performance status 
(Louis et al. 2007). 
 
GBM has been categorised relatively recently according to the prevalence of mutations of known 
oncogenes, and activation of downstream signaling pathways as classical, mesenchymal, neural and 
proneural (Verhaak et al. 2010). Classical subtypes are characterized by abnormally high levels 
of epidermal growth factor receptor (EGFR) signaling. Furthermore, EGFR gene amplification or 
deletion mutation (EGFRvIII) driving high tumour proliferation rates; paired chromosome 7 
amplification and chromosome 10 loss; aberration of the retinoblastoma (RB) pathway following 
CDKN2A deletion; high expression of Nestin; activation of Notch and SHH pathways are very common. 
EGFR abnormalities are found at a much lower rate in the mesenchymal, neural and proneural 
subtypes (Verhaak et al. 2010). The classical group shows the best patient outcome in response to 
aggressive radio-chemotherapy. The tumour suppressor gene TP53 is the most frequently altered 
gene in GBM through mutation or loss of heterozygosity (LOH). This gene is not mutated in the classical 
subtype, however, TP53 genetic alterations are prevalent (>50%) in proneural tumours. Proneural 
tumours also have the highest prevalence of mutant-IDH; PDGFRA amplification which activates the 
PI3K/AKT and RAS signaling pathways; high expression of OLIG2 and SOX genes. Patients with 
proneural tumours are generally of younger age and show better survival, which is not dependent on 
aggressive treatment. The mesenchymal subtype is characterised by mutations of the NF1 tumour 
suppressor gene which activates the MAPK pathway, and mutations of the PTEN gene which activates 
the RAS pathway, as well as high expression levels of CHI3L1, VEGF, CD44 and c-MET. The neural 
subtype tumours express normal neuronal markers such as NEFL and GABRA1 and have worse patient 
outcome compared to classical GBM (Verhaak et al. 2010).   
 
Both WHO High Grade III and Grade IV gliomas can be classified within the proneural subtype, while 
mesenchymal and classical subtypes are mostly limited to WHO Grade IV gliomas.  While 
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mesenchymal and classical subtypes are predominantly characterised by presence of necrosis, the 
proneural subtype may or may not present with extended necrosis (Phillips et al. 2006). There is a 
considerable age difference between patients with mesenchymal and proneural tumours as they are 
common in old and young patient age groups, respectively. While classical subtypes are the most 
proliferative tumours, mesenchymal subtypes are the most angiogenic and express significantly higher 
levels of CD31 and VEGFR2 compared to other subtypes (reviewed in Campos et al. 2016). Analysis of 
88 primary and 22 recurrent GBM tumours, Li and colleagues found that the mesenchymal subtype as 
the most common GBM subtype, accounting for 41% and 45% of primary and recurrent tumours 
respectively (Li et al. 2015). On the other hand, the classical subtype was found to be somewhat more 
prevalent in primary (36%) compared to recurrent tumours (22%), whereas the proneural subtype was 
detected less in primary (15%) compared to recurrent GBM (23%). These observations are likely to 
reflect the wide range of mutational spectra characterising GBM tumours, as well as rapid mutation 
rate which may manifest itself in recurrences. 
 
1.1.2 Current therapies in GBM  
The current standard of therapy for glioblastoma involves de-bulking surgery followed by 
radiotherapy, and an adjuvant carmustine and alkylating drug TMZ in MGMT methylated tumours 
(Hegi et al. 2005). In the Zurich annual meeting of the European Association of Neuro-Oncology/ World 
Federation of Neuro-Oncology Societies (EANO/WFNOS) 2017 several clinical trials were presented 
including the antiangiogenic agent Bevacizumab, anti-EGFR agent ABT-414, immunotherapy drugs 
Nivolumab and Ipilimumab, and vaccination against EGFRvIII using Rindopepimut.  However, the 
results of single or combination therapies were invariably disappointing and clearly showed that we 
are far from a breakthrough for GBM. For instance, although GBM is highly angiogenic the use of 
antiangiogenic drugs like Bevacizumab eventually failed to stop tumour growth following 
development of resistance and/or tumour recurrence (Kumar and Arbab 2013). As a result, still to 
date there is no significant increase in patient overall survival in response to any of these new agents. 
Patient survival remains dismal at approximately 15 months after surgery followed by radiotherapy 
and temozolomide chemotherapy.  
 
1.1.3 GBM invasion and recurrence 
Recurrence is very common in GBM (Loeffler et al. 1990) and is mainly attributed to the infiltrative 
nature of cancer cells (Gerstner et al. 2010 and Hanahan and Weinberg 2011). Following primary 
tumour resection and irradiation, tumour cells infiltrate the brain parenchyma and frequently 
populate microvessels in the normal brain.  This typically results in partial removal of the tumour mass, 
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and evasion of the infiltrating tumour cells from subsequent radiotherapy and chemotherapy resulting 
in tumour recurrence. Gritsenko and colleagues have described how cancer cells migrate and invade 
either as single-cells or as collective strands and multicellular networks (Gritsenko, Leenders, and 
Friedl 2017). Invasion is known to take place along white matter tracks and alongside blood vessels 
frequently in response to chemotactic factors such as CXCL12 (Brooks et al. 2013). RNA-sequencing 
analysis of 75 glioma biopsy samples obtained from core (contrast-enhancing), or infiltrative (non-
enhancing) margins of GBM tumours using radiography guided techniques, showed higher proneural, 
classical and mesenchymal subtype molecular signatures in the core region of the tumours, compared 
to neural subtype signature in the tumour margins (Gill et al. 2014). Further, the infiltrative margins 
of proneural subtypes showed higher expression of oligodendrocyte-related genes, while the margins 
of mesenchymal tumours showed a more of astrocytic and microglial related gene signatures, 
indicating differences amongst different subtypes as to the composition of cells contributing to 
tumour infiltration (Gill et al. 2014).   
 
A key feature of GBM tumours is that they frequently undergo subtype evolutionary changes (Wang, 
Cazzato, et al. 2016). For instance, using comprehensive genomic profiling of 10 primary and recurrent 
GBM tumour pairs, Neilsen and co-workers observed both common and distinct genetic alterations in 
the primary and recurrent tumours (Neilsen et al. 2018). The most common genetic alterations 
observed were CDKN2A and CDKN2B deletion, EGFR mutation, EGFR amplification and telomerase 
reverse transcriptase (TERT) mutation in 86% versus 53%, 52% versus 10%, 81% versus 45% and 95% 
versus 51%, respectively for each gene, in primary and recurrent GBMs (Neilsen et al. 2018). However, 
when primary and recurrent tumours were compared by Andor et al, more mutations were found in 
patients with recurrent tumours following radio-chemotherapy, as well as MutL Homologue1 encoded 
by the MLH1 gene conferring TMZ resistance in recurrent compared to primary tumours (Andor et al. 
2014). Further, molecular analysis of 26 paired astrocytomas showed that while 18 tumours 
maintained their molecular subtype, 7 shifted from proneural to mesenchymal upon recurrence, and 
additionally showed upregulation of STAT3, YKL40 and CD44, and loss of OLIG2 expression (Phillips et 
al. 2006). Similarly, transcriptome analysis of radioresistant GSCs showed significant transition from 
proneural to mesenchymal signatures with activation of proinflammatory pathways, and STAT3 by IL-
6, being major mediators of this transition (Stanzani et al. 2017).  
 
1.2 The brain tumour perivascular niche 
The perivascular niche (PVN) is known as the distinct area around blood vessels, known to provide 
signaling cues that maintain the self-renewal and pluripotency of postnatal stem cells in different 
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tissues (reviewed in Oh and Nor 2015). Endothelial cell secreted factors promote the survival of 
haematopoietic stem cells in the bone marrow. While several studies support the existence of 
perivascular progenitor cells in different tissues giving rise to cell lineages typically originating from 
mesenchymal stem cells such as osteoblasts, myocytes or adipocytes, other studies suggest that 
pericytes are pluripotent and may give rise to such mesenchymal derived lineages (reviewed in Oh 
and Nor 2015). In the brain, studies support the existence of mesenchymal stem cells with an 
expression profile similar to pericytes, which together with endothelial cells, astrocytes and neurons 
form an important brain structure termed the neurovascular unit. The neurovascular unit plays 
important roles in angiogenesis, the development and maintenance of a functional blood brain barrier 
(BBB), the homing and survival of neural stem cells and repair mechanisms in the brain (reviewed in 
Appaix et al. 2014). In brain tumours, the PVN provides a conducive environment for glioma stem cells 
(GSCs), the self-renewing and tumorigenic cancer cells (reviewed in Ho and Shim 2017). The 
perivascular niche supports the maintenance of stemness through EC-secreted nitric oxide and Dll4 
ligand activation of Notch signaling in GSCs (reviewed in Sharma and Shiras 2016), invasion by 
modifying the  ECM through secretion of MMPs (reviewed in Manini et al. 2018), resistance through 
activation of PI3K/AKT signaling (Hambardzumyan et al. 2008), and protection from host immunity 
through exploitation of  immune checkpoints PD-1 and CTLA-4 (Beatty and Gladney 2015)  through 
maintaining a well-orchestrated signal communication mechanisms involving various cell types 
(Schiffer et al. 2015; Yan et al. 2014 and Louis et al. 2007). As a result GSCs are well protected from 
therapy and are markers of a poor prognostic patient outcome (Gilbertson and Rich 2007).  
 
The brain tumour PVN comprises of glioma stem cells, cancer cells, endothelial cells, astrocytes, 
pericytes/smooth muscle cells (SMCs) and immune cells (Schiffer et al. 2015 ans Goldman and Chen 
2011). The development of efficacious therapies for glioblastoma will require understanding of the 
precise nature of these cellular interactions and the molecular mechanisms that maintain them 
(Charles and Holland 2010). Within the PVN there is a direct relationship between tumour associated 
macrophages (TAMs) and GSCs (Figure 1.1) as they share common locations including around blood 
vessels and hypoxic regions (reviewed in Codrici et al. 2016). Most GSCs are located around capillary 
blood vessel endothelial cells (ECs) located in the hippocampus and SVZ (Jain et al. 2007). Interestingly, 
while GSCs associated with PVN show high activation of Notch signaling, GSCs around hypoxic niches 
do not, but unlike GSCs associated with the PVN they show high expression of the stem cell marker 
CD133, thus exemplifying the high level of heterogeneity of GSCs and/ or the influence of different 
microenvironmental niches (Bayin et al. 2017).  
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Figure 1.1 The brain perivascular and hypoxic niche 
There are two characteristic and well-defined niches in the brain: perivascular and the hypoxic niche. 
The two niches are different in terms of cell types involved. The perivascular niche is highly populated 
by GSCs, immune cells, pericytes and astrocytes while the hypoxic niche is more commonly populated 
by immune cells. Overtime, the perivascular niche may become a hypoxic niche as tumour growth 
outweighs the blood supply. Adapted from Hambardzumyan and Bergers, 2015  (Hambardzumyan 
and Bergers 2015).   
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1.2.1 Endothelial cells  
The PVN primarily consists of the tumour vasculature and associated cell types on the type of blood 
vessel (Armulik et al. 2011 and Nagy et al. 2009). The vasculature is lined by endothelial cells (ECs) 
connected to form the Blood Brain Barrier. Under normal conditions the brain is well protected by the 
Blood Brain Barrier (BBB) which separates the blood from the cerebrospinal fluid and presents a 
barrier to the passages of cells, particles, large molecules and pathogens. The BBB is comprised of 
pericytes, astrocytic end-feet and SMC/pericytes (Cabezas et al. 2014), and it is mainly made of tightly 
interconnected ECs with continuous intercellular junctions and restricted transcellular transport 
(Obermeier, Daneman, and Ransohoff 2013). In addition to providing cells with nutrients and oxygen, 
both in vitro and in vivo experiments show that ECs secret different factors which promote tumour 
growth (Gilbertson and Rich 2007) and stem cell self-renewal (Charles and Holland 2010 and Yan et 
al. 2014). For instance, ECs secrete SHH, nitrous oxide (NO) and Notch ligands to promote GSCs 
stemness by activating Sonic Hedgehog (SHH) and Notch signaling pathways in cancer cells (Yan et al. 
2014). SHH (Clement et al. 2007) and Notch signaling (Hovinga et al. 2010) promotes GSC stemness, 
proliferation and self-renewal, growth and survival, and chemo-radioresistance. Further, in addition 
to increasing GBM cell proliferation, tumour ECs also protect GBM cancer cells from chemotherapy 
and radiotherapy potentially through regulation of MGMT gene (Borovski et al. 2013). GBM associated 
ECs have characteristic features of large and flat cell morphology, slow proliferation rate and 
resistance to cytotoxic therapies, increased production of growth factors such as IL-8 and VEGF 
(Charalambous, Chen, and Hofman 2006). Wang and colleagues showed that macrophages are 
positioned closely to ECs in the tumour microenvironment and that their recruitment follows release 
of IL-6 from ECs which promotes cell invasion (Wang et al. 2018) 
 
1.2.2 Glioma stem cells  
Glioma stem cells (GSCs) are stem cell-like cells which are a subpopulation of cancer cells with stem 
cell property and self-renewal capacity and are responsible for both in vitro and in vivo tumour growth 
(Singh et al. 2004). Although there is no universal marker for GSCs, they can be identified using various 
markers including Nestin, CD133, SOX2, OLIG2, NANOG, Musashi, OCT4 and CD44 (Codrici et al. 2016). 
GSCs locate preferentially in the PVN (Chen et al. 2015) along blood vessels in order to proliferate and 
self-renew in manner analogous to their neural stem cell (NSC) counterparts - the self-renewing, 
multipotent cells that generate the cells of the central nervous system during development 
(Gilbertson and Rich 2007), located in the subventricular zone (SVZ). Yan et al. observed CD133+ GSCs 
in close proximity with SHH+ ECs in glioblastoma multiforme tissue, and when they co-cultured ECs 
with GSCs they observed increased GSC tumorigenicity, and that expression of stemness markers such 
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as OLG2, SOX2, OCT4, NANOG, c-Myc, Bmi1 and CD133 increased (Yan et al. 2014). These proteins are 
expressed in GSCs and play important roles in tumorigenesis and stem cell behavior. For example, 
CD133 promotes proliferation (Brown et al. 2017), SOX2/NANOG self-renewal and stemness (Zbinden 
et al. 2010 and Berezovsky et al. 2014), and CD44 promotes survival and differentiation (Mooney et 
al. 2016). Unlike NSCs which assume a quiescent state following therapy, GSCs residing in the 
perivascular niche activate survival pathways, antagonize apoptosis and promote drug resistance 
(Kalkan 2015). GSCs modulate tumour ECs through the release of vascular endothelial growth factor 
(VEGF) which is a key angiogenic growth factor (Charles and Holland 2010). VEGF signaling results in 
the activation of proliferative and survival pathways in ECs, including MAPK/ERK and PI3K signaling 
(Chung and Ferrara 2011). On the other hand, GSCs are attracted to ECs through activation of the 
CXCL12/CXCR4 signaling axis, with ECs secreting stromal derived factor (SDF-1), aka CXCL12, which 
interacts with CXCR4 expressed by GSCs (Cheng et al. 2013). GSCs are regulated in the PVN by different 
signaling pathways which include TGF-ß, Notch, Wnt/ß-catenin, OCT4 and c-Myc (Schiffer et al. 2015). 
For instance, while Wnt/ß-catenin signaling plays an important role in tumour growth and invasion by 
promoting GSC stemness (Lee et al. 2016), TGF-ß regulates stemness, angiogenesis, invasion and 
resistance, and also plays an immunosuppressive role (Joseph et al. 2013).  
 
1.2.2.1 Nestin 
Nestin, a type VI intermediate filament protein, is a marker of neuronal stem cells (Yan et al. 2016) 
and immature, poorly differentiated and proliferating endothelial cells (Liang et al. 2015). A study 
conducted in embryonic mouse brain and heart showed the importance of Nestin in organ 
development through regulating cell proliferation, and activation of the PI3K/AKT pathway (Liu et al. 
2015). Another study demonstrated that when Nestin is down-regulated there is a severe reduction 
in the number of neurons in the brain, as a consequence of reduced PI3K signaling and survival, 
highlighting the importance of Nestin in neuronal progenitor cell (NPC) development (Xue and Yuan 
2010).  
In addition to undifferentiated stem cells, Nestin is a marker of neurogenic tumours such as 
glioblastoma (reviewed in Neradil and Veselska 2015). Immunohistochemical analysis of low and high 
grade glioma patient samples showed positive correlation between Nestin, CD133 expression and 
tumour grade (rs=0.89). Moreover, the higher the expression of Nestin, the poorer the patient 
prognosis (Zhang et al. 2008). Suzuki et al demonstrated that Nestin was expressed by endothelial 
progenitor cells of mouse brain tissue following injury, and this expression declined as these cells 
become differentiated in culture, or not detected in non-injured brain tissue (Suzuki et al. 2010). 
Furthermore, the same study reported that in addition to the endothelial cell marker CD31 and nestin, 
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newly formed blood vessels were positive for the proliferation marker Ki67,  while mature blood 
vessels expressed high levels of  von Willebrand factor (vWF) and were negative for Nestin (Suzuki et 
al. 2010).  In vitro experiment by Liang and colleagues demonstrated how VEGF regulates neo-
angiogenesis through stimulation of Nestin expression, and that deletion of Nestin reduces EC 
migration by affecting filopodia extension, potentially through the MAPK-ERK pathway (Liang et al. 
2015). A characterisation study of the vasculature in human colorectal liver metastases showed Nestin 
positivity of newly formed vessels, although immunofluorescence staining did not confirm this 
potentially due to low levels of Nestin expression in ECs (Klein et al. 2014). Klein et al. also showed 
through bone marrow transplantation experiments utilising Nestin-GFP transgenic mice, that these 
Nestin positive ECs are likely to be resident cells, rather than derived from the bone marrow (Klein et 
al. 2014).  
 
1.2.2.2 CD133  
CD133, also known as Prominin-1, is a transmembrane protein (Shmelkov et al. 2005) expressed by 
stem cells and stem-like cells including GSCs (Shmelkov et al. 2008). CD133+ cancer cells have the 
capacity to proliferate, renew themselves, and form tumour growth both in in vivo and in vitro (Singh 
et al. 2004). There is a strong correlation (rs=0.89) between CD133 and Nestin expression in glioma, 
and their combined increased expression is associated with poor patient survival (Zhang et al. 2008). 
On the other hand, Dahlrot et al reported that while there was no association between level of CD133 
expression and WHO grade of glioma and OS, high level of Nestin expression was found a marker of 
poor progression free survival (PFS) in WHO grade II tumours (Dahlrot et al. 2014). Further, CD133+ 
glioma cells are thought to be the GSCs responsible for radioresistant and tumour recurrence (Bao et 
al. 2006). 
 
1.2.2.3 SOX2 
SRY-box2 (SOX2) is a transcription factor that plays important roles in the formation of many tissues 
and organs during embryonic development. SOX2 is essential for maintaining self-renewal and 
pluripotency of embryonic stem cells, and plays key roles in maintenance of neural stem cells 
(Berezovsky et al. 2014). SOX2 knockdown in GSCs isolated from patient GBM tumours resulted in 
down-regulation of YAP, a component of the Hippo pathway which controls stemness and 
tumorigenicity, and inhibition of the capacity of GSCs to form spheres in culture. On the other hand, 
SOX2 knockdown increased expression of the tumour suppressor NF2, which is important regulator of 
growth of the nervous system (Basu-Roy et al. 2015).  Hence SOX2 is important in maintaining cell 
stemness and function of the nervous system (Basu-Roy et al. 2015). On the other hand, Phi et al. had 
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suggested that SOX2 is a marker of glial cells rather than stem cells (Phi et al. 2008). This was mainly 
because the majority of SOX2 positive cells are also positive for GFAP and Nestin in GBM, while SOX2 
was also expressed in different grade tumours including Grade III gliomas (Phi et al. 2008). However, 
Leiss and colleagues showed that SOX2 is not expressed in glial cells in healthy brain but is upregulated 
in patient GBM (Leiss et al. 2017). The levels of SOX2 expression in GBM appear to depend on the 
molecular subtype, and whether the tumour is primary or recurrent. Classical, mesenchymal and 
proneural subtypes do significantly express CD133, Nestin and OLIG2 respectively. While nestin is 
expressed by all subtypes, the expression of SOX2 appears highly variable (Phillips et al. 2006).    
1.2.2.4 OLIG2 
Oligodendrocyte transcription factor 2 (OLIG2) is a transcription factor which is only expressed in CNS 
and promotes proliferation and brain cancer development (Tsigelny et al. 2016). Although OLIG2 is 
expressed in both NSCs and GSCs, it appears to be more abundant in GSCs (Gilbertson and Rich 2007). 
OLIG2, like SOX2, is essential for GBM propagation (Ceccarelli et al. 2016). Using organoid spheres, 
Hubert et al. (2016) showed that in a proliferative outer rim of tumour spheres, GSCs co-express SOX2 
and OLG2 (Hubert et al. 2016). Interestingly, in the central hypoxic zone of the sphere, where more of 
nascent GSCs are found, cells positive for a single marker can also be identified  (Hubert et al. 2016). 
In terms of subtype specific expression, immunofluorescent staining of various cultured cells from the 
different molecular subtypes showed uniform expression of SOX2 and Nestin, while the expression of 
OLIG2 and GFAP varied amongst different subtypes (Xie et al. 2015). Strong OLIG2 positivity is a marker 
of poor outcome in pediatric GBM (Cloughesy, Cavenee, and Mischel 2014). Verhaak and co-workers 
reported that OLIG2 is highly expressed in proneural tumours where it promotes tumour proliferation 
by down-regulating the tumour suppressor CDKN1A (Verhaak et al. 2010). 
 
1.2.2.5 NANOG, OCT4, Musashi, and CD44 
Other GSC markers include transcriptional factors NANOG and Octamer transcription factor 4 (OCT4); 
RNA binding protein Musashi1 and cell surface receptor protein CD44 (Bradshaw et al. 2016). Both 
NANOG and OCT4 are transcription factors (Rodda et al. 2005), while Musashi is an RNA-binding 
protein (Muto et al. 2012). NANOG is associated with formation of GSC spheres, proliferation and 
tumorigenicity (Zbinden et al. 2010); OCT4 regulates pluripotency and self-renewal (Rooj, Bronisz, and 
Godlewski 2016); Musashi1 promotes tumour growth and survival (Chen et al. 2017); CD44, a 
transmembrane protein, regulates tumour progression (Xu, Stamenkovic, and Yu 2010). While there 
is a strong correlation between CD44 and CD133 in GBM (Brown et al. 2017), NANOG, OCT4 and SOX2 
expression have a positive correlation (Yi et al. 2016). 
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1.2.3 Pericytes and Vascular smooth muscle cells 
Pericytes are mural cells embedded within the basement membrane (BM) of capillary blood vessel 
wall that regulate vascular morphogenesis during development as well as under pathological 
conditions (Armulik, Genove, and Betsholtz 2011). Vascular smooth muscle cells (SMCs) normally 
compose the wall of larger calibre blood vessels and have a contractile phenotype maintaining 
vascular tone. The definition of pericyte is often controversial and a combination of morphology, 
location and gene or protein expression are often used to define pericytes. Although pericytes, just 
like SMCs take a periendothelial location, unlike SMCs they have a continuous cytoplasmic process 
over the abluminal surface of ECs of the blood vessels often covering several ECs (Armulik, Genove, 
and Betsholtz 2011). Further, the lack of SMCs in capillaries, and the unique anatomical morphology 
of SMCs of circumferential orientation around arteries, arterioles and precapillaries differentiate 
these larger blood vessels from capillaries (Hill et al. 2015). Berthiaume and co-workers demonstrated 
that ablating pericytes leave capillaries uncovered and dilated although they quickly make an 
extension to cover it afterwards (Berthiaume et al. 2018). Pericytes are dynamic and their expression 
of molecular markers depends on the developmental and pathological states of blood vessels. Hence, 
there is no single pericyte specific marker identified to date, but different markers have been 
described and validated including PDGFRb, a-SMA, NG2 and Desmin (reviewed in Armulik, Genove, 
and Betsholtz 2011).  
 
The origin of pericytes is not unique, studies show that they originate from local normal tissue, but 
also from bone marrow stem cells (Hanahan and Weinberg 2011). The neural crest has been indicated 
as the most common origin of brain pericytes, which involves their recruitment through different 
signaling axis including PDGFB/PDGFRb, TGF-b/TGF-bR, ANG-1/TIE2 and CXCL12/CXCR4 (Armulik, 
Genove, and Betsholtz 2011). Pericytes communicate with ECs through both direct cell-cell contact 
and through paracrine signaling (Charles and Holland 2010 and Bergers et al. 2003). For example, TGF-
ß plays an important role in the maintenance of the attachment of pericytes and ECs by up-regulating 
N-cadherin, mediating physical contact between ECs and pericytes (Armulik, Genove, and Betsholtz 
2011). The activation of PDGFRß on pericytes by EC secretion of PDGFB leads to proliferation and 
migration of pericytes, while Ang-1/Tie 2 signaling leads to maturation and stability of blood vessels 
through close alignment of pericytes with blood vessels (Hill et al. 2015).  
 
Under physiological conditions, pericytes exist in close association with ECs (Charles and Holland 2010) 
and cover 22-99% of the abluminal surface of the vasculature (Hill et al. 2015). Pericytes play an 
essential role in maintaining the integrity of BBB (Hill et al. 2015 and Daneman et al. 2010) and in 
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guidance of sprouting angiogenesis (Charles and Holland 2010 and Bergers and Benjamin 2003). Using 
pdgfb deficient mice Armulik et al. showed how pericytes are crucial for BBB permeability (Armulik et 
al. 2010). The mice deficient in pdgfb showed decreased pericyte blood vessel coverage, increased 
blood vessel diameter and increased permeability of the BBB to water and tracers of different 
molecular weights (Armulik et al. 2010). Another study showed that as well as inhibiting pericyte 
recruitment, endothelial pdgfb deletion led to formation of hyperplastic endothelial cells (Bjarnegard 
et al. 2004). Pericytes are found in tumour blood vessels, however they are fewer in number and their 
attachment to endothelial cells is looser, which contributes to increased tumour blood vessel 
permeability (Armulik et al. 2010), increased metastasis (Chung and Ferrara 2011), as well as higher 
vulnerability of tumour ECs to radio-chemotherapy (Cheng et al. 2013). In GBM, there is increased 
presence of pericytes compared to low grade glioma, while more pericytes have been detected in the 
core region compared to the boundary of tumours (Takeuchi et al. 2010).  It has been postulated that 
increased pericyte coverage protects tumour blood vessels from antiangiogenic therapy, while 
targeting both pericytes and endothelial cells reduces tumour growth more effectively than targeting 
endothelial cells lining the blood vessels alone (Takeuchi et al. 2010).  
 
1.2.4 Astrocytes 
Astrocytes are glial cells which are tightly attached to the basement membrane of the ECs through 
integrin, agrin and dystroglycan, and maintain the integrity of BBB both through physical contact and 
release of soluble factors (Watkins et al. 2014). However, expanding or invading cancer cells can 
displace these astrocytic end-feet, and the BBB becomes more permeable resulting in molecules such 
as albumin and cadaverine leaking into parenchyma (Watkins et al. 2014). GFAP, a marker for 
astrocytes as well as stem cells, is expressed more in mesenchymal and proneural subtypes than in 
the classical subtype. Deletion of GFAP and vimentin from reactive astrocytes in mice caused lack of 
intermediate filaments (Hol and Pekny 2015). In addition to GFAP, reactive astrocytes also co-express 
Musashi1 and Nestin (Oki et al. 2010). 
 
Astrocytes are activated and undergo morphological and functional changes in response to CNS injury 
to become reactive astrocytes (Pekny and Nilsson 2005). Reactive astrocytes are one of the 
components of PVN in tumours and play an important role in cancer cell survival by secreting 
interleukin-6 which enables them to resist apoptosis (Sin et al. 2016). Reactive astrocytes contribute 
to tumour growth through secretion of metalloproteinases and connective tissue factors (Deb, 
Wenjun Zhang, and Gottschall 2003). The gap junction protein Connexin (Cx) 43, which is also 
expressed in reactive astrocytes, contributes to intercellular communication via calcium signaling (Sin 
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et al. 2016). Assessment of eight normal brain tissue samples and 44 astrocytic tumours by 
immunohistochemistry (IHC) and Northern blot analysis showed high expression of Cx43 in normal 
brain and lower grade gliomas, while the expression was very low in GBM (Pu et al. 2004). Aberrant 
Cx43 expression has been associated with poor patient outcome (Bonacquisti and Nguyen 2019). In 
melanoma reactive astrocytes protect tumour cells from chemotherapy (Lin et al. 2010), and similarly 
in glioma astrocytes protect cancer cells from therapy through direct physical contact via gap junctions 
(Lin et al. 2016).  
 
1.2.5 Microglia and Macrophages 
Brain resident microglia and infiltrating macrophages are tumour associated macrophages (TAMs) 
which are abundant in brain tumours (Roggendorf, Strupp, and Paulus 1996) and may account for 8-
78% of the total GBM tumour microenvironment cell population (Lorger 2012 and Morantz et al. 
1979). Further, another study showed that TAMs represent about 20-50% of all cells within the tumour 
microenvironment (Lapa et al. 2015). While activated microglia in healthy brain play antigen 
presenting and phagocytic roles (Lorger 2012), in tumours they either suppress or promote tumour 
growth depending on whether they are naive or activated (Charles and Holland 2010; 
Hambardzumyan, Gutmann, and Kettenmann 2016  and Schiffer et al. 2015). Macrophages are the 
main immune cells in brain tumours including GBM, and they are attracted to tumour sites through 
HIF-1α which activates the CXCL12/CXCR4 signaling pathway (Hambardzumyan, Gutmann, and 
Kettenmann 2016), and tumour cell derived chemoattractants (Charles and Holland 2010). For 
instance, macrophages are attracted to glioma secreted granulocyte colony stimulating factor (G-SCF), 
and following infiltration they start secreting growth factors that promote angiogenesis (Du et al. 
2008) and invasiveness (Markovic et al. 2005), such as MMPs, VEGF and MT1-MMP (Hambardzumyan, 
Gutmann, and Kettenmann 2016). Macrophages and microglia are more abundant around necrotic 
areas and perivascular regions (Schiffer et al. 2015).  
 
Unfortunately, it can be challenging to differentiate macrophage and microglia. While infiltrating 
macrophages are usually characterised by strong CD45 positivity and round shaped morphology, 
resident microglia show weaker CD45 staining positivity (Lapa et al. 2015). Further, macrophage/ 
microglia are typically divided into the anti-tumorigenic, M1, and pro-tumorigenic, M2, phenotypes. 
The use of M1 specific marker, CD86, and M2 macrophage specific, CD204, showed that the type of 
macrophage abundant in GBM is the M2 type (Nijaguna et al. 2015). From the analysis of 80 brain 
tumour biopsy samples Roggendrof and Paulus identified 3 subgroups of microglia/ macrophages in 
the brain: ramified, ameboid and perivascular (Roggendorf, Strupp, and Paulus 1996). While they 
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detected low microglia/ macrophage abundance in low grade glioma, a high number of microglia/ 
macrophages were observed in anaplastic gliomas and GBM. More recent studies also showed that 
the higher the abundance of microglia/ macrophages in the intratumoural space, the denser the 
tumour and the poorer the patient prognosis is (Chung and Ferrara 2011). In vivo studies also show 
that there is a high infiltration of F4/80+ macrophages in tumour tissue following irradiation (Morganti 
et al. 2014). 
 
1.3 GBM vasculature 
1.3.1 Normal brain blood vessels 
Just like in other organs, blood vessels in the brain initially develop from a vascular plexus (Wacker 
and Gerhardt 2011), which later develops further to supply oxygen and nutrients and remove waste 
substances from the body. The process of formation of the vascular plexus is termed vasculogenesis, 
while the growth of new blood vessels from pre-existing ones is termed angiogenesis (Adams and 
Alitalo 2007) (Herbert and Stainier 2011) (Chung and Ferrara 2011). In order for blood vessels to form 
a functional vasculature following vasculogenesis and angiogenesis, they have to undergo extensive 
remodelling and maturation. For example, many blood vessels that start sprouting but are not 
incorporated in the developing plexus or the expanding vasculature, are pruned leaving behind ‘empty 
sleeves’ characteristic of the remodelling process (Simons et al. 2015). Formation of the lumen which 
allows the flow of blood is a critical stage in the process of new vessel formation (Eilken and Adams 
2010). The recruitment of pericytes/SMCs through signaling pathways regulated by PDGFB, TGF-b and 
angiopoietins (Chung and Ferrara 2011) is critical for the stabilisation of the newly formed blood 
vessels (Kuhnert et al. 2008). 
In the adult, under physiological conditions except during wound healing and the female reproductive 
cycle, endothelial cells in blood vessels remain quiescent, due to a balance between angiogenesis 
inducers such as VEGF-A, and inhibitors of angiogenesis such as trombospondin-1. However, this 
balance is tipped in tumours where angiogenesis promoters prevail, leading to activation of the 
angiogenic switch (reviewed in Hanahan and Weinberg 2011). During this process, the surge of VEGF-
A makes the blood vessels to start sprouting from a leading cell called the tip cell (Friedl and Gilmour 
2009 and Carmeliet and Jain 2011)). In addition to the VEGF receptor VEGFR2, which makes them 
responsive to VEGF, tip cells also express DLL4, which binds to Notch receptors on the trailing 
endothelial cells called stalk cells. This downregulates the expression of VEGFR-2 to allow the blood 
vessel to extend from the tip cell, and prevents surplus angiogenesis. This mechanism is controlled by 
a VEGF-A gradient which leads to proliferation and migration of the tip cells while the stalk cells are 
unresponsive to VEGF (Carmeliet and Jain 2011). In abnormal circumstances like in cancer, excessive 
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expression of VEGF-A results in development of aberrant blood vessels through uncontrolled 
sprouting angiogenesis which involves high rate of proliferation and collective migration of ECs 
(Jakobsson et al. 2010; Chung and Ferrara 2011 and Neufeld, Planas-Paz, and Lammert 2014). Overall, 
the abnormally expressed proangiogenic growth factors in tumours lead to formation of highly 
branched, convoluted, enlarged and leaky blood vessels with poor blood flow, as endothelial cells 
remain in a proliferative and sprouting phenotype (Hanahan and Weinberg 2011). 
 
1.3.2 Mechanisms of blood vessel development in GBM 
Although it was known for over a century that tumours have their own blood supply, the mechanism 
by which they do this only came to recognition since 1970s (Nagy et al. 2009). Today, several molecular 
mechanisms (Figure 1.2) have been identified by which tumor cells form their own blood vessels. 
These mechanisms include sprouting angiogenesis, vessel co-option, vasculogenesis, vasculogenic 
mimicry, and transdifferentiation (reviewed in Hardee and Zagzag 2012 and Viallard and Larrivee 
2017). 
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Figure 1.2 Neovascularisation in GBM 
Diagram depicting proposed mechanisms by which GBM forms its own blood vessels with theories 
ranging from classic angiogenesis and co-option where normal ECs line the lumen of blood vessels, to  
vasculogneic mimicry and transdifferentiation where cancer cells line the blood vessels lumen 
unmodified or having transdifferentiated to ECs. 
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1.3.2.1 Sprouting angiogenesis 
The proangiogenic factors and signaling pathways implicated in brain tumour angiogenesis are: 
VEGFA/VEGFR1/2, bFGF/FGFR1, placental growth factor, Angiopoietin 2 and IL-8/CXCR1/2 which 
interestingly often appear to be activated in cancer cells (reviewed in Anderson, McFarland, and 
Gladson 2008 and Cea, Sala, and Verpelli 2012). The proliferation of ECs and development of blood 
vessel in GBM is thought to be a direct consequence of increased and uncontrolled VEGF secretion 
(Soda et al. 2013 and Schiffer et al. 2015). It is thought that tumour cells at early stages of tumour 
growth rely on pre-existing blood vessels (He, Niu, and Li 2012). However, once the tumours exceed 
1-2mm they start to become hypoxic (Kienast et al. 2010). Hypoxia induces production of 
proangiogenic growth factors and cytokines through upregulation of the transcription factors HIF-1a 
and HIF-2a with consequent upregulation of VEGF expression (Ellis and Hicklin 2008; Chung and 
Ferrara 2011 and Schiffer et al. 2015). Normally, under normoxia, prolyl hydroxylase domain (PHD) 
enzymes hydroxylate the α-subunits of HIF in the cell, however under hypoxia PHD remains inactive 
and HIF-1α enters the nucleus and transcription of genes takes place which leads to cancer cell 
proliferation, survival, angiogenesis and metastasis (reviewed in Sormendi and Wielockx 2018). 
 
VEGF driven angiogenesis is the most common mechanism of blood vessel formation in glioblastoma 
and other tumours, however anti-angiogenic drugs like Bevacizumab (Avastin) failed to increase the 
overall survival of GBM patients. Although VEGFA/VEGFR2 signaling is the main signaling pathway for 
endothelial cell proliferation and blood vessel sprouting, it has been noted that established and 
mature blood vessels are also abundant in GBM tumours (Bergers and Song 2005). Pericytes appear 
to be involved in several stages of new vessel formation   (Eilken et al. 2017). As the deposition of 
basement membrane and pericytes are important for the stabilisation of newly formed blood vessels, 
the basement membrane of the pre-existing vessels must be destroyed and the pericytes must first 
dissociate for ECs to migrate (Patel-Hett and D'Amore 2011). Metalloproteases are key enzymes 
involved in this process, as well as in the degradation of extracellular matrix during the migration of 
endothelial cells within or towards the tumour. For example, MMP9 is actively involved in this process 
in brain tumours (Anderson, McFarland, and Gladson 2008). Following blood vessel sprouting and 
expansion, coverage of the blood vessels by pericytes results in mature and stable blood vessels, a 
step thought to be overridden in most cancers. 
 
1.3.2.2 Co-option 
Co-option is a mechanism by which tumour cells migrate towards, and colonise existing blood vessels 
(Holash et al. 1999 and Winkler et al. 2009). In addition to early development a number of tumours 
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also use this mechanism for invasion and expansion (Qian 2013). Hence, the proliferating and 
migratory tumour cells hijack the nearest capillaries for their nutrient and oxygen needs (Dome, Timar, 
and Paku 2003 and Dome, Timar, and Paku 2003)). It has been reported that co-option is common in 
blood vessel dense tissues like GBM (Coelho et al. 2017). For instance, Dome et al. demonstrated how 
glomeruloid bodies are formed from proliferating endothelial cells through co-option (Dome, Timar, 
and Paku 2003). They showed, using intracarotid artery injection of the melanoma cancer cell line 
A2058, that tumour blood vessels progressed from simple coiled structures at approximately 14 days 
post injection, to tortuous and chaotic glomeruloid vascular aggregates around 28 days post injection. 
Similarly, Kuczynski and co-workers observed in hepatocellular carcinoma formation of new blood 
vessels through co-option of normal blood vessels in the liver, which later became resistant to 
sorafenib treatment (Kuczynski et al. 2016). Co-option therefore uses pre-existing blood vessels, 
however this may take place alongside classic angiogenesis, while tumours may switch between these 
two modes following therapy. Further, these cellular mechanisms are tumour and organ specific, while 
their interchange may provide an escape mechanism from anti-angiogenic therapy (reviewed in 
Donnem et al. 2018). 
 
1.3.2.3 Vasculogenesis 
Vasculogenesis refers to the de novo formation of blood vessels (Chung and Ferrara 2011). Under this 
paradigm, endothelial progenitor cells (EPCs) mobilised from the bone marrow are the source of 
tumour blood vessel endothelial cells (Schiffer et al. 2015). CXCL12 and VEGF signalings have been 
implicated as a mechanism by which cancer cells recruit VEGFR2 expressing EPCs from the bone 
marrow (Soda et al. 2013). Although some studies reported the formation of tumour blood vessels 
from bone marrow derived EPCs as high as 18% in U87 glioma xenograft, other studies do not support 
the existence of vasculogenesis in GBM tumours (reviewed in Hardee and Zagzag 2012). 
 
1.3.2.4 Vasculogenic mimicry (VM) 
The term vasculogenic mimicry was first described in melanoma, when blood conducting channels 
were observed lined by melanoma cancer cells (Maniotis et al. 1999). Laser capture microdissection 
and gene profiling of blood vessels formed by VM and sprouting angiogenesis in melanoma showed 
the upregulation of angiogenesis and cancer cell related genes (Demou and Hendrix 2008). Common 
angiogenic molecules and signaling components identified in melanoma VM include VE-cadherin, 
EphA2, PI3K, FAK, MMPs and hypoxia related signaling pathways (Hendrix et al. 2016). Evidence for 
VM in GBM has been provided by Scully and colleagues who described blood vessels in patient 
tumours that are lined by  cells expressing SMA, PDGFRb and VEGFR2, but not CD31 or VE-Cadherin 
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(Scully et al. 2012). Expression of EGFR by these cells supported the idea that they originate from 
cancer cells (Scully et al. 2012).  
  
1.3.2.5 Transdifferentiation 
Ricci-Vitiani and co-workers showed that a large proportion of endothelial cells in GBM show similar 
genomic alterations to GSCs suggesting that endothelial cells in GBM have a neoplastic origin (Ricci-
Vitiani et al. 2010). Using both in vitro and in vivo experiments the authors showed that endothelial-
like cells were generated from GSCs (Ricci-Vitiani et al. 2010). While culturing GSCs produced 
endothelial-like cells, culturing of the non-stem cancer cells failed to do so. Using a mouse model GBM 
tumorigenesis, Soda and colleagues also showed that cancer cells may transdifferentiate to 
endothelial cells and form functional blood vessels (Soda et al. 2011). This was particularly observed 
in the deep hypoxic regions of the experimental tumours compared to their periphery, while hypoxia 
was shown to be the key driver of transdifferentiation of GSCs to ECs, a process refractile to VEGF 
inhibition which could explain the resistance of GBM to Avastin (Soda et al. 2011).  In support, Wang 
and co-workers had demonstrated that it was only when Notch 1 or g-secretase were inhibited, but 
not when VEGF or VEGFR2 were blocked that transdifferentiation of cancer cells to endothelial cells 
stopped (Wang et al. 2010). 
 
1.3.3 Characteristic features of GBM blood vessels 
Tumour blood vessels have been generally described as the most irregularly branched, haphazardly 
interconnected, chaotic, mostly immature, highly heterogenous ranging from leaky and thin walled, 
enlarged capillaries, to a network of glomeruloid blood vessels (Carmeliet and Jain 2011). Hence, 
tumour blood vessels are both structurally and functionally abnormal. Abnormally regulated 
proangiogenic growth factors are usually responsible for the formation of such highly branched, 
convoluted, enlarged and leaky blood vessels with poor blood flow (Hanahan and Weinberg 2011). 
Studies show the presence of both angiogenic and established vessels in GBM (Bergers and Song 
2005). In much earlier experiments, Benjamin and colleagues had performed in vivo experiments 
whereby VEGF was conditionally expressed in the rat C6 glioma model. In the absence of VEGF all 
immature blood vessels regressed while the mature blood vessels which had already recruited 
pericytes persisted (Benjamin et al. 1999). They found that the proportion of immature blood vessels, 
which yet not recruited peri-endothelial cells, was proportionally higher in pre-clinical models but also 
in patient primary tumour samples.  
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Despite the lack of overall agreement on the characterisation of blood vessels in GBM (Preusser et al. 
2006), the presence of certain morphologies has been associated with poorer patient prognosis. 
Rojiani and Dorovini-Zis identified aggregates of microvascular structures termed glomeruloids in 50% 
of the 24 GBM specimens analysed (Rojiani and Dorovini-Zis 1996). Further, characterisation of 78 
GBM samples by Chen and colleagues using CD34/Periodic Acid-Schiff (PAS) dual staining identified 5 
different clusters of microvascular patterns (MVPs) which were later classified into type I MVPs 
(microvascular sprouting and vascular cluster) and II MVPs (vascular garland, glomeruloid vascular 
proliferation and vasculogenic mimicry) (Chen et al. 2015). Accordingly, patients with more of type II 
MVPs had poorer PFS and OS compared to patients with type I MVPs (Chen et al. 2015).  Similarly, 
Birner et al. using CD34 staining of 114 primary GBM patient samples found poor survival in patients 
with a higher proportion of abnormal vascular patterns (glomeruloid, garland and clusters), compared 
to patients with classical angiogenic blood vessel patterns (Birner et al. 2003).  
 
1.4 Radiotherapy in GBM  
1.4.1 Effects of radiation on GBM tumour growth 
Ionising radiation kills tumour cells by damaging DNA and is an effective therapy in cancer (Baskar et 
al. 2014). Various doses of ionising radiation have been used in orthotopic mouse models of 
glioblastoma and shown significant reduction in tumour growth (Table 1.1).  In patients, radiotherapy 
is the most important treatment modality, following gross resection, increasing patient survival by 
approximately 1 year (Zinn et al. 2013). However, development of radio-resistance and tumour 
recurrence, typically within a 2cm margin of the post-operative cavity, is an ongoing challenge (Li et 
al. 2018).  GSCs are thought to be primarily responsible for radio-resistance and tumour recurrence, 
and interestingly they appear to localise in the SVZ between the striatum and the lateral ventricles 
from where they are thought to repopulate the excised tumour following irradiation (reviewed in 
Smith, Mehta, and Wernicke 2016). In vivo studies by Goffart and co-workers showed that SVZ located 
GSCs display a mesenchymal phenotype (Goffart et al. 2017). The molecular mechanism behind their 
radio-resistance was found to be upregulation of CXCL-12, and consequently, targeting the 
CXCL12/CXCR4 pathway improved the radio-sensitivity of GSCs. Further, using both in vitro and in vivo 
models Bao et al. demonstrated that CD133+ enriched cancer stem cells were responsible for radio-
resistance (Bao et al. 2006). When CD133+ cancer cells were irradiated their CD133+ expression 
increased by four-fold compared to untreated controls, while this was not observed in CD133- cells. 
Radiotherapy also increased the overall incidence of CD133+ cells over 3-fold in vivo (Bao et al. 2006).  
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One interesting finding in the studies by Bao and co-workers was the presence of increasingly more 
activated checkpoint proteins such as ATM, Rad17, Chk1 and Chk2 in CD133+ cancer cells compared 
to CD133- cancer cells following DNA damage. This eventually led to the downstream effect of cell 
cycle arrest and DNA repair, which was then reversed by checkpoint inhibition (Bao et al. 2006), 
demonstrating that radio-resistance may be overcome by inhibition of certain signaling pathways that 
are deregulated by ionising radiation. Analysis of samples taken from GBM patients before and after 
irradiation using micro-dialysis showed increased expression of IL-8, IL-6 and MCP-1 at various stages 
following therapy (Tabatabaei et al. 2017), suggesting that these molecules may also be involved in 
radio-resistance and may constitute potential therapeutic targets. In addition to upregulation of 
signaling pathways which promote survival, it has also been postulated that some cancer cells are 
intrinsically resistant to irradiation but the molecular basis of this resistance is not understood 
(Sambade et al. 2011).  Interestingly, Huang et al demonstrated upregulation of activated caspase-3, 
an apoptotic marker, following irradiation in vivo which led to repopulation of tumour cells (Huang et 
al. 2011). Counterintuitively, this high caspase-3 expression was associated with high recurrence rate 
and poor prognosis. These observations were backed by in vivo experiments using both caspase-3 
knockout mice and caspase-3 deficient tumours which showed increased radio-sensitivity in the 
absence of caspase-3 (Huang et al. 2011). Interestingly, high caspase-3 expression has also been 
associated with poor survival in breast cancer patients (Pu et al. 2017). 
 
1.4.2 Effect of irradiation on the tumour vasculature 
Ionising radiation targets dividing cells. Like cancer cells being highly proliferative, tumour ECs also 
proliferate at a 20-2000 times faster rate than ECs in normal tissue. This effectiveness of radiation 
against cancer cells and the microenvironment has established radiotherapy one of the most 
commonly applied therapeutic tools in cancer patients (Hobson and Denekamp 1984). However, 
although irradiation does target ECs, its effects on other components of the tumour 
microenvironment are highly complex and mainly involve inflammation and immunomodulation, 
hypoxia, revascularisation and ECM remodelling which may support, rather than compromise tumour 
growth (Barker et al. 2015). For instance, hypoxia not only hinders the effects of radiotherapy and 
immunotherapy (Barker et al. 2015), but also plays an important role in promoting tumour cells to 
migrate from perinecrotic region to blood vessel rich regions as a result of up-regulation of  HIF-1 
(Harada et al. 2012).  
 
Following irradiation, unlike ECs in normal blood vessels, tumour ECs undergo G2 arrest (senescence), 
both in vitro and in vivo (Borovski et al. 2013). In vitro, irradiation with as small a dose as 2Gy results 
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in reduced survival of HUVEC (Helm et al. 2016). Various doses of ionising radiation have been used in 
orthotopic mouse models of glioblastoma as shown in Table 1.1 with varying responses to which 
endothelial damage appeared to contribute.  Although there are some contradicting reports regarding 
the effect of radiation on brain tumour blood vessels, overall an optimal radiation dose of 5-
10Gy/fraction appears to have a measurable but limited effect on the morphology and function of the 
tumour vasculatures at early stages of growth, while this effect diminishes as the tumour advances. 
However, higher doses of irradiation (>10Gy/fraction) can damage blood vessels and contribute to 
tumour regression (reviewed in Park et al. 2012). Interestingly, larger blood vessels appear more 
radioresistant, as in a human melanoma xenograft irradiation experiment in vivo 5-15 µm blood 
vessels were significantly damaged by 16Gy irradiation doses, while larger, 25-35 µm diameter blood 
vessels required a higher dose of 20Gy to regress (Park et al. 2012).  
 
Studies show that radiation induces detachment of ECs from the basement membrane, increased 
endothelial cell permeability, recruitment of immune cells, increased acid sphingomyelinase which is 
linked with vascular damage and development of hypoxia (reviewed in Barker et al. 2015). Hence, one 
characteristic feature of the irradiated tumour is the reduction of tumour microvascular density 
(MVD), which subsequently leads to decreased vascular perfusion and increased tumour hypoxia (Tsai 
et al. 2005). Furthermore, some of the structural changes of tumour blood vessels following irradiation 
include thickening of the intima and consequently atherosclerosis, thrombosis, fibrosis and necrosis 
(Barker et al. 2015). However, the effect of radiotherapy on tumour vasculature also depends on 
several factors including the location, size, stage of tumour and dose of radiation used, the 
characteristic nature of high endothelial cell proliferation rate, presence of basement membrane and 
pericyte coverage of blood vessels in the tumour compared to the surrounding parenchyma (Barker 
et al. 2015). For example, Potiron et al. observed increased susceptibility of tumour blood vessels to 
irradiation when pericyte coverage was less (Potiron et al. 2013). However, Tsai and co-workers had 
provided earlier evidence that pericytes do not protect ECs from irradiation (Tsai et al. 2005).  
 
Different signaling mechanisms have been identified in tumour regrowth following irradiation which 
may involve effects on the vasculature. For instance, radiation induces the expression of CXCL12, 
which in turn promotes vasculogenesis by recruiting CD11b+ monocytes (Walters et al. 2014). In an in 
vivo experiment, when Liu et al. blocked the chemokine CXCL12 following irradiation, this inhibited 
recurrence of a rat brain tumour (Liu et al. 2014). In another in vivo experiment using a combination 
of CXCR7 blockade and irradiation, significantly reduced tumour growth and recurrence in mice were 
observed (Walters et al. 2014). Irradiation also activates inflammatory signals (TNF-a and IL-1) and 
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increases recruitment of local immunosuppressive and relatively radioresistant tumour associated 
macrophages (TAMs), myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs) (Barker 
et al. 2015). Hence, despite its effectiveness in targeting cancer cells and blood vessels, radiation also 
modulates the tumour microenvironment in a way conducive to tumour progression. Normalisation 
of these microenvironmental responses should increase the effectiveness of radiotherapy in the 
treatment of brain tumours. 
 
1.4.3 Effects of radiation on tumour invasion 
Despite its popular usage in cancer treatment, ionising radiation increases the invasive potential of 
several cancer cells including breast, brain and lung (Artacho-Cordon et al. 2012). One of the 
mechanisms of this increased invasiveness is the upregulation of MMPs (Artacho-Cordon et al. 2012). 
Hence, both in vivo and in vitro experiments have implicated several genes in the induction of tumour 
invasion in response to irradiation. One of the characteristics of this increased invasiveness following 
irradiation is the change of cell morphology. For instance, in endometrial carcinoma, ionising radiation 
increased cell invasion of HEC1A cells  through epithelial-mesenchymal transition (EMT) and 
upregulation of Twist, inhibition of which reduced invasion (Tsukamoto et al. 2007). Fujita et al. 
demonstrated increased invasiveness of the normally amoeboid pancreatic cancer cell line MIA PaCa-
2 following ionising irradiation through increased expression of MMP-2, while inhibition of MMP2 
induced the reverse of EMT mesenchymal-amoeboid transition (Fujita et al. 2011). In in vivo 
experiments using the C6 cell line Park et al. demonstrated increased metastasis of cancer cells 
following radiotherapy through activation of markers associated with EMT markers including MMPs 
(Park et al. 2012). In human melanoma irradiation increased IL-8 mRNA production and tumour 
metastasis in vivo in immunocompromised mice.  
 
In U251 cells, ionising radiation highly upregulates expression of the MET oncogene through activation 
of the ATM-NF-kB pathway, which consequently leads to tumour invasion and radioresistance (De 
Bacco et al. 2011). Using a spheroid assay Gogineni et al. reported a reduced invasion and consequent 
apoptosis of malignant meningioma cells in siRNA mediated knockdown of MMP-9 and this was 
through activation of MAPK-ERK & AKT signaling pathways (Gogineni et al. 2009). Similarly, in both 
U87 and U251 glioma cell lines, inhibition of MMP-2 using siRNA and radiotherapy significantly 
reduced cancer cell growth, invasion and angiogenesis in spheroid assays (Badiga et al. 2011). Further, 
using matrigel assay, Dong et al. demonstrated increased invasion of U87 cells in response to 
irradiation through nuclear translocation of ß-cantenin (Dong et al. 2015). The translocation of ß-
cantenin into the nucleus increased transcription and upregulation of downstream target genes 
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including MMP2/9, AXIN2, CD44 and VEGF (Dong et al. 2015). It has also been demonstrated that 
irradiation increase IL-8 secretion from melanoma cells and in in vitro experiments using matrigel, IL-
8 transfected melanoma cells up-regulated MMP-2 and increased invasion (Luca et al. 1997). Ionising 
radiation also increased migration and invasion of neuroblastoma cells in spheroid and matrigel assays 
by increasing expression of MMP-9, VEGF and uPA. Altogether, these studies support the presence of 
a common mechanism by which  ionising radiation increases nuclear translocation of ß-cantenin in 
cancer cells with subsequent increase in invasion through upregulation of MMPs and other matrix 
modifying enzymes, and concomitant increase in angiogenic factors (Gialeli, Theocharis, and 
Karamanos 2011). In support, conditioned media from irradiated neuroblastoma cells increased 
angiogenesis in human microvascular endothelial cells (HMECs) (Jadhav and Mohanam 2006). 
 
There is evidence that Rho GTPase signaling play a role in the stimulation of invasion in response to 
irradiation. ROCK and Rac1 have an opposing effect on glioma invasiveness. While activation of Rac1 
increases cell invasion, this invasion was supressed when ROCK was activated (Hara et al. 2016). 
Further, the role of Rac in cell migration and invasion has been somewhat controversial and reported 
to depend on cell type. For instance, in the rat glioma cell line C6 suppression of Rac by dominant-
negative Rac (RacN17) increased cell migration and this migration was further stimulated by 
irradiation (Hwang et al. 2006). However, it must be noted that the use of dominant negative 
counterparts of Rho GTPases is unreliable, as their overexpression may act to mop up guanine 
nucleotide exchange factors (GEFs) and GTPase activating proteins (GAPs) which act on multiple Rho 
proteins. Nevertheless, those studies eluded to a mechanism of increased migration through 
activation of JNK and reduction of adhesion molecules such as paxillin and FAK (Hwang et al. 2006). 
Interestingly, Rac1 knockdown reduces random cell motility but increases directional migration in U87 
cells (Pankov et al. 2005), suggesting that the levels of Rac1 activation must be accurately controlled 
during the process of invasion. 
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Table 1.1 Review of published in vivo brain tumour experiments to determine the effects of RT 
 
Sr. 
No. 
Tumour 
model 
Strain, Sex, 
age 
Dose  Irradiation 
post 
implantation 
Effects of 
radiotherapy 
Reference 
1 GL261 C57BL/6J  
mice 
Female 
10-12 weeks 
old 
 
8Gy 
WBRT 
4Gy/day 
24hr 
interval 
Day 15 & Day 
17 
Improved survival 
(6 days). 
Combination with 
immunotherapy 
(83 days). 
 
(Newcomb 
et al. 2010)  
2 GL261 C57BL/6J 
mice 
Female 
6-8 weeks 
old  
20Gy 
WBRT 
2Gy/ 
day 
 
Day 10 Improved survival 
(21 days). 
Reduced 
invasiveness in 
combination with 
CXCR4 targeting 
(37 days).  
(Yadav et al. 
2016)  
3 SMA-560 
(murine 
glioblasto
ma) 
Syngenic 
VM/Dk mice 
 
6Gy Day 4 Improved survival 
(14 days) in 
combination with 
blocking CD95L 
(Fas ligand). 
(Blaes et al. 
2018) 
4 U87-MG Nude mice 
Female 
5-6 
30Gy 
Subcut 
5Gy/ 
day 
 
Day 5 Improved survival 
(6 days). 
 
(Bradley et 
al. 1999)  
5 U87-MG 
 
 
Balb/c_Nude 
mice 
Female 
8-week old 
10Gy  
Focal RT 
2Gy/ 
day  
Day 15 Improved survival 
in combination 
with targeting of 
TIGAR expressed in 
glioma cells.  
(Zhang et al. 
2017) 
6 C6 glioma Wistar rats 
Male 
6-8 weeks 
old 
 
40Gy 
WBRT 
8Gy/ 
day 
Day 5 Improved survival 
(~10 days). 
Increased tissue 
permeability. 
(Zawaski et 
al. 2012) 
7 Patient-
derived 
GBM 
(U1242)  
Nude mice 
Female 
 
10Gy 
WBRT 
2.5Gy/ 
day 
Day 11 Improved survival 
(21 days). 
Combination with 
inhibitor of gene 
MDA-9/Syntenin 
(37 days). 
 
(Kegelman 
et al. 2017). 
8 Patient-
derived 
GBM 
(GB130) 
Nude mice 30Gy 
6Gy/ 
day 
Day 75 
AMD 
treatment D70 
Inhibition of 
CXCL12 with AMD 
improved 
sensitivity. 
(Goffart et 
al. 2017) 
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Table shows different tumour models used in pre-clinical studies in vivo ranging from GBM syngeneic 
models to established cell lines and patient-derived GBM cancer cells orthotopically implanted in mice 
followed by delivery of whole brain irradiation (WBRT) or focal irradiation. The time and dose of 
irradiation varies and in most cases the total dose was delivered over days in a fractionated form. In 
general, there was significantly higher overall survival in response to irradiation which improved 
further in some combination therapies.  
 
1.5 Dedicator of cytokinesis 4 (DOCK4)  
Mammalian Rho GTPases comprise 20 small intracellular signaling molecules which regulate normal 
cell migration and tumour metastasis, through control of the actin cytoskeleton amongst other 
mechanisms of action (Hiramoto, Negishi, and Katoh 2006). The prototypical members of Rac1, RhoA 
and Cdc42 have been studied extensively (Etienne-Manneville and Hall 2002; Kobayashi et al. 2014 
and Gadea and Blangy 2014). The majority of Rho proteins cycle between a GTP-bound active and a 
GDP-bound inactive form (Figure 1.3). This cycling is regulated by positive regulators, guanine 
exchange factors (GEFs) which catalyse the exchange of GDP for GTP and negative regulators, GTPase-
activating proteins (GAPs) which accelerate the intrinsic GTPase activity for the hydrolysis of GTP to 
GDP. Guanine nucleotide-dissociation inhibitors (GDIs) retain GDP-bound Rho proteins in the 
cytoplasm precluding their activation by GEFs in the plasma membrane (Ridley 2012; Bustelo, 
Sauzeau, and Berenjeno 2007 and Nobes and Hall 1995). There are 11 mammalian subfamilies of the 
Dock180 superfamily which serves as a GEF for the Rho family GTPases (Hiramoto, Negishi, and Katoh 
2006). Dock4, dedicator of cytokinesis 4, located on chromosome 7q31 in human (Yajnik et al. 2003), 
is a member of the evolutionarily conserved superfamily of Dock180 proteins which regulates several 
biological activities within a cell by activating Rho GTPase signaling (Cote and Vuori 2002). 
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Figure 1.3 The role of DOCK4 in Rac1 cycle 
DOCK4 activates a GDP bound inactive Rac1 through addition of phosphate group, GTP, and cycle 
continues by GAP which removes a phosphate group from GTP bound active Rac1 back to inactive and 
GDP bound Rac1. 
 
Adherens junctions are transmembrane molecules which has an important role in vasculogenesis and 
angiogenesis through cell-cell adhesion, cell morphogenesis and intracellular signaling mechanisms 
(Petzelbauer, Halama, and Groger 2000). DOCK4 activates Rap GTPases which results in increase of 
adherens junctions and tighter cell-cell contacts (Yajnik et al. 2003). In HEK293T cells Hiramoto et al 
showed that DOCK4 is a GEF for Rac1 and that consistently, DOCK4 interacts with Rac1 but not with 
Cdc42 or RhoA (Hiramoto, Negishi, and Katoh 2006). The DHR-1 (CZH-1) and DHR-2 (CZH-2) domains 
of DOCK4 (Figure 1.4) are conserved throughout all the DOCK180 family, while in addition DOCK4 
possess an SH3 (Src-homology 3) domain at its N-terminus and proline-rich region on its C-terminus 
(Hiramoto, Negishi, and Katoh 2006). The DHR-2 domain mediates the exchange of GDP for GTP and 
thus a DOCK4 mutant which lacks the DHR-2 region does not activate Rac1 (Hiramoto, Negishi, and 
Katoh 2006). Being a large multimeric protein DOCK4 is able to interact with other proteins, namely 
ELMO (Xiao et al. 2013 and Hiramoto, Negishi, and Katoh 2006)) and DOCK9 (Abraham et al. 2015) 
through its SH3 domain (Abraham et al. 2015), and with cortactin (Ueda et al. 2013).  
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Figure 1.4 The structure of DOCK4 
DOCK4 has DHR1 and DHR2 domains, which are ubiquitously conserved in all DOCK families, and SH3 
domain on its N-terminus while proline-rich domain is located on the C-terminus. 
 
1.5.1 The role of DOCK4 in angiogenesis 
The Rac subfamily of Rho GTPases, Rac1, Rac2, Rac3 and RhoG proteins share sequence similarity and 
stimulate lamellipodia formation and extension of cell membrane during phagocytosis by activation 
of Rac GEF DOCK180 proteins (Heasman and Ridley 2008). For instance, attachment VEGF ligand to its 
cell surface receptor VEGFR2 activates an intracellular Rho GTPase signaling cascade that leads to the 
induction of angiogenesis (Holmes et al. 2007; Eilken and Adams 2010 and Abraham et al. 2015).   Tan 
et al demonstrated how Rac1 is involved in EC migration, lumen formation, and adhesion in response 
to VEGF and sphingosine-1-phosphate (S1P) (Tan et al. 2008). Once Rho proteins are activated they 
interact with the proteins known as effectors to initiate cellular responses including migration, 
adhesion, morphogenesis, and neuronal development (Heasman and Ridley 2008).  
 
 Abraham et al showed the role of the DOCK4-Rac1 signaling axis in sprouting angiogenesis (Figure 
1.5) through the control of filopodia formation downstream of RhoG activation (Abraham et al. 2015). 
ELMO is a downstream effector of the DOCK4-Rac1 axis, while Rac1 activation by DOCK4 activates 
Cdc42 through the GEF DOCK9 (Figure 1.5). The study further demonstrated that DOCK4 controls 
blood vessel lumen formation in a tissue culture organotypic angiogenesis assay through early 
remodelling of the actin cytoskeleton and lateral cell-cell adhesion; and blood vessel lumen size in the 
normal brain, and in a model of breast cancer brain metastases (Abraham et al. 2015). DOCK4 controls 
lateral filopodial protrusions in endothelial cells however, proximal tip filopodia can exist in the 
absence of Dock4 (Abraham et al. 2015). The work of Abraham et al concluded that the signaling 
cascade of RhoG-Dock4-Rac1-Dock9 and Cdc42 (Figure 1.6) leads to the formation of lateral filopodia, 
which is important in sprouting angiogenesis (Abraham et al. 2015). 
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Figure 1.5 VEGF downstream signaling pathway in endothelial cells (ECs)  
The DOCK4 signaling pathway controls filopodia formation and lumen size by switching the GDP-
bound inactive form of Rac1 into GTP-bound active state of Rac1, and regulating filopodia formation 
and sprouting at the downstream of VEGF. Modified from Lena Claesson-Welsh [(Simons, Gordon, and 
Claesson-Welsh 2016). Nat Rev Mol Cell Biol 2016]. 
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1.5.2 The role of Dock4 in neuronal cells and cancer cells  
DOCK4 and Rac1 are essential for normal development as their global deletion is embryonic lethal 
(Heasman and Ridley 2008 and Abraham et al. 2015). Furthermore, both Rac1 and DOCK4 are highly 
expressed in the brain with DOCK4 expression being more restricted to neuronal cells and endothelial 
cells (Ueda et al. 2008 and Abraham et al. 2015). DOCK4 is temporally regulated during rat brain 
development with expression detected from E18 through to the adult stage reaching the highest levels 
on postnatal day 20 in hippocampal neurons (Ueda et al. 2008). When different regions of the brain 
were compared the highest DOCK4 expression was found in the hippocampus, cortex and cerebellum, 
in a decreasing order. DOCK4 is particularly localised in dendritic spines and plays an important role 
in spine formation by interacting with cortactin, while dysfunction of DOCK4 in dendrites resulting 
from germline mutations is associated with psychiatric problems such as schizophrenia, autism and 
dyslexia (Gadea and Blangy 2014). In an in vitro cultured hippocampal neurons experiment, 
knockdown of DOCK4 resulted in impairment of dendritic growth and branching which was reversed 
by overexpression of DOCK4 and its binding partner ELMO (Ueda et al. 2008).  
 
The fact that DOCK4 controls both cell-cell adhesion and migration makes it both a tumour suppressor 
and tumour promoter (Gadea and Blangy 2014). Studies reported Dock4 mutations in ovarian cancer, 
human prostate, gliomas, breast and mouse osteosarcoma cells (Kuo et al. 2009 and Yajnik et al. 2003). 
Kuo et al detected homozygous Dock4 deletion in high grade serous carcinoma using SNP arrays and 
analyses of DNA copy number changes in 37 ovarian serous neoplasms (Kuo et al. 2009). Quantitative 
real-time PCR analysis detected downregulation of several genes including Dock4 in CD133+/CD34+ 
cancer cells from chronic myeloid leukemia patients (Okamoto et al. 2007). Sundaravel et al found a 
low expression of DOCK4 in myelodysplastic syndromes (MDS) (Sundaravel et al. 2015). Recently, 
Debruyne and colleagues found reduced expression of DOCK4 in mitotic, proliferative and SOX2 & 
OLIG2 positive GBM cells (Debruyne et al. 2018). However, in breast cancer cells DOCK4 controls 
migration suggesting it may be involved in the process of metastasis. DOCK4-dependent activation of 
Rac1 downstream of EGFR and EphA2 (Figure 1.6) is regulated by the small GTPase RhoG and requires 
the downstream effector ELMO (Hiramoto, Negishi, and Katoh 2006). It has been observed that 
EphA2, DOCK4 and the actin regulator cortactin co-localise at the tip of migrating breast cancer cells 
and in such cells activated RhoG binds to ELMO and then recruits DOCK4 to form a complex which 
translocate to the plasma membrane where it activates Rac1 (Hiramoto, Negishi, and Katoh 2006). In 
support of its putative role in breast cancer metastasis DOCK4 was found to be a potential biomarker 
of the risk of breast cancer metastasis to the bone (Westbrook et al. 2018). In lung adenocarcinoma 
(ADC) high DOCK4 expression has been directly associated with increased Smad activation and poor 
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patient survival, implying essential role of DOCK4 in the TGF-b/Smad pathway to enhance the 
extravasation and metastasis of lung cancer cells to the liver (Yu et al. 2015). The mechanism for this 
involvement of DOCK4 in the Wnt pathway had been demonstrated earlier by Upadhyay and 
colleagues (Upadhyay et al. 2008).     
 
 
Figure 1.6 DOCK4 signaling pathway in endothelial cells and cancer cells 
DOCK4 functions downstream of the tyrosine kinase receptor (RTK) VEGFR2 in endothelial cells, and 
EGFR in cancer cells to regulate actin cytoskeleton, sprouting angiogenesis and cancer cell migration.  
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Normally, b-catenin interacts with protein complex which includes adenomatosis polyposis coli (APC), 
the signaling scaffold protein Axin, and serine-threonine kinase glycogen synthase kinase 3b (GSK3b) 
which phosphorylates b-catenin. This allows its ubiquitination and degradation by the proteasome 
(Choi et al. 2004). When Wnt3A binds to its surface receptor DOCK4 interacts with the degradation 
complex and displaces b-catenin leading to its stabilisation and subsequent translocation to the 
nucleus where it serves as transcription factor (Figure 1.7) leading to increased cell growth and 
neoplasia (Upadhyay et al. 2008). Differentiated GBM cancer cells respond differently to b-catenin 
translocation to the nucleus with growth arrest, explaining the tumour suppressing effects of DOCK4 
overexpression in GBM cancer cells (Debruyne et al. 2018). Consistently, Debruyne et al found low 
levels of DOCK4 in GBM cancer stem cells (Debruyne et al. 2018), but the effects of DOCK4 knockdown 
were not investigated. Altogether, these published studies show that DOCK4 plays different roles in 
different cancers and at different stages of tumour development and progression. 
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Adopted from Upadhyay et al., 2008 
 
Figure 1.7 DOCK4 forms complex with GSK3b, AXIN and APC downstream of Wnt signaling  
Figure depicts the involvement of DOCK4 in Wnt signaling. In absence of DOCK4 GSK3b phosphorylates 
b-catenin allowing its degradation by the proteasome (not shown). However, when DOCK4 binds AXIN 
and APC, b-Catenin is released from the degradation complex resulting in its translocation into the 
nucleus where it activates gene transcription. 
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2.1 Cell culture techniques 
2.1.1 Cell lines 
Patient-derived GBM cells, GBM1 and GBM20, originally isolated by Wurdak et al, were kindly 
obtained from Prof Susan Short’s lab, Leeds Institute of Medical Research at St James’s (LIMR, 
University of Leeds). The established cell line U251 (Sigma Aldrich) was also obtained from Prof Susan 
Short’s lab. CT2A cell line which was originally from David Stojdl and Charles Lefebvre of the Children’s 
Hospital of Eastern Ontario (CHEO) Research Institute in Ottawa, Canada was kindly donated by Dr 
Wurdak’s Group (LIMR, University of Leeds). GL261 murine cancer cells were from Dr G Mavria’s lab 
(LIMR, University of Leeds). While Human Umbilical Vein Endothelial Cells (HUVEC) and Human 
Embryonic Kidney (HEK 293T) cell line (originally from Clontech Laboratories) were from Mavria’s lab, 
the Human Cerebral Microvascular Endothelial Cells (HCMEC) were kindly donated by Prof Cook’s 
group (LIMR, University of Leeds).  
 
2.1.2 Coating cell culture flasks 
Unlike U251, GL261 and CT2A, the patient-derived primary samples do not grow in non-coated normal 
flasks. Hence, any flasks used to grow these patient-derived GBM cells were coated firstly with poly-
L-ornithine (Sigma P3655 (100µg/10ml/T75 flask in TC grade water)) and kept at room temperature 
for 1 hr before washing it off with TC grade water. Then, each flask was coated again with laminin 
(Invitrogen 10267092 (20ug/ 10ml/T75 flask in TC grade PBS)). These flasks were sealed and left 
overnight at room temperature and then stored in a freezer until needed or used straightaway. HEK 
293T cells and HCMECs flasks were coated using either Poly-L-lysine (Cat.No. P8920, Sigma-Aldrich) in 
a 1:40 dilution in PBS or 0.2% gelatin freshly prepared in the lab. 
 
2.1.3 Culturing mammalian cells  
GBM1 and GBM20 cells were cultured in neurobasal medium (Invitrogen #21103049) with 
supplements including 0.5 x B27 Serum-Free Supplement (Invitrogen #17504044) and 0.5 x N2 
Supplement (Invitrogen #17502048), and growth factors 40 ng/ml recombinant human EGF (R&D 
Systems #236-EG-200) and 40 ng/ml recombinant human basic fibroblast growth factor (bFGF) (R&D 
Systems #233-FB-025/CF) in laminin-coated flasks. The cells were trypsinised when they reached 
about 80% confluence and centrifuged at 1200 rpm for 3 minutes in order to get rid of trypsin before 
passaging or using for the next experiment. Both CT2A and GL261 cancer cell lines were cultured in 
Dulbecco's Modified Eagle's Medium (DMEM) (Sigma Life Science) supplemented with 10% foetal calf 
serum (Gibco), 1% L-Glutamine (Gibco) and 1% penicillin and streptomycin (Gibco). U251 cells were 
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cultured in a similar medium as CT2A and GL261 cell lines except the absence of L-Glutamine. All cells 
were cultured in appropriate flasks and kept in a humidified incubator at 37°C with 5% CO2.  
 
Both HUVEC and HCMEC cells were cultured on Poly-L-lysine coated flasks using Human Large Vessel 
Endothelial Cell (HLVEC) basal medium (Cat. No. KC1015) supplemented with growth factors (KC1014) 
and antibiotic, Amphotericin B/Gentamycin, 1000X (KC1019). HEK 293T cells were cultured on poly-
lysine coated flasks using DMEM basal medium supplemented with 10% FBS (Biosera Ltd), 1% L-
Glutamine, and 1% P/S (Sigma Aldrich). All cultured cells were allowed to grow in a 370C incubator 
with 5% CO2 and cells were trypsinised and passaged when they reached ~ 80% confluence. Cells were 
frozen down using 90% foetal calf serum (FCS) and 10% dimethyl sulfoxide (DMSO) and were 
temporarily kept in –800c freezer until they were moved into liquid nitrogen for a long-term storage.  
 
2.1.4 Standard solutions  
The lists of different solutions used throughout this thesis for purposes like cell culture, western blot 
(WB), polymerase chain reaction (PCR), spheroid assay and IHC/IF are shown in Table 2.1. These 
solutions were either purchased or prepared in the lab. 
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Table 2.1 Commonly used standard solutions in this study 
Sr.No. Solution Recipes or Cat. No 
1 PBS 500 ml distilled water (disH20) + 2 PBS tablets (Cat.No. P4117, Sigma) + 
1 PBS tablet (Ca.No. BR0014G, OXOID) 
2 Lysis Buffer 
(PCR) 
100 mM Tris (PH 8.5), 5 mM EDTA, 0.2% SDS, 200 mM NaCl 
3 Lysis buffer 
(WB) 
50 mM TRIS PH 7.4, 10% Glycerol, 1% NP40, 5 mM MgCl2, 100 mM 
NaCl  
4 Rac Lysis buffer 50 mM TRIS PH 7.4, 10% Glycerol, 1% NP40, 5mM MgCl2, 100 mM 
NaCl, 25x Complete Inhibitor (no EDTA) and 1mM DTT 
5 10xTBS 100 ml 1M Tris-Base PH 7.5 + 200 ml 5M NaCl  
(900 ml disH20 + 24 gm Tris Base + 88 mg NaCl) 
6 1xTBS 900 ml disH20 + 100ml 10xTBS  
7 TBST 1xTBS + 0.1% Tween-20  
(900 ml disH20 + 200 ml 10TBS + 1 ml Tween-20) 
8 Running Buffer 50 ml 20xT.A + 950 ml disH20 
9 Transfer Buffer 70% disH20, 20% methanol and 10% 10XTBS  
10 4% PFA 500 ml PBS + 20 gm PFA powder (PH adjusted using 1M NaOH) 
11 5X DMEM 100 ml disH220 + 6.74 gm DMEM + 40 gm or 1.85 gm or 0.37gm 
NaHC03 
12 Laura Broth 
(LB) medium  
20 gram LB powder in 1 litre distilled water and then autoclaved 
13 LB agar  15 gram agarose powder in 1 litre LB medium 
14 Tris-EDTA (TE) 
buffer (PCR) 
5ml 1M Tris (PH8), 1ml 0.5M Na2EDTA 
15  Access 
Revelation 
(10x) 
Antigen Retrieval (Cat.No. MP-607-X500, MenaPath) 
16 TBS 
Automation 
Wash Buffer 
(20x) 
Washing buffer (Cat. No. MP-945-X500, MenaPath) 
17 5xDMEM 674 mg of DMEM powder + 37 mg of NaHCO3 in 10ml distilled water 
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2.1.5 Culturing bacteria 
A total of 6 plasmids including Dock4sh1, Dock4sh2, empty vector and non-targeting, envelope 
(pMD2G) and packaging (psPAX2) were amplified from scrapes of stock plasmid glycerol with 
ampicillin (100 µg/ml) in a liquid broth (LB). The mix was incubated overnight at 370C in a shaking 
incubator (220/min) and next day the mix was centrifuged at full speed for 30-45 minutes once 
aliquoted into 50 ml falcon tubes. This was followed by either maxiprep (Life Technologies) or 
Miniprep (QIAGEN) for purification of plasmid DNA. As the total DNA production from the maxiprep 
and miniprep was too small, particularly for the packaging and envelope plasmids, I transformed more 
plasmids from StbI3 E.Coli which was stored in our lab at -80oc. Briefly, 20-30ul of StbI3 was aliquoted 
into 3 different eppendorf tubes and 1µl each from pGIPZ1, pPAX and pMD2 plasmids were added to 
respective tubes and placed on ice for 30 minutes without mixing by pipetting. The bugs were heat-
shocked by incubating on 420c for 45 seconds and placed back on ice and kept for 2 minutes. After 
this, 250 µl LB medium was added to each tube and incubated for 1 hr in a shaking incubator at 225 
rpm in a 370c incubator. After 1hr, 200 µl was taken from each eppendorf tubes and plated on pre-
warmed agar plate with ampicillin and incubated overnight at 370c. Next day, 2-3 colonies from the 
plates were seeded in a 15 ml falcon tubes containing LB in the presence of ampicillin and run 
overnight in an incubator at 225 rpm at 370c and continued with miniprep then after. 
 
2.1.6 Lentivirus production 
Following purification of enough DNA plasmids the Trono lab protocol was followed to generate the 
respective lentiviruses. Briefly, HEK 293T cells were seeded on Poly-Lysine (Sigma) coated 10 cm dishes 
at a density of 4x106 cells and the next day, cells were transfected with lentiviral plasmids in Opti-
MEM (Gibco) using Lipofectamine 2000 (Invitrogen) when they reached 70-80% confluence they. 
Medium was removed on second day following lentiviral transfection and fresh medium was added. 
The supernatant was harvested on third day and filtered through 0.45 µm Millex HV filter and stored 
as first harvest and then repeated on day 4 and stored as second harvest. Both harvests were kept in 
-800c until required for transduction.  
 
2.1.7 Lentiviral transduction  
Dock4 shRNA 
In order to knockdown DOCK4 protein from cancer cells, DOCK4 shRNA plasmids, which were originally 
from Dharmachon GE Life Science, were transduced into cancer cells. Two types of DOCK4 shRNA 
were used: 
DOCK4 shRNA1 mature antisense – CTCAGTATTTGCAGATATA and 
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DOCK4 shRNA2 mature antisense - CGCAAGGTCTCTCAGTTAT 
 
Cells to be transfected (U251 and patient-derived GBM1) were cultured and brought to confluence, 
50-80%, before transducing them with lentivirus (virus to media ratio was 1:5 for Dock4 and 1:10 for 
empty vector). Lentiviral vectors play an important role in transducing Dock4 shRNA into the cell 
nucleus and consequently knockdown a gene of interest. The cell cultures were incubated at 37°C in 
a humidified incubator with 5% CO2 overnight with the lentivirus and polybrene at 1µl/1ml of the 
transfection solution. The media was replaced the next morning with a fresh media. The transfection 
efficiency was monitored using vector incorporated reporter genes such as enhanced green 
fluorescent protein (eGFP), which gives green fluorescent light when observed under EVOS® 
microscope after 24 hrs.  
 
2.1.8 Cell sorting  
Transduced cells were trypsinised, mostly after 72 hrs, neutralised with cell culture medium, 
centrifuged, filtered  and collected in polystyrene capped 5ml FACS tubes at a maximum concentration 
of 5x106 cells/ml. Cells were sorted using the LIMM cell sorting facility for the brightest cells. GFP 
positive cells were cultured for experimental use and in order to confirm efficiency of DOCK4 gene 
knockdown cell lysates were prepared and used to run western blot (WB).  
 
2.1.9 Cell lysate and Western blot 
For WB assay cells were cultured on 10 cm plate and allowed to grow to a confluence of ~80% and 
lysed using lysis buffer (Table 2.1). A typical 1ml Rac lysis buffer was composed of 50μl of 1M TRIS (PH 
7.4), 250μl of 40% Glycerol, 100μl of 10% NP40, 5μl of 1M MgCl2, 20μl of 5M NaCl, 40μl of 25X 
Complete Protease Inhibitor (Roche Applied Science), 1μl of 1M Dithiothreitol made to 1ml with 
distilled water (dis H2O). Before lysis the supernatant medium was removed and cells were washed 3X 
using 10ml PBS. Then the 10cm plate was immediately placed on ice and 200μl of the lysis buffer was 
added. The plate was scraped using a scraper in order to release cells adhered to the plate. The cells 
were repeatedly pipetted up and down in order to lyse the cells and the cell lysate was transferred to 
an eppendorf tube. Another 200μl buffer solution was added and the above steps were repeated. 
Finally, the lysate was centrifuged at 13000 rpm for 5 minutes in a 40C centrifuge and the supernatant 
was kept at -800C until needed for WB. 
 
The protein concentrations of cell lysate samples were quantified using both spectrophotometer 
cuvette tubes using BSA standard curve or the 96 well plate Pierce BCA Protein Assay kit (Thermo 
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Fisher Scientific) methods. Once protein quantification was completed and calculated for WB, the 
samples were placed on a heater at 1000C for 10 minutes to breakdown the DNA. Following this, the 
samples were loaded on to gel (SDS-PAGE - sodium dodecyl sulphate polyacrylamide gel 
electrophoresis) while in a 1L running buffer holding Electrophoresis apparatus (both from Invitrogen) 
along with 5µl DNA ladder. Next, 435µl NuPAGE® Antioxidant (Invitrogen) was added onto the buffer 
and the gel was run at 150 volts for 1-2 hrs. This was later transferred onto a membrane (Immobilon™-
FL PVDF Transfer Membrane (Sigma-Aldrich)) using TE42 Standard Transfer Tank (Hoefer) and transfer 
buffer, and run at 0.1A in a cold room overnight. Finally, the membrane was blocked, fixed with 
primary and secondary antibodies and the result of the knockdown was demonstrated using ECL 
detection system (GE-Healthcare-Amersham). After the first ECL was stripped of using 50 ml disH20 
and 50 ml 0.1M NaOH for 10 minutes each, the membrane was fixed with GAPDH in order to check 
whether equal amounts of proteins were loaded. 
 
2.1.10 Spheroid assays 
In order to study cancer cell invasion in in vitro model different cancer cell types with or without 
endothelial cells were cultured using a spheroid assay as previously described (Cheng et al. 2015). 
Briefly, cells were cultured in appropriate flasks and were trypsinised at confluence, counted and 
diluted to 5x103 cells/ml in their respective culture medium. Next, 1-2x103 cells were seeded in a low 
adherent and round bottom 96-well plates (Sigma cat No. 7007) in 200 µl 5xDMEM, neurobasal, 
5xDMEM and HLVEC or neurobasal with HLVEC medium for U251, GBM and or when these cells were 
seeded with ECs, respectively. After 3-5 days when a sphere was formed, supernatants were removed 
and 100µl collagen was added per well at 6.8 : 1 ratio of Collagen to respective medium and 
neutralised by 0.7% 1M NaOH. Finally, 100µl of the respective medium was added to each well and 
the plate was incubated at 37o and 5% CO2. Cancer cell invasion was measured at Days 0, 3, 7, and 11 
following the addition of collagen using EVOS at 4x magnification. ImageJ 32 software was used to 
measure and calculate cancer cell invasion. Briefly, a polygon shape was used to draw a line along the 
edge of the sphere starting from the day collagen was added and this was repeated 2-3 days apart 
until the spheres appeared to reach their maximum growth and invasion. Other than the first day, 
where a proper circle was drawn around the sphere, the drawing covered at least 75% of the 
outgrowth of the invading tumours from which total area was calculated by the software. Finally, 
Migration Index (MI) was calculated by subtracting the core area from the respective outgrowth area 
and then divided by the outgrowth area.   
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2.2 Patient sample processing and characterisation  
2.2.1 Patient-derived samples 
GBM tissue samples were collected from patients who attended Leeds Teaching Hospital (LTH) 
following their consent and ethical approval from the University of Leeds Research Ethics Committee. 
Out of a total of 52 FFPE blocks available for IHC analysis only 21 blocks were chosen following 
exclusion of blocks with either small or inadequate sample size or those samples with predominantly 
necrotic regions (Appendix 1). Furthermore, 10 pairs of primary and recurrent patient-derived GBM 
samples were obtained from Imperial College through Brain UK (Appendix 2). Altogether, I 
characterised a total of 26 primary GBM patient samples and 15 pairs of primary and recurrent WHO 
Grade IV GBM samples. One normal brain tissue sample dissected from a corpse was also included as 
a control. 
 
2.2.2 Immunohistochemistry (IHC)  
Both patient and mouse brain tumour tissue samples which were embedded in paraffin were 
sectioned at 4 µm thickness and mounted on a Superfrost Plus microscope slides (Thermo Fisher 
Scientific). For IHC staining slides were placed on a heater (700C) to melt the wax followed by antigen 
retrieval process using Mena Path Access Revelation solution (Cat. No. MP-607-X500) in a pressure 
cooker for about 40 minutes. At the end of the antigen retrieval the slides were immediately rinsed in 
preheated Mena Path TBS Automation washing Buffer (Cat. No. MP-945-X500) or TBST (1xTBS and 
0.2% Tween 20) followed by washing under a running tap water. A hydrophobic pen (Vector Lab) was 
used to encircle around the tumour tissue samples on each slide and washed in washing buffer, and 
all endogenous antibodies were blocked using BloxAll (SP-6000) for 15 minutes in a wet chamber. 
Then, slides were washed in a wash buffer and incubated for another 15 minutes in a Normal Horse 
Serum (Vector lab) to avoid non-specific binding. Then, slides were washed in a washing buffer and 
incubated with the right antibody at the right dilution depending on the type of staining - single or 
double staining (Table 2.2).  
 
All primary antibodies were diluted in Antibody Diluent Solution (Invitrogen; 00-3218) and 100-200 µl 
volume was added depending on the size of the tissue on the slide. Then, slides were washed in 
washing buffer, 3x 3 minutes each, before incubating with the appropriate secondary antibody for 30 
minutes. ImmPRESS HRP anti-rabbit IgG (Cat. No. MP-7401) and ImmPRESS HRP anti-mouse IgG (Cat. 
No. MP-7400) both raised in horse and pre-prepared Vector secondary antibodies were used. This was 
followed by 3x 3 minute washes and the slides were incubated for 5 minutes with ImmPACT DAB 
peroxidase substrate Vector SK-4105 (Vector lab) mixing one drop DAB CHROMOGEN and 1ml DAB 
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Diluent to produce a brown staining which is insoluble in alcohol and xylene. While all the single 
antibody staining directly go through a quick H&E counterstaining procedure, except Eosin, slides with 
double primary antibodies were stained for Fast Red Cocktail (ImmPACT Vector Red – Alkaline 
phosphatase; SK-5105) for 15 minutes before finishing off with Haematoxylin counterstaining for 
nuclei. All patient-derived GBM tumour tissue samples were stained for rabbit polyclonal anti-CD31 
and mouse monoclonal anti-nestin antibody using the double immunostaining techniques. In addition, 
selected patient GBM tumour samples and mouse tumour samples were stained for IHC using 
different antibodies (Table 2.2). 
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Table 2.2 List of primary and secondary antibodies used in immunohistochemistry 
Sr.No. Primary Antibody Dilution Reactivity Cat No./ Source 
1 Rabbit polyclonal Anti-
CD31 antibody 
1:30 Mouse, Human, Pig Ab28364/ABCAM 
2 Mouse Monoclonal anti-
CD31 antibody 
1:20 Human M0823/DAKO  
3 Mouse monoclonal Anti-
human Nestin antibody 
1:10,000 Human MAB1259/ R&D 
Systems  
4 Mouse/Rat monoclonal 
anti-mouse Nestin 
antibody 
1:10,000 Mouse, Rat MAB2736/ R&D 
Systems 
5 Rabbit polyclonal anti-
DOCK4 antibody 
1:100 Human, Mouse A302-263A/ Bethyl 
Laboratories 
6 Rabbit polyclonal anti-
alpha smooth muscle 
Actin antibody 
1:100 Mouse, Human and 
others 
Ab5694/ ABCAM  
7 Rabbit polyclonal anti-
alpha SMA antibody 
1:100 Human, Mouse, Rat 55135-1-AP/ 
Proteintech 
8 Mouse monoclonal anti-
SMA 
1:400 Human M0851/DAKO 
9 Rabbit polyclonal anti-
Carbonic Anhydrase IX 
antibody 
1:1000 Human ab15086/ ABCAM 
10 
 
Rabbit polyclonal anti-
OLIG2 antibody 
1:1000 Human HPA003254-1/ 
SIGMA 
11 Rabbit polyclonal anti-
GFAP antibody 
1:2000 Human, Mouse and 
more 
Z0334/ DAKO 
12 Rat monoclonal F4/80 1:200 Human, Mouse  ab16911/Abcam 
13 Rabbit polyclonal anti-
Cleaved caspase-3 
1:100 Human, Mouse Asp175/ Cell 
Signaling Technology 
14 Rabbit monoclonal anti-
PDGFRb Ab 
1:100 Mouse, Rat, Human ab32570/ ABCAM 
15 Rabbit monoclonal anti-
gH2AX Ab 
1:400 Human, Mouse, Rat, 
Monkey 
9718S/ Cell Signaling 
Technology 
16 Rabbit polyclonal anti-
CD45 Ab 
1:100 Mouse/Rat/Human/Pig ab10558/ABCAM 
17 Mouse monoclonal anti-
hCD68 
1:100 Human M0876/DAKO 
18 Mouse monoclonal anti-
SOX2 Ab 
1:25 Human/Mouse/Rat MAB2018/ R&D 
Systems  
19 Rabbit polyclonal anti-
Ki67 
1:1000 Mouse/Human/others ab15580/ABCAM 
20 Mouse monoclonal anti-
RFP Ab 
1:1000 Mouse GTX82561/ GeneTex 
 
Secondary Antibodies 
1 Horse anti-Rabbit HRP  RTU Rabbit MP-7401/ Vector lab 
2 Horse anti-mouse HRP RTU  Mouse MP-7402/ Vector lab 
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2.2.3 Immunofluorescence (IF)  
For immunofluorescence staining patient-derived GBM tumour tissue samples were sectioned from 
FFPE blocks, mounted on Superfrost Plus slides and heated at 90 degree for at least 30 minutes. The 
slides were deparaffinised in xylene, 2x 10 minutes and rehydrated in graded ethanol for 5 minutes 
while being agitated every 30 seconds. For antigen retrieval water bath was set at 95oC and slides 
were kept in Menarin antigen retrieval solution in the water bath for 20 minutes. After cooling down 
and washing under running water for 5 minutes, the slides were blocked using a blocking solution 
containing 1% BSA and 2% FCS in PBS for 1hr on a rocking platform. Primary antibodies diluted in a 
blocking solution were added to the slides and incubated overnight in a cold room. GBM tumour tissue 
samples were stained using different primary antibodies as shown in Table 2.3. Next day, fluorophore-
conjugated secondary antibodies were added following 3x 5 minute washes in TBST. The slides were 
then incubated in 1µg/ml DAPI in PBS for 10 minutes to stain nuclei at room temperature. Finally, 150-
200 µl Vector True View (Cat. No: SP-8400) was used to quench autofluorescence for 5 minutes and 
20 µl Vectashield Hardset mounting medium (Cat. No: H-1400) was applied on each tissue sample 
before adding coverslip. Images were acquired using Nikon A1 confocal microscope or AxioImage Z1 
fluorescence microscope (Zeiss).  
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Table 2.3 List of primary and secondary antibodies used in immunofluorescence  
No. Primary Antibody Dilution Cat No./ Source 
1 Mouse monoclonal anti-hNestin Ab 1:5000 MAB1259/ R&D Systems 
2 Rabbit polyclonal anti-CD31 Ab 1:30 Ab28364/ ABCAM 
3 Mouse monoclonal anti-hCD31 Ab 1:20 M0823/DAKO 
4 Rabbit monoclonal anti-PDGFRb Ab 1:100 Ab32570/ ABCAM 
5 Mouse monoclonal anti-hSMA Ab 1:200 M0851/ DAKO  
6 Rabbit polyclonal anti-SMA Ab 1:100 55135-1-AP/ Proteintech 
7 Mouse monoclonal ant-SOX2 Ab 1:25 MAB2018/ R&D Systems 
8 Rabbit polyclonal anti-GFAP antibody 1:1000 Z0334/ DAKO 
9 Mouse monoclonal anti-hCD68 1:50 M0876/DAKO 
 
Secondary IF Antibodies 
1 Alexa Fluor 488 Goat-anti Rabbit IgG 1:200 A11034/ Invitrogen 
2 Alexa Fluor 594 Goat-anti Mouse IgG 1:200 A11032/ Life-Technologies 
3 DAPI for nuclear counterstaining with excitation 
wavelength of 340  
1ug/ml Sigma-Aldrich 
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2.2.4 Characterisation and quantification of patient GBM tumour vasculatures 
Each tumour tissue sample was characterised and quantified for different blood vessel morphologies 
and expression level of different proteins.  Briefly, the stained slides were scanned using Apeiro AT 
Virtual Slide scanner and characterised using Apeiro ImageScope software. An area of 1mm2 boxes 
were placed on the viable non-necrotic part of the tumour tissue at low magnification (Figure 3.2). At 
least 75 % of the viable, non-necrotic tissue regions from each sample was covered by boxes in order 
to represent different regions of the tumour tissue sample. All boxes were given an identification 
number and as a guideline a minimum of 9 and a maximum of 16 representative boxes were randomly 
selected based on the size of the tissue specimen for GBM vasculature characterisation study. Where 
the maximum available total number of boxes on a given tumour specimen was less than 9, all of them 
were characterised. Once the boxes were identified, each blood vessel was characterised using 
ImageScope software at 20x magnification. All blood vessels with length £ 20 µm were excluded if 
they were found with a minimum lumen diameter less than 10 µm, at 20x magnification as it was 
found practically difficult to characterise such small blood vessels.  
 
Overall, a total of 5,829 blood vessels (3,819 from LTH and 2,010 from Imperial College) were 
characterised based on predefined and optimized morphologies. The characterisation of vascular 
morphologies was based on 5 different glioblastoma vascular morphologies (Fig. 3.3 & 3.4). In this 
study, while ‘Normal’ vessel morphology refers to that of normal brain blood vessels, 4 more distinct 
morphologies were identified in glioblastoma patient samples: Normal-like, Nestin +ve, Glomeruloid 
nestin -ve and Glomeruloid nestin +ve. The extent of nestin expression by ECs and that of their 
surrounding stroma was mainly used in GBM blood vessel morphology classification and 
characterisation. In parallel, the diameter of each blood vessel was also measured using ImageScope 
software.  
 
2.3 In vivo mouse models 
All in vivo experiments were conducted in accordance with the Animal (Scientific Procedures) Act 1986 
and NCRI Guidelines and approved by Home Office Project Licence governing body and locally by 
University of Leeds Animal Welfare and Ethical Review Committee. In order to further my 
understanding of how glioblastoma tumours form their vasculature I mostly used Dock4 heterozygous 
mice and their litter mates in this thesis. This was mainly because homozygous Dock4 deletion is 
embryonically lethal (Abraham et al. 2015). However, I also used some Dock4 conditional knockout 
mice in a pilot study to see the effect of endothelial cell specific Dock4 gene deletion on tumour 
growth. 
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2.3.1 Mouse lines and breeding  
Heterozygous Dock4 mice with C57BL/6J background were crossed with BL6 mice and pups were ear 
biopsied for genotyping at 3 weeks old. All genotyping was processed by Transnetyx (TN, USA). 
Conditional Dock4 knockout mice were bred using Dock4f/f  which were generated and imported from 
Ozgene, Australia and VEC-Cre;Rosa26Td mice from Beatson Institute, Glasgow. In order to confirm 
endothelial specific deletion of Dock4 and to test how well VEC-Cre deleted the stop codon 2mg 
tamoxifen/mouse was injected intraperitoneally for 5 consecutive days. Tumour tissue samples from  
mice carrying Dock4f/f gene with either Cre+ or Cre-;Rosa26TdTomato gene were stained using red 
fluorescent antibody (RFP) to confirm Dock4 deletion which allows TdTomato to be expressed in the 
presence of Cre. All mice were bred and kept in St James’s Biological Services (SBS) animal facility, 
University of Leeds.  
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Table 2.4 In vivo experiments conducted in this study 
 Exp. 
No. 
Cell type and 
dose  
Number of mice, sex 
strain and age 
Overall Survival 
(average days) 
Comments 
1 5x10^5 CT2A 
4x10^4 GL261 
2F BL6@ 9wks 
2F BL6 @10wks 
21 
20.5 
Mice developed 
neurological 
symptoms 
2 1x10^5 CT2A  8F Dock4 het @18-
22 wks 
5F BL6 @ 18-22 wks 
Mice were taken 
down following 
observation of 
symptoms in one 
mouse  
(Day 28) 
Targeted 
radiotherapy (RT)  
5x2Gy and 
3x5Gy using 
SARRP 
3 1x10^5 CT2A-luc 4F Dock4 het @8 
wks 
4M DOCK4 het @ 8 
wks 
9M BL6 @ 8 wks 
Mice were taken 
down following 
observation of  
symptoms in one 
mouse (Day 21) 
Whole brain 
irradiation 
(WBRT) using X-
ray irradiator 
(IVIS + MRI) 
4 1x10^5 CT2A-luc 26F Dock4 het @8-
10 wks 
26F BL6 @ 8-10 wks 
WT ctrl – 21.2 
Het ctrl – 20.1 
WT RT – 33.7 
Het RT - 32 
WBRT using 
SARRP (IVIS + 
MRI),   
3 mice/Group 
taken down early 
5 1x10^5 CT2A  5F&7M VE-cad-
iCreERT-Cre Dock4f/f 
@ 9wks 
4F&3M VE-cad-
iCreERT+Cre Dock4f/f 
@ 9wks 
18.5 (of 4 mice) 
 
19 (2F&1M) 
12 mice taken 
down 11 days 
post injection 
and 7 mice upon 
development of 
symptoms 
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2.3.2 Genotyping  
Ear biopsy samples were collected from 3 weeks old mice and placed in a pre-designated 96 well 
plates. The samples were either sent to Transnetyx straightaway or kept at -20 degree freezer until 
collected. For shipping purpose each plate was sealed in FedEx envelope at room temperature and 
sent to Transnetyx the same day which usually took 2-3 days to reach them. The samples were 
processed according to Transnetyx protocol 
(https://www.transnetyx.com/home?gclid=EAIaIQobChMIoaPi6MaX3wIVCYjVCh1KNgX_EAAYASAAE
gKy-_D_BwE) and the results were obtained within 72 hours. 
 
2.3.3 Intracranial injection 
For all in vivo experiments the murine brain tumour model CT2A was used, except the initial 
comparison made against GL261 cell line. A total of 1x105 CT2A cancer cells in 2µl DMEM were injected 
intracranially into the right hemisphere of the brain of 8-10 week-old mice (Table 2.4). Stereotactic 
machine was used to inject mice as described previously (Lorger et al. 2009). Briefly, mice were 
anaesthetised using isoflurane and the head regions were shaved using hair clipper a day before 
surgery. Two mice were restrained at the same time on a stereotactic machine, which was connected 
to a source of isoflurane and oxygen generator through one tube and a scavenger unit to extract the 
isoflurane waste through another tube, and ear bars were applied to fix the heads firmly for 
intracranial injection. Mice were injected 5mg/ml Metacam (Boehringer Ingelheim, UK) and 2.5% 
Baytril (BAYER) before making a small incision over the injection site. A small dent or hole was drilled 
1mm to the right and 1mm anterior to bregma using a driller in order to ease the advancement of 
Hamilton syringe. A Hamilton syringe with 5 µl needle was loaded with cancer cells and injected 4mm 
deep into the striatum using a ruler on a stereotactic machine as a guide. The 2 µl tumour cells were 
injected at 3mm depth, 1 µl at a time at 1 minute interval and then gradually withdrawn 1 mm at a 
time after every 30 seconds. Finally, after withdrawal of the needle wax was applied to seal the hole 
and skin incision was stitched back together using glue.  Mice were allowed to recover in a recovery 
chamber (37oC) before putting them back in their cages. They were routinely monitored and checked 
for development of neurological symptoms.  
 
2.3.4 Irradiation 
Mice in the ionising radiation treatment group received either a total of 10Gy or 15Gy ionising 
radiation post tumour implantation using either Small Animal Radiation Research Platform/SARRP 
(Xstrahl Life Sciences) or RAD X-ray irradiator (RS2000 X-ray Irradiator – Rad Source). Most brain 
tumour irradiation experiments in this study were conducted using SARRP and both whole brain and 
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targeted irradiation were used. While whole brain ionising irradiation was carried out using 9 mm x 9 
mm collimator, targeted therapy was delivered using 3mm x 9mm collimator. In both cases an Arch 
beam from 60o to -60o was used in order to avoid damage to sensitive body parts like the throat region. 
Mice were first imaged using cone beam computed tomography (CBCT), SARRP, and the images were 
uploaded onto Muriplan software in order to locate the area of irradiation. The total radiation dose 
was delivered to the tumour with a maximum dose at the centre and gradually decreasing towards 
the edge of the tumour using isocentre as a centre of reference to the tumour.  
 
For the irradiation experiment conducted using X-ray irradiator as a source of ionising radiation mouse 
was anaesthetised and placed on aluminium shelf plate at level 5 in the RAD Source (RS 2000) X-ray 
irradiator machine.  A total irradiation dose was calculated at 160 kV and 25 mA and delivered at a 
rate of 4.5 Gy/min to the brain region guided by a collimator with a red light laser. The ionising 
radiation dose was calculated based on the level the shelf holding the mouse in the RS 2000 irradiator. 
 
2.3.5 IVIS imaging  
Tumour growth was monitored in CT2A-luc implanted mice using non-invasive bioluminescence IVIS 
spectrum imaging (PerkinElmer) 2x/week, with a maximum of 5-6 IVIS imaging/mouse. Each mouse 
was injected with luciferase subcutaneously and imaged after 20 minutes. The images were processed 
using IVIS spectrum software and tumour growth rate was determined for different groups. 
 
2.3.6 Magnetic resonance Imaging (MRI) 
Selected mice from different treatment groups were scanned in axial or coronal slices using M7 
Compact Magnetic Resonance Imaging (MRI). Briefly, isoflurane was used to anaesthetise mouse in 
an anaesthetic chamber and moved over to the LSD23 Head Coil bed and restrained. The restrained 
and stably breathing mouse was transferred into the MRI machine gently and continuously monitored 
while in MRI for respiration and pulse using physiological monitoring software. Using Aspect imaging 
software orientation (feet first), scout (Mouse Head), axial or coronal section and slice thickness were 
selected and scanned to capture a T2-Weighted MR image. 
 
2.3.7 Terminal perfusion 
Mice were taken down by terminal perfusion either at the same timepoint when one single mouse 
developed neurological symptoms or individually when each mouse started to show neurological 
symptoms. Once mice were perfused using PBS and 4% PFA, brain tissue samples were collected and 
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the samples were fixed in 4% PFA overnight in a fridge. The next day the samples were transferred 
into 70% ethanol and kept in a fridge until embedded in paraffin.  
 
2.3.8 Processing of mouse tumour samples 
Mouse tissue samples from in vivo experiments which were fixed in 4% PFA overnight and then 
transferred into 70% ethanol were paraffin embedded. Briefly, fixed tumour tissue samples were 
placed in different size cassettes and labelled. Then the cassettes went through a series of dehydration 
(70% -100% graded ethanol), clearing (3x xylene) and infiltration (3x paraffin wax) at 65oc using 
automatic tissue processor overnight. The next day the cassettes were taken out form the tissue 
processor and placed in a paraffin dispenser machine. The tissue samples were removed from their 
cassettes and placed in a metal box in order to embed using pure paraffin in a desired orientation for 
sectioning. Finally, the original cassette was placed back on the metal box and more paraffin was 
added to complete the embedding process. The block was placed on a cold place and then stored at 
room temperature until sectioned. 
 
The embedded mouse tumour tissue samples were sectioned almost exactly the same way as the 
patient GBM tissue samples as described under Section 2.2.2 above. Briefly, mouse brain tumour 
tissue samples were cut at 4 µm thickness using a coronal section from anterior to posterior starting 
from olfactory region. The 4 µm tissue samples were mounted on Superfrost Plus slides, left overnight 
to dry in 37oC incubator and stained for different antibodies (Table 2.2). Stained slides were scanned 
as above (2.2.2). An area of 0.5mm x0.5mm (0.25mm2) boxes were placed on the tumour tissue 
samples at low magnification and blood vessels were characterised at 20x magnification. All boxes 
were given an identification number and a minimum of 2 and a maximum of 6 boxes were analysed 
per tumour tissue sample. Blood vessels with length £20 µm and/or lumen <10 µm were excluded 
from this study. ImageScope software at 20x magnification was used to measure blood vessel lumen 
diameter. Percentage lumenised vessels was defined as total number of vessels with lumen ³ 10 µm 
divided by total vessel count with length >20 µm and/or lumen > 10 µm.  
 
2.4. Statistical Analysis 
All data were analysed using GraphPad Prism and a P value of <0.05 was considered as statistically 
significant. 
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Chapter 3 
 
Characterisation of the patient glioblastoma 
vasculature 
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3.1 Introduction 
Microvascular proliferation is a hallmark of glioblastoma. However, there are contradictory reports as 
to the role of GBM vasculature in relation to patient outcome. Most previous studies described 
aberrant GBM blood vessels in terms of microvascular density (MVD), and only a handful of studies 
considered vascular structures to assess the prognostic values of these blood vessels in GBM 
((Preusser et al. 2006) and (Birner et al. 2003)). Further, the majority of these reports are descriptive 
and lack fundamental components of molecular cell biology and mechanisms as to the formation of 
such abnormalities. Various mechanisms including sprouting angiogenesis, co-option, vasculogenesis, 
vascular mimicry and transdifferentiation have been described as potential mechanisms of GBM blood 
vessel development. However, there is considerable disagreement as to how and to what extent each 
mechanism contributes to the abnormality of glioblastoma blood vessels. For instance, while some 
studies supported transdifferentiation of GSCs to GBM blood vessels ((Ricci-Vitiani et al. 2010); (Soda 
et al. 2011)), others reported that GSCs transdifferentiation only gives rise to pericytes (Cheng et al. 
2013). In a consequent experiment, the same group demonstrated improved efficacy of 
chemotherapy by targeting pericytes (Zhou et al. 2017).  However, other studies in this area did not 
support the existence of such mechanisms (El Hallani et al. 2014). Hence, to this date the precise 
identity, prevalence, and prognostic value of GBM blood vessel morphologies are not well defined. 
 
In this study, I set out to characterise the vasculature in GBM patient samples and define the 
prevalence of different blood vessel morphologies using immunohistochemical techniques to identify 
ECs and other cell types within the brain perivascular niche. Five different blood vessel morphologies 
were previously identified in the laboratory which I first confirmed and then quantified using the EC 
marker CD31 and stem cell marker nestin, in order to interrogate the presence of GSC-derived ECs. 
Blood vessel morphologies were scored in randomly selected areas within viable tumour tissue 
regions from a patient cohort treated in Leeds which was used as a training cohort. More samples 
were obtained from Imperial College to validate the findings. Within these patient cohorts paired 
primary and recurrent tumour samples, where available, were analysed in order to understand the 
effects of therapy on blood vessel characteristics. Further, blood vessel morphologies were associated 
with patient outcome. 
 
3.2 Patient GBM blood vessels are abnormal 
In order to identify the different types of blood vessel structures present in GBM, the endothelial cell 
marker CD31 and stem cell marker Nestin were used. As some studies suggested that GSCs 
transdifferentiate to ECs of GBM  blood vessels ((Ricci-Vitiani et al. 2010; Soda et al. 2011)) or cancer 
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cells themselves form blood transporting vessel channels (Wang et al. 2013 and Yao et al. 2015) it was  
appropriate to expect at least a proportion of GBM blood vessels to stain Nestin positive and CD31 
negative. Nestin/CD31 double immunostaining of normal brain tissue identified about 85% as CD31 
positive small size capillaries (<10 µm) and larger blood vessels (with >10 µm had average diameter 
of 23 µm) lined by spindle shaped ECs with relatively low to none nestin positivity (Figure 3.1). In 
glioblastoma patient samples there were both small calibre capillaries and larger calibre blood vessels, 
often organised in glomeruloid structures, which appeared lined by rounded cells with strong nestin 
positivity (Figure 3.1). The term glomeruloid is commonly used to describe blood vessels organised in 
close proximity within common stroma (Rojiani and Dorovini-Zis 1996; Sundberg et al. 2001 and Brat 
and Van Meir 2001). The strongly nestin positive blood vessels were similar in appearance to the 
cancer cells within the tumour cell compartment (Figure 3.1), suggesting that they could represent 
the transdifferentiated CD31 positive GSCs described by Soda and co-workers (Soda et al. 2011).  
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Figure 3.1 Blood vessel morphologies in normal brain and glioblastoma tissue  
Normal brain or glioblastoma tissue samples were formalin fixed, paraffin embedded and sectioned. 
Following antigen retrieval, the samples were immunostained using antibodies against the stem cell 
marker Nestin and endothelial cell marker CD31. Black arrows point to blood vessels. Note abnormal 
blood vessels in GBM in a glomeruloid organisation within common stroma (red dotted circle). Scale 
bar, 100 µm. 
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In order to characterise in detail and quantify blood vessels in the GBM patient samples, 1mm2 boxes 
were placed at 1x magnification on scanned images of stained slides to cover the non-necrotic, viable 
tumour tissue area (Figure 3.2A).  Blood vessels in each box were analysed at 20x magnification of the 
scanned sample (Figure 3.2B). As the size of available patient tumour samples varied, the total number 
of boxes characterised ranged between 2 and 16.  Blood vessels with a minimum length of 20 µm 
length and or with minimum diameter of 10 µm were characterised as it was found difficult to 
practically measure those smaller vessels. For the number of boxes and total number of blood vessels 
analysed from each tumour see Appendix 3. Overall, GBM blood vessels were morphologically 
classified as Single perivascular, Multi perivascular, Nestin +ve, Glomeruloid nestin -ve and 
Glomeruloid nestin +ve. Single-perivascular and Multi-perivascular blood vessels were predominantly 
characterised by their unique spindle shaped and CD31 positive ECs just like those blood vessels in 
normal brain. The multi-perivascular blood vessels are different from the single-perivascular in that 
the former have additional layers of cells around CD31 positive ECs resembling higher calibre blood 
vessel in the normal brain. Hence, the single- and multi-perivascular blood vessels were considered as 
‘Normal-like’ blood vessels in GBM (Figure 3.3).  
 
One of the most characteristic features of the blood vessels found in GBM was their strong nestin 
positivity. While blood vessels in the normal brain stained weakly positive for nestin, blood vessels in 
GBM showed a range of nestin positivity with some blood vessels being predominantly lined by round 
and strongly nestin positive cells (Figure 3.1). Some nestin positive blood vessels showed a 
glomeruloid organisation (Figures 3.1 and 3.4). Glomeruloid blood vessels that appeared negative for 
nestin were also identified as Glomeruloid nestin negative (Figure 3.4). Hence, most nestin positive 
blood vessels appeared to show a total replacement of spindle-shaped CD31 positive ECs (Figure 3.4).  
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Figure 3.2 Areas of characterisation in patient tumour samples  
(A) Image depicts a scanned slide following staining for Nestin (brown) and CD31 (red). Boxes of 1mm2 
size were placed on viable tumour tissue to cover a minimum area of 75% of the sample (black arrows).  
Red arrow points to a necrotic region excluded from the analysis. 
(B) Image showing zoomed area in ‘A’ using ImageScope. Blood vessels were characterised at 20x 
magnification. Scale bar, 100 µm. 
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Figure 3.3 Normal-like blood vessel morphologies identified in patient GBM samples 
GBM patient samples were stained for Nestin (brown) and CD31 (red). In the Single perivascular 
morphology blood vessels are lined by spindle-shaped CD31 positive ECs; Multi-perivascular blood 
vessels are lined by spindle-shaped CD31 positive ECs and layers of non EC perivascular cells. Single-
perivascular and multi-perivascular blood vessels have been together classified as ‘Normal-like’ due 
to the EC lining being similar to those in the normal brain. Insets on the left-hand panels are shown at 
higher magnification on the right-hand side. Scale bar, 100 µm. 
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Figure 3.4 Abnormal blood vessel morphologies identified in patient GBM samples 
GBM patient samples were stained for Nestin (brown) and CD31 (red). Nestin positive blood vessel 
morphology is characterised by the presence of nestin positive, rounded cells appearing to replace 
spindle-shaped ECs lining the blood vessels. Glomeruloid blood vessels are arranged as a network 
within common stroma lined by either nestin positive or nestin negative cells. Nestin positive and 
glomeruloid morphologies were only found in tumour samples and were hence classified together as 
‘Aberrant morphologies’. Insets on the left-hand panels are shown at higher magnification on the 
right-hand side. Scale bar, 100 µm. 
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3.3 GBM patients present with different degrees of blood vessel abnormality 
Analysis of sixteen samples from Leeds patients (Appendix 1) with primary GBM showed high level of 
heterogeneity in tumour blood vessel morphologies. All 5 morphologies were identified in almost all 
tumours (Figure 3.5). In 12/16 (75%) of samples analysed the Normal-like morphology was 
significantly higher than the abnormal morphologies detected in those primary tumours. One tumour 
only, GBM37, had a significantly higher proportion of Nestin +ve blood vessels compared to normal-
like blood vessels. This analysis showed that GBM patients present with different degrees of 
abnormality, although abnormal blood vessels appear at lower or similar abundance to normal-like 
blood vessels in primary tumours. In order to validate these findings in a new patient I analysed 10 
more primary GBM patient samples from Imperial College, London (Appendix 2). These analyses 
confirmed that there are different degrees of blood vessel abnormality in GBM patients (Figure 3.6) 
in accordance with the findings from the Leeds patient cohort. All primary GBM tumours in the 
Imperial had a significantly higher proportion of normal-like blood vessel morphologies compared to 
the aberrant blood vessel morphologies. 
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Figure 3.5 Quantification of GBM blood vessel abnormalities in the Leeds patient cohort 
Primary GBM patient samples were characterised for the prevalence of different blood vessel 
morphologies. Histogram shows blood vessels showing a particular morphology as percentage of total 
blood vessels characterised in a sample ± SD; N = number of 1mm2 areas analysed (shown in Appendix 
3); an average of 176 blood vessels were characterised per patient sample; note that all patient 
samples showed both normal-like and aberrant blood vessel morphologies. P values *<0.05, **<0.01, 
*** <0.001 relative to normal-like. 
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Figure 3.6 Quantification of patient GBM blood vessel abnormalities in the Imperial patient cohort 
Primary GBM patient samples were characterised for different blood vessel morphologies. Histogram 
shows blood vessels as percentage of totals, N = No. of 1mm2 areas, Mean ± SD (Appendix 3). Multiple 
1mm2 areas were analysed and an average of 261 blood vessels were characterised per patient sample 
and all patients demonstrated both Normal-like and aberrant morphologies. P values *** <0.001 
relative to normal-like. 
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3.4 Association between nestin positivity and GBM patient survival 
Since the presence of rounded cells with strong nestin positivity was a prevalent feature of blood 
vessels in GBM, I investigated whether nestin positivity was particularly associated with poor patient 
outcome. Here, this analysis was only possible for the Leeds patient cohort since clinical data were 
available (Table 3.1), whereas clinical data were not available for the Imperial patient cohort. Li and 
colleagues used median value as a cut-off point to calculate the association of patient outcome and 
level of protein expression (Li et al. 2017). The Human Protein Atlas also considers median value as  a 
cut-off value to calculate the association of high and low protein expression against patients’ outcome. 
Here, while the median glomeruloid nestin +ve blood vessels was 11.5 that of overall nestin positivity 
was 30. Hence, in this study I used 10% and 30% as a cut-off point for glomeruloid nestin +ve and 
overall nestin positive blood vessels, respectively. A survival curve showed that patients with low 
nestin positivity or relatively low nestin positive glomeruloids did not have a significantly better overall 
survival (Figure 3.7). Further, despite the observed trend, there was no statistically significant 
correlation between blood vessel nestin positivity and GBM patient survival (Figure 3.8).  
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Table 3.1 Leeds GBM patient data and summary of blood vessel characterisation 
 
 
Table shows list of Leeds patient clinical data including overall survival (OS), GBM blood vessel 
morphologies, molecular subtype, mutations tumour location and type of treatment received 
following surgery. F- Female; M – Male; Tumour location was identified by two letters (the one on the 
left-hand side indicates whether the tumour was in the right or left hemisphere, and the letter on the 
right  hand side indicates whether the tumour is in temporal, occipital, parietal, frontal or central) e.g.  
LF – left frontal. Most patients received radiotherapy (RT), and combination of RT and temozolomide 
(RT + TMZ). 
 
 
 
 
 
 
 
 
 
 
 
 
Normal-like 
Total  
nestin 
positive
Nestin 
positive 
glomeruloid
GBM13 22 95 5 3 Proneural No unknown F/ 79 LF RT
GBM14 39 53 47 2 Proneural/ 
mesenchymal
No Moderate M/ 58 RC RT + TMZ
GBM16 3 64 36 13 unknown No No F/63 LP RT
GBM20 17 66 34 9 Proneural/ 
mesenchymal
No No M/50 RT RT (Sep-Nov)&TMZ
GBM21 5 44 56 18 unknown No Yes M/72 LT RT
GBM25 58 85 15 0 unknown Yes Yes F/38 LF RT + TMZ
GBM 26 5.5 33 67 21 unknown No No M/63 RT RT + TMZ
GBM 30 26 87 13 10 Classical No No F/50 RF RT + TMZ, PCV avastin
GBM33 9 46 54 30 unknown No No M/42 R TMZ
GBM 36 42 68 32 18 unknown No No M/64 LP-O RT + TMZ + Lamustine
GBM 37 49 15 85 22 unknown No No F/61 RF RT + TMZ
GBM 39 6 82 18 2 unknown No No M/47 RF RT+TMZ
GBM46 10 77 23 15 unknown unknown M/66 RP RT
GBM47 21 71 29 19 unknown unknown M/52 LF RT+TMZ
GBM52 9 80 19 2 Classical No unknown M/56 RO TMZ
GBM63 15 75 25 0 Classical No No M/57 LP RT+TMZ,AV
Tumour 
location Treatment OS
Blood vessels (% total)
IDH 
mutation
MGMT 
methylation
Gender/ 
Age
Molecular 
subtype
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Figure 3.7 Overall patient survival and blood vessel nestin positivity  
High nestin positivity defined as over 30% blood vessels showing coverage by round, strongly nestin 
positive cells and high glomeruloid nestin positivity was defined as over 10%. Overall log-rank test,  
P-values: 0.75 (nestin positivity) and 0.93 (glomeruloids). 
(A) Kaplan-Meier curve of overall survival in GBM patients according to level of blood vessel nestin 
 positivity. N = number of tumours with overall nestin expression on blood vessels morphologies of 
 < 30%, 8 and >30%, 8.  
(B) Kaplan-Meier curve of overall survival in GBM patients according to level of blood vessel nestin 
positive glomeruloids. N = number of tumours with overall nestin expression on glomeruloid blood 
vessel morphologies with <10%, 8 and >10%, 8. 
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Figure 3.8 Correlation between nestin positivity and patient survival 
Linear regression curves show lack of significant correlation between patient OS and nestin positivity 
or Glomeruloid nestin positive blood vessels. 
(A) Lack of correlation between overall nestin +ve blood vessels and patient’s OS (R2 = 0.002, p=0.9).  
(B) Glomeruloid nestin +ve blood vessels and OS (R2=0.03, p=0.6).  
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3.5 GBM blood vessels are larger in calibre compared to vessels in normal brain 
A well-described effect of VEGF action on pre-established blood vessels in animal models is blood 
vessel dilation due to detachment of pericytes, followed by further increase in vessel calibre  by 
formation of glomeruloid structures and/or coverage by pericytes and smooth muscle cells (Nagy et 
al. 2009).  Given the abundance of abnormal blood vessel morphologies including vessels that appear 
larger in diameter compared to normal blood vessels in the brain (Figures 3.3 and 3.4)  I sought to 
quantify the blood vessel size in the GBM patient samples. Microvascular capillary size ranges between 
8 µm and 20 µm in the normal human brain (Xiong et al. 2017). As stated earlier, the resolution of 
images from the scanned stained slides allowed me to characterise with confidence blood vessels that 
were over 10 µm diameter. Firstly, I found a higher proportion of smaller blood vessels in a normal 
brain tissue sample. Analysis of the Leeds patient cohort showed abnormally high blood vessel 
diameters in GBM. Figure 3.9 shows that in 11 out of 16 patients (69%) with primary GBM analysed, 
there was a higher number of blood vessels of larger calibre (20-50 µm and >50 µm) compared to 
smaller calibre blood vessels (10 - 20 µm). GBM blood vessel size was comparable to normal brain in 
patients GBM13, GBM25, GBM52 and GBM63. In the Imperial patient cohort, 4 out of 10 patients 
(40%) had a higher proportion of blood vessels with abnormally high size (Figure 3.10).  
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Figure 3.9 Quantification of patient GBM blood vessel lumen size in the Leeds patient cohort  
Primary GBM patient samples were characterised for blood vessel lumen size. Note that tumours 
showed various degrees of relatively small (10-20 µm), medium (20-50 µm) and large (>50 µm) blood 
vessel diameters. Histogram shows blood vessels as percentage of totals, N = No. of 1mm2 areas, Mean 
± SD (Appendix 3). *<0.05, **<0.01 and *** <0.001. 
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Figure 3.10 Quantification of patient GBM blood vessel diameter in the Imperial patient cohort  
Primary GBM patient samples were characterised for blood vessel lumen size.  
Note that tumours showed various degrees of relatively small (10-20 µm), medium (20-50 µm) and 
large (>50 µm) blood vessel diameters. Histogram shows blood vessels as percentage of totals, N = 
No. of 1mm2 areas, Mean ± SD (Appendix 3). *<0.05, **<0.01 and *** <0.001. 
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3.6 Tumour blood vessel abnormality increases with tumour recurrence 
Following characterisation of blood vessel morphologies in primary GBM tumour samples I 
investigated whether these morphologies change following recurrence. I compared 5 recurrences 
available in the Leeds cohort to their corresponding primary tumours. Analysis showed that the same 
morphologies were present, but their prevalence had changed considerably in the recurrences (Figure 
3.11).  In 4 out of 5 recurrences the percentage of abnormal morphologies was significantly higher 
compared to the primary tumours. Consistently, normal-like blood vessels decreased with recurrence. 
Significant changes were observed in nestin positive morphology and glomeruloid nestin positive 
morphology for which higher proportions were found in recurrent compared to primary tumours. In 
order to find out whether those changes held in a larger cohort of paired samples, I analysed the 
recurrent tumours of the Imperial GBM patients. Consistent with the analyses of the Leeds samples, 
in 8/10 of the tumour samples analysed, the aberrant morphologies increased significantly upon 
recurrence (Figure 3.12).  
 
3.7 Blood vessel calibre increases with tumour recurrence 
Aberrant blood vessel morphologies appeared associated with increase in blood vessel calibre. To test 
this, I compared the calibre of blood vessels both in the Leeds and Imperial GBM samples. Analysis of 
the 5 Leeds pairs showed that the number of smaller calibre vessels (10-20µm) decreased in all 
recurrent tumours. Blood vessels with large lumen size also sharply increased in recurrent tumours 
(Figure 3.13). Again, I analysed additional 10 pairs of Imperial College tumour samples and 8/10 
recurrent tumours had an increased blood vessel lumen size compared to primary GBM samples 
(Figure 3.14). However, in two tumour samples, GBM6 & GBM7, the small size blood vessels showed 
a trend of slight increase upon recurrence. Overall, this analysis showed that it is not only the 
prevalence of aberrant morphologies that increased with recurrence, but also the abundance of 
higher calibre blood vessels.  
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Figure 3.11 Comparison of the abundance of patient GBM blood vessel abnormalities in primary 
and recurrent tumours in the Leeds patient cohort 
Recurrent GBM patient samples were characterised for the prevalence of different blood vessel 
morphologies and compared to primary GBM tumours. Images depict most prevalent morphologies 
in samples. Histograms show blood vessel morphologies as percentage of total blood vessels 
characterised in the primary (P) and recurrent (R) samples ± SD; N = number of 1mm2 areas analysed 
as shown in Appendix 3; Scale bar, 100 µm. P values *<0.05, **<0.01, *** <0.001 relative to Normal-
like.  
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Figure 3.12 Comparison of the abundance of patient GBM blood vessel abnormalities in primary 
and recurrent tumours in the Imperial patient cohort 
Recurrent GBM patient samples were characterised for the prevalence of different blood vessel 
morphologies and compared to GBM tumours. Histograms show blood vessel morphologies as 
percentage of total blood vessels characterised in the primary (P) and recurrent (R) samples ± SD;  
N = number of 1mm2 areas analysed as shown in Appendix 3; P values *<0.05, **<0.01, *** <0.001 
relative to Normal-like.  
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Figure 3.13 Comparison of blood vessel lumen size in primary and recurrent GBM in the Leeds 
patient cohort. 
Blood vessels lumen size from normal brain and 5 pairs of primary and recurrent Leeds GBM tumour 
samples were measured using ImageScope and classified into 3 groups: small lumen size (<20µm), 
medium size (20-50µm) and large blood vessels (>50µm). N= % blood vessel sizes per 1mm2 areas, 
Mean +/- SD (Primary, 5 and Recurrent, 5 tumours; Number of 1mm2 per tumour shown in Appendix 
3). The average number of blood vessels analysed for primary and recurrent tumours were 221 and 
57, respectively. P, Primary and R, recurrent tumours. 
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Figure 3.14 Comparison of blood vessel lumen size in primary and recurrent GBM in the Imperial 
patient cohort 
Blood vessels lumen size from normal brain and 10 pairs of primary and recurrent Imperial GBM 
tumour samples were measured using ImageScope and classified into 3 groups: small lumen size 
(<20µm), medium size (20-50µm)  and large blood vessels (>50µm). N= % blood vessel sizes per 1mm2 
areas, Mean ± SD (Primary, 10 and Recurrent, 10 tumours; the number of 1mm2 boxes analysed per 
tumour are shown in Appendix 3). P, Primary and R, Recurrent tumours.  
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3.8 Recurrent GBM tumours have less MVD than primary GBM tumours 
Given the increases in aberrant morphologies and blood vessel calibre I sought to determine whether 
the overall density of the blood vessels increased in the recurrences. I quantified the number of blood 
vessels per unit area based on their Nestin/CD31 positivity after excluding smaller size blood vessels 
< 10µm in diameter as those blood vessels could not be identified and quantified reliably. Figure 3.15 
shows the pooled MVD from the Leeds and Imperial patient cohorts. The quantifications showed that 
there was significantly less microvascular density (MVD) in recurrent tumours compared to primary 
tumours, a trait found both in samples obtained from Leeds (Figure 3.15A) and Imperial (Figure 3.15B).  
 
Altogether the analysis of primary and recurrent patient GBM showed that there was a shift in blood 
vessel morphology seen both in the Leeds and Imperial patient samples from higher proportion of 
normal-like blood vessels in primary tumours, to higher proportion of strongly nestin positive and 
glomeruloid aberrant type in recurrent tumours (Figure 15C, D). In addition, there was increased blood 
vessel calibre in recurrent tumours in both patient cohorts (Figure 15E, F). Consistently, the number 
of blood vessels per unit area decreased in the recurrent tumours when compared to primary tumours 
(Figure 15 A, B).   
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Figure 3.15 Quantification of MVD,  abundance of blood vessel morphologies and lumen size in 
primary and recurrent GBM tumours  
Primary and recurrent GBM tumours were analysed from the Leeds (5 pairs) and Imperial (10 pairs) 
patient cohorts. 
(A, B) Dot plots show number of blood vessels per 1mm2 area. Lines are the mean ±SD. (A) Primary 
GBM (N= 43 1mm2 areas) against recurrent GBM (N= 32 1mm2 areas) in the Leeds cohort. (B) Primary 
GBM (N= 85 1mm2 areas) against recurrent GBM (N= 83 1mm2 areas) in the Imperial cohort.  
(C, D) Histograms show quantification of blood vessel morphologies as % total blood vessels±SD. (C) 
Primary GBM (N= 41 1mm2 areas) against recurrent GBM (N=31 1mm2 areas) in the Leeds cohort. (D) 
Primary GBM (N= 92 1mm2 areas) versus recurrent GBM (89 1mm2 areas) in the Imperial cohort.  
(E, F) Dot blots show vessel diameter with lines representing the mean ±SD.  (E) Primary GBM N= 749 
blood vessels measured) against recurrent GBM (N=325 blood vessels measured) in the Leeds cohort. 
(F) Primary GBM (N= 995 blood vessels measured) against recurrent GBM (N= 1018 blood vessels 
measured) in the Imperial cohort. **p<0.01; ***p<0.001 by two-tailed t-test. 
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3.9 Nestin positive GBM blood vessels are lined by CD31 positive ECs  
Following the findings of heterogenous blood vessel morphologies in both primary and recurrent GBM 
patient samples I characterised further the nestin positive blood vessels seen in abundance in GBM 
and particularly in recurrent tumours. Previous studies had described how blood vessels in tumours 
maybe lined directly by cancer cells, a process termed vasculogenic mimicry (Maniotis et al. 1999  and 
Wang et al. 2013), or by ECs which are transdifferentiated from cancer cells (Ricci-Vitiani et al. 2010 
and Soda et al. 2011). Hence, in order to better understand the identity of those nestin positive blood 
vessels, I stained serial sections of selected GBM tumour samples (primary and recurrent), exhibiting 
a range of the characterised morphological abnormalities. An interesting finding of this analysis was 
the presence of intact CD31 positive blood vessels which normally appeared to be lined by nestin 
positive cells upon nestin and CD31 double staining. Hence, a single staining for CD31 showed that 
blood vessels were clearly lined by CD31 positive cells, whereas nestin positive cells were situated on 
the abluminal side of the tumour blood vessels. Surprisingly, the single CD31 staining in this study 
clearly showed that almost all blood vessels maintained their CD31 positivity both in primary and in 
recurrent tumours (Figure 3.16).  
 
Following the observation that nestin and CD31 positivity by IHC appeared to overlap, particularly in 
recurrent tumours, I investigated whether the same cells were expressing both markers and whether 
these cells were distinct from each other. Therefore, in order to determine the degree of co-
expression of CD31 and Nestin, I stained tumour tissue samples from both primary and recurrent GBM 
samples by immunofluorescence (IF). This staining showed complete lack of co-localisation or co-
expression of these two markers (Figure 3.17). While CD31 positive cells lined the blood vessels, nestin 
positive cells were distinct but at close proximity to the CD31 positive endothelial cells (Figure 3.17). 
Hence, it can be concluded that GBM blood vessels maintained their CD31 positivity and that CD31 
positive cells are distinct to the nestin positive cells. 
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Figure 3.16 Nestin positive blood vessels are lined by an uninterrupted layer of CD31 positive ECs  
Serial sections of selected tumour samples (GBM16P, GBM36P, GBM13R, GBM14R and GBM20R) 
were stained by IHC for Nestin and CD31. Blood vessels were first identified based on their positivity 
for Nestin/CD31 and then the corresponding slides were checked for the presence of CD31 positivity. 
P=Primary & R=Recurrent. Scale bar, 100µm. 
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Figure 3.17 Lack of co-expression of Nestin and CD31 in patient GBM blood vessels  
Serial sections of selected tumour samples (GBM16P, GBM36P, GBM13R, GBM14R and GBM20R) 
were stained by IF for Nestin and CD31. Note the presence of nestin positive cells around blood vessels 
particularly in recurrent GBM samples, but absence of co-expression of nestin and CD31. P=Primary & 
R=Recurrent. Scale bar, 50 µm. 
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3.10 Nestin positive GBM blood vessels are negative for stem cell and immune cell markers, but 
positive for pericyte and smooth muscle cell (SMC) markers 
Following the establishment that nestin positive GBM blood vessels are distinct from endothelial cells, 
I examined whether any of the perivascular cells in the brain tumour microenvironment such as cancer 
cells, cancer stem cells, immune cells or pericytes could have contributed to the formation of nestin 
positive blood vessels. I stained serial sections from the selected 5 tumour samples (GBM16P, 
GBM36P, GBM13R, GBM14R and GBM20R) first for two other stem cell markers expressed by GBM 
cancer cells, OLIG2 and SOX2. Figure 3.18A shows that blood vessel perivascular cells lacked positivity 
for these stem cell markers. In addition to the 5 selected samples, analysis of further 4 randomly 
selected GBM samples  (total of 629 tumour blood vessels analysed from 9 GBM samples) showed 
complete absence of SOX2 positivity in all blood vessels analysed which included normal-like, Nestin 
+ve and Glomeruloid blood vessels. Interestingly, CD45 and CD68 staining revealed that there were 
immune and/ or macrophage/ microglia cells in the GBM perivascular niche as previously reported (Yi 
et al. 2011 and Hambardzumyan, Gutmann, and Kettenmann 2016)), however they were distinct to 
the nestin positive cells, and more associated with the tumour cell compartment (Figure 3.18B, C). 
The nestin positive blood vessels were negative for the differentiated cancer cell and astrocyte marker 
GFAP (Figure 3.18D) but positive for the smooth muscle cell (SMA) and pericyte markers a-SMA and 
PDGFRß (Figure 3.18C, D). Further, the nestin positive perivascular cells were proliferative as 
evidenced by positivity for the proliferation marker Ki67 (Figure 3.18B).  Analysis of tumour blood 
vessels from the 5 selected GBM tumours showed different degrees of nestin and a-SMA positivity 
that has been summarised on Table 3.2. The data show that in 3/5 GBM samples there was a positive 
correlation between nestin and a-SMA expression in agreement with the IF analysis. 
 
Increase in blood vessel size may result from blood vessel dilation following detachment of pericytes 
in response to the action of angiogenic growth factors, or blood vessel development and maturation 
(Nagy et al. 2009). Given GBM blood vessels showed increased coverage by a-SMA cells, particularly 
in recurrences, I investigated whether this was related to the larger blood vessel calibre observed in 
GBM and in recurrent tumours (Figures 3.13 and 3.14 showing blood vessel diameters in recurrent 
Leeds and Imperial samples). Figure 20 shows that there was a positive correlation between blood 
vessel size and coverage by a-SMA positive cells.   Altogether, this larger vessel size and coverage by 
a-SMA positive cells suggests that the aberrant, strongly nestin positive blood vessels in GBM 
represent mature and stable blood vessels. 
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Based on the finding that most nestin positive blood vessels also stained positive for SMA and PDGFRß, 
I hypothesised that nestin expressing cells are the same as a-SMA and PDGFRß expressing cells in the 
tumour blood vessels. Accordingly, I took tissue samples from previously selected GBM tumours and 
stained for combinations of different markers such as Nestin, a-SMA, PDGFRß and CD31 by IF. The 
stainings showed co-expression of nestin and a-SMA, and also co-expression of nestin and PDGFRß; 
however, the a-SMA cells were distinct from CD31 cells (Figure 3.19A) as seen in Nestin/CD31 staining 
(Figure 3.17). In order to quantify a-SMA expression I used a scoring system shown in Figure 3.19B. 
When I quantified SMA expression in respect with different morphologies, I found that Nestin +ve and 
Glomeruloid morphologies had significantly higher proportion of SMA positivity compared to normal-
like morphologies (Figure 3.19C). This indicated that the nestin positive tumour blood vessels are 
distinct from cancer stem cells, immune cells, astrocytes or ECs, but represent pericytes and SMCs.  
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Figure 3.18 Nestin positive GBM blood vessels are negative for the stem cell markers OLIG2 and 
SOX2 and immune cell markers, but positive for the pericyte and smooth muscle cell (SMC) 
markers PDGFRb and a-SMA 
Sections from patient GBM (GBM20R) were stained for Nestin, SOX2, OLIG2 and CD31 (A); Nestin, 
CD31, Ki67 and CD45 (B); CD31, a-SMA and CD68 (C); and PDGFRb and GFAP (D).  Red arrows point to 
blood vessels with lack of positivity for the markers SOX2, OLIG2, CD68 and GFAP in different antibody 
markers in panels A, C and D; and Ki67 positivity in B. Scale bar, 100µm.  
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Figure 3.19 Nestin positive perivascular cells express high a-SMA and PDGFRb  
(A) Images show expression of a-SMA and PDGFRb in Nestin +ve blood vessels by IF (GBM20). 
(B) Images depict weak, moderate and strong a-SMA levels by IHC staining. Moderate and strong 
expression were considered as High SMA in (C).  
(C) Expression of a-SMA in blood vessels with different morphologies as defined by their nestin 
positivity. Blood vessels in GBM samples GBM13, GBM16, GBM36, GBM13R, GBM14R, GBM20R, 
GBM37, GBM30R and GBM39 were scored based on the intensity of a-SMA expression on parallel 
sections as shown in (B). Each dot represents the average percentage of blood vessels with high a-
SMA expression in a tumour. The number of areas and blood vessels scored are shown in Appendix 3. 
Samples with £3 blood vessels per 1mm2 for a particular morphology were excluded from the scoring. 
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Table 3.2 Expression of Nestin, OLIG2 SOX2 and a-SMA in GBM patient samples 
 
 
Five GBM (GBM16 and GBM36 primary; and GBM13, GBM14 and GBM20 recurrent) patient samples 
were serially sectioned and stained for their expression of stem cell markers (Nestin, SOX2 and 
OLIG2), and pericyte/SMCs marker a-SMA.  A total of 310 blood vessels were analysed and the 
expression was scored as indicated in Figure 3.19B.  P, Primary and R, recurrent tumours.  
 
 
 
 
GBM16P GBM36P GBM13R GBM14R GBM20R
Total blood vessel count 82 123 34 48 23
Number of Nestin +ve vessels count 52 56 21 19 22
% of Nestin +ve blood vessels 63 46 62 40 96
Number of SOX2 +ve vessels count 0 0 0 0 0
% of SOX2 +ve vessels 0 0 0 0 0
Number of OLIG2 +ve vessels count 0 0 0 0 0
% of OLIG2 +ve vessels 0 0 0 0 0
Number of a-SMA +ve vessels count 49 29 25 40 18
% of a-SMA +ve vessels 60 24 74 83 78
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Figure 3.20 Association of blood vessel lumen size with levels of a-SMA expression 
The percentage of blood vessels with high a-SMA positivity is shown with corresponding blood vessel 
diameters <50 µm (N=152), 51-100 µm (N=230), 101-150 µm (N=150), 151-200 µm (N=96), 201-250 
µm (N=100), 251-300 µm (N=26), 301-350 µm (N=51), 351-400 µm(N=2), >400 µm (N=4) were 
counted from a total of 9 GBM patient samples (GBM13P, GBM16P, GBM36P, GBM37P, GBM39P, 
GBM13R, GBM14R, GBM20R and GBM30R). A total of 6 x 1mm2 areas per each tumour sample was 
analysed except in GBM30R where only 5 of such areas were available. The percentage blood vessels 
with high a-SMA expression was plotted against the blood vessel diameters. Note the significant 
correlation between blood vessel size and a-SMA positivity. Each dot represents the percentage of 
blood vessels with high a-SMA expression for the respective blood vessel diameter range. R, 
Spearman's rank correlation coefficient. P, Primary and R, Recurrent tumour. P value, statistical 
significance. 
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3.11 Nestin positive blood vessels and glomeruloids are situated close to areas of necrosis 
One way of defining distinct areas within the heterogenous GBM tumours is through reference to the 
tumour edge and tumour core. Kim and co-workers showed that tumour cells at the edge of tumours 
are viable and highly invasive through expression of MMPs, while the core is characterised by 
widespread areas of necrosis (Kim et al. 2011). Scoring of blood vessels within the 5 selected tumours 
for their proximity to tumour necrosis showed that the single perivascular blood vessels were mainly 
located away from areas of necrosis (Figure 3.21A, B). Separate analysis of these samples as primary 
and recurrent showed that in primary tumours normal-like blood vessels are located away from areas 
of necrosis, whereas abnormal nestin positive vessels are situated close to areas of necrosis (Figure 
3.21C).  On the other hand, a significantly higher proportion of nestin positive blood vessels were 
associated with necrotic regions in the recurrent tumours (Figure 3.21D).   
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Figure 3.21 Proximity of blood vessels with different morphologies to necrotic regions  
Blood vessels with different morphologies were scored based on their proximity (100 µm) to areas of 
necrosis. 
(A) Images depict Nestin +ve and Nestin -ve blood vessels close to necrosis (left-hand panel), and 
within viable tumour areas (right-hand panel). Scale bar, 100 µm. 
(B) Quantification of blood vessel morphologies according to their proximity to areas of necrosis 
shown as percentage total blood vessels ± SD (N=number of 1mm2 areas analysed in 5 tumours). 
(C) As in (B) for the primary tumours only (2 tumours). 
(D) As in (B) for the recurrent tumours only (3 tumours). 
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3.12 Recurrent tumours are more hypoxic than primary GBM tumours 
The observation that nestin positive blood vessels were associated with areas of necrosis raised the 
question whether they contributed to hypoxia and necrosis, or protected cancer cells from cell death.  
GBM is characterised by widespread hypoxia (Kaur et al. 2005). In order to investigate whether the 
presence of hypoxia is associated with particular blood vessel morphologies, I stained the 5 tumour 
cohort for the hypoxia marker CAIX (Wykoff et al. 2000) and used the  scoring shown in Figure 3.22A 
to assign negative, weak, moderate or strong hypoxia levels to cancer cells around blood vessels. First, 
quantification showed overall higher hypoxia in recurrent tumours compared to primary tumours 
(Figure 3.22B). Next, I investigated the potential association of hypoxia with blood vessel type and 
lumen size in the recurrent tumours. Strikingly, I found low hypoxia levels around blood vessels with 
SMA positivity suggesting that these vessels are functional (Figure 3.23 and 3.24A), whereas blood 
vessels with normal-like morphologies were associated with higher levels of hypoxia (Figure 3.24B). 
To summarise, recurrent tumours appeared more hypoxic than primary tumours. Within recurrent 
tumours Normal-like blood vessel morphologies which are mostly small in size, are more hypoxic 
compared to large size Nestin +ve and Glomeruloid blood vessels.  
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Figure 3.22 Hypoxia levels are higher in recurrent tumours compared to primary tumours 
(A) Images depict intensities of CAIX staining  
(B) Histogram shows the scoring of hypoxia in cancer cells around immediate proximity of blood 
vessels. N= number of blood vessels per 1mm2 area ± SD (GBM16, 40; GBM36, 75; GBM13R, 36; 
GBM14R, 12 and GBM20R, 34) *<0.05 and ***<0.001.  
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Figure 3.23 Nestin +ve blood vessels are less hypoxic than Normal-like blood vessels in recurrences  
CAIX  and  a-SMA staining of recurrent GBM tumour samples show that a-SMA positive blood vessels 
have less hypoxia around them (left-hand panels), while occluded or normal-like blood vessels had 
the highest hypoxia around them (right-hand panels). Scale bar, 100 µm. 
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Figure 3.24 Serial sections of GBM samples stained for Nestin/CD31 and CAIX/SMA and 
quantification of association with normoxia and hypoxia 
(A) Double immunostaining of serial sections of recurrent patient GBM tumour tissue samples using 
Nestin/CD31 and CAIX/SMA. Note low levels of hypoxia around nestin +ve blood vessels and 
glomeruloids. Scale bar, 100µm. 
(B) Histogram shows quantification of blood vessel morphologies in normoxic and hypoxic tumour 
areas surrounding blood vessels (100 µm) as percentage total blood vessels ±SD in the 3 recurrent 
GBMs (GBM13, GBM14 and GBM20) of the 5 selected tumour cohort. *<0.05. 
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3.13 Conclusions 
The analysis of blood vessel morphologies in this chapter identified 5 different blood vessel 
morphological types in patient-derived GBM samples based on expression of the stem cell marker 
nestin and endothelial cell marker CD31. While the blood vessel types Normal-like, Single-perivascular 
and Multi-perivascular were also detected in the normal brain, Nestin +ve and Glomeruloid (nestin –
ve and nestin +ve) blood vessel morphologies were only found in GBM samples. Notably, the majority 
of glomeruloid blood vessels were nestin positive, making nestin positivity a hallmark of aberrant GBM 
blood vessels. The analysis shows that overall, at the point of first surgery which is normally close to 
the time of diagnosis, blood vessel morphologies are heterogenous and normal-like morphologies 
prevail. However, when primary and recurrent patient samples were compared, the aberrant 
morphologies increased significantly and in 11 out of 15 paired samples analysed those were more 
abundant than the normal-like morphologies. In addition to morphology, the analysis showed that 
blood size was also heterogeneous in patient samples. Consistent with the increase in the abundance 
of highly nestin positive and glomeruloid blood vessels in recurrent tumours, abnormal blood vessel 
size also increased in recurrence. Altogether, the analyses show high nestin positivity is a key feature 
of GBM.  Interestingly, I also found that as tumours recurred the microvascular density (MVD) 
decreased, pointing to dominance of a fewer number of blood vessels with larger calibre in recurrent 
tumours.  
 
Previous studies had shown that cancer cells can line the lumen of GBM tumour blood vessels, a 
phenomenon resembling vasculogenic mimicry in melanoma (Maniotis et al. 1999; Wang et al. 2013 
and Francescone et al. 2012), or following transdifferentiation of cancer stem cells to endothelial cells 
(Ricci-Vitiani et al. 2010 and Soda et al. 2011). CD31 staining of tumours showed uninterrupted 
coverage of blood vessels showing that unlike melanoma, GBM blood vessels are only lined by CD31 
positive endothelial cells. In almost all GBM tissue samples analysed blood vessels consistently 
maintained their intact CD31 positivity. Further, the strongly nestin positive blood vessels initially 
observed by means of nestin/CD31 double immunostaining, were also entirely covered by intact CD31 
positive cells, while the use of double immunofluorescence showed that CD31 positive ECs were 
distinct to nestin positive peri-vascular cells, as there was no co-localisation or co-expression of nestin 
and CD31 by IF. When I further stained the GBM tissues for additional cancer cell markers (SOX2 and 
OLIG2) that were expressed abundantly in the tumour cell compartment, those were not expressed 
by the perivascular nestin positive cells, which were also negative for immune cell markers CD45 and 
CD68. However, the nestin positive cells were positive for pericyte and smooth muscle cell markers a-
SMA and PDGFRb. 
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Altogether, the pericyte/SMCs coverage together with the larger vessel calibre and changes in MVD 
identified through the analysis of primary and recurrent tumours indicates that there is a variable 
proportion of stable and mature blood vessels in primary patient tumours accounting for 28% (0 -82%) 
of total GBM vessel morphologies that increased with tumour recurrence to 39% (9-86%). Notably, 
glomeruloids, scored as single entities here, have a much wider area coverage, and therefore 
represent a significant proportion of the tumour vasculature as seen in Figures 3.1 and 3.4.   Scoring 
for the proximity of nestin positive blood vessels and glomeruloids to areas of necrosis and hypoxia 
showed they are associated with areas of necrosis. On the other hand, there was a higher proportion 
of nestin positive and glomeruloid blood vessels associated with normoxia in the tumour cell 
compartment surrounding the blood vessels compared to normal-like vessels. Strikingly, there was 
widespread hypoxia associated with normal-like blood vessels in recurrent tumours. There are high 
levels of VEGF expression in GBM (Wang, Zhang, et al. 2016). Tumour cells at the edge of tumours are 
viable and highly invasive, and capable of moving to the normal brain parenchyma where they co-opt 
new blood vessels. Dvorak and co-workers have shown that established blood vessels in experimental 
models respond to high levels of VEGF first by dilation, which leads to the development of unstable 
vessel structures termed mother vessels (Nagy et al. 2009). This is followed either by vessel maturation 
and recruitment of SMCs, or formation of glomeruloid structures which were also reported to be 
immature and unstable. The inability of normal-like blood vessels in GBM to support normoxia 
suggests that they represent mother vessels. And that maturation to the Nestin/a-SMA positive 
aberrant vessels is necessary to support tumour growth.    
 
Overall, this study shows that the nestin positive cells surrounding blood vessels in GBM have smooth 
muscle cell characteristics, namely a-SMA expression and tight association with larger calibre blood 
vessels. Particularly, the larger the blood vessels the higher the a-SMA positivity, consistent with a 
more mature and stable phenotype.  
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Chapter 4 
 
The role of DOCK4 in blood vessel growth 
and tumour progression in GBM and in 
radiation therapy 
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4.1 Introduction 
One characteristic feature of the glioblastoma vasculature observed in the patient-derived GBM 
samples was their large size and abnormal coverage by nestin positive pericyte/smooth muscle cells. 
Tumour blood vessel lumen size increased in recurrent patient GBM tumour samples compared to 
primary samples. The aberrant vasculatures of the tumour support the development of hypoxia 
(Brown and Giaccia 1998) which is thought to contribute to radiotherapy resistance through 
stabilisation of HIF-1a (Marampon et al. 2014 and Moeller et al. 2004). It has been proposed that 
normalisation of tumour blood vessels through inhibition of the molecular regulators of abnormal 
vascularisation can improve therapy (Goel et al. 2011). A key driver of abnormal blood vessel 
formation in tumours including glioblastoma and target of HIF-1 is the proangiogenic factor VEGF 
which controls development of new blood vessels (Aonuma et al. 1999). Previous work in our 
laboratory has shown that downstream of VEGF signaling by the Rac1 exchange factor DOCK4 is 
important for blood vessel growth (Abraham et al. 2015). Global heterozygous deletion of Dock4 
reduced blood vessel lumen size in EO771 tumours (a model of breast cancer brain metastases) 
growing intracranially in mice (Abraham et al. 2015). Hence, I hypothesised that Dock4 deletion could 
normalise tumour blood vessels and potentially improve radiotherapy in GBM, which I set out to test 
in the heterozygous Dock4 knockout model since homozygous deletion is embryonic lethal (Abraham 
et al. 2015). 
 
Two syngeneic tumour models were compared for these studies, as patient-derived GBM tumours 
don not grow in immunocompetent mice: GL261 (Szatmari et al. 2006) and CT2A (Martinez-Murillo 
and Martinez 2007) are the two most commonly used syngeneic tumour models in pre-clinical studies. 
Tumour cells were expanded in culture, trypsinised and injected into the striatum of the right brain 
hemisphere, and mice were monitored for tumour growth using IVIS and neurological symptoms. The 
tumour tissue samples were fixed in 4% PFA, paraffin embedded, sectioned and stained for analysis. 
Analysis showed that CT2A tumour growth resembled more that of patient GBM compared to GL261 
tumours as cancer cells readily co-opted blood vessels in the tumour periphery, and therefore the 
CT2A tumour model was used in the subsequent in vivo experiments. The increase in blood vessel 
abnormality seen in recurrent tumours was following treatment of patients with radiotherapy and 
temozolomide chemotherapy. In order to investigate the potential contribution of radiotherapy in the 
development of aberrant blood vessel morphologies, tumour bearing mice were irradiated using the 
X-Ray irradiator or the small animal radiation research platform (SARRP) which delivers radiation 
accurately and specifically to the tumour mass. Blood vessel lumen size was analysed in wild type and 
Dock4 heterozygous knockout mice in the presence or absence of irradiation. Further, lumen size 
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analyses were carried at different stages of tumour growth post irradiation. Finally, a Dock4 
conditional knockout mouse line was bred to homozygosity and endothelial-specific Dock4 deletion 
and a pilot experiment was conducted using these mice. 
 
4.2 Establishing an experimental tumour model which recapitulates patient glioblastoma growth 
in vivo 
In order to elucidate the role of DOCK4 in the glioblastoma tumour vasculature I started experiments 
using two commonly employed mouse glioblastoma tumour models; CT2A and GL261. I found that 
while GL261 tumours have a more of restricted and circumscribed edge, CT2A tumours are more 
infiltrative with cancer cells co-opting blood vessels in the surrounding normal brain parenchyma, a 
trait not observed extensively in the GL261 tumour model (Figure 4.1A). In addition, while 
Haematoxylin and Eosin (H&E) staining of GL261 tumours showed a large number of vacuole-like 
empty spaces the CT2A tumour tissue appeared dense and largely similar to patient GBM tumour 
samples. Specifically, when sections of CT2A tumour tissues were stained for endothelial cell marker 
CD31 blood vessels with smaller lumen size were observed in the Dock4 het mice compared to WT 
control mice (Figure 4.1B). Vessel co-option mechanism is one of characteristic features of 
glioblastoma tumours (Holash et al. 1999) and hence I decided to take forward CT2A as chosen tumour 
model for further in vivo experiments.  
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Figure 4.1 The growth patterns of GL261 and CT2A mouse glioma cell lines in vivo 
GL261 and CT2A tumour cells (4x104 and 1x105 respectively) were injected intracranially into the 
striatum of C57BL/6 wild type and Dock4 heterozygous knockout mice.  
(A) H&E staining of CT2A and GL261 tumours. Arrows point to blood vessels. Note the invasive edge 
of CT2A tumours and co-option of blood vessels (top arrow) compared to circumscribed periphery of 
GL261 tumours. Scale bar, 100 µm.  
(B) CD31 staining of CT2A tumours grown in wild type (WT) or Dock4 heterozygous (het) mice.  Red 
arrows point to large blood vessels in WT control CT2A tumour sample and green arrows point to 
smaller diameter blood vessels in Dock4 heterozygous mice. Scale bar, 50 µm. 
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4.3 Optimisation of radiotherapy in the CT2A tumour model using SARRP 
Previous in vivo experiments have used clinically relevant doses of ionising radiation, ranging from 
4Gy to 30Gy, to treat different glioblastoma tumour models in mice. For example Newcomb and co-
workers (Newcomb et al. 2010) and Yadav and co-workers (Yadav et al. 2016) showed inhibition of 
glioblastoma tumour growth when delivering total doses of 8Gy over two days (4Gy/day) and 20Gy 
over 10 days (2Gy/day) respectively. In this study, initially I compared doses of 10Gy and 15Gy 
delivered at 2Gy/day and 5Gy/day, respectively. CT2A tumour cells were injected intracranially and 
after one week following implantation, mice were irradiated using a small animal radiation research 
platform (SARRP) available in our Institute. SARRP enables researchers to image the animal using Cone 
beam-CT, contour tumour and organs at risk, calculate and deliver the desired dose with an accuracy 
equivalent to the current clinical radiotherapy used in patients.  All the mice were sacrificed following 
the onset of neurological symptoms in control mice.  
 
H&E staining of tumour samples showed a significant reduction of tumour mass with irradiation 
(Figure 4.2).  None of the mice showed any signs of toxicity following irradiation at either 10Gy or 
15Gy. There was a smaller tumour mass remaining with a dose of 15Gy compared to 10Gy, with a 
dose of 15Gy ablating almost all tumour growth (Figure 4.2). Interestingly, at a higher magnification, I 
could observe small colonies of cancer cells around blood vessels with visible lumens in irradiated 
tumours which were more prominent at 15Gy. Following this finding I decided to use a 10Gy 
irradiation regime in experiments with combination of Dock4 deletion, in order to be able to assess 
the contribution of Dock4 in residual tumour growth.  
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Figure 4.2 Comparison of 10Gy and 15Gy radiation doses in CT2A tumours  
CT2A cells (1x105) were injected intracranially into the striatum of C57BL/6 wild type and two different 
doses of targeted irradiation were applied using SARRP (3mm x 9mm collimator). 2Gy/day for 5 
consecutive days (total 10Gy) or 5Gy/day for 3 consecutive days (total 15Gy).  Mice were sacrificed 
upon development of neurological symptoms in control mice. Tumour tissue samples were embedded 
in paraffin and sectioned using a microtome. Images show haematoxylin and eosin (H&E) staining of 
4 µm tumour sections.  
Top panels: Microscopic images at 1x magnification show tumour lesions in different groups (dotted 
red circles).  
Bottom panels: Enlarged images of boxed areas in top images. The images are representative of 
different tumours for each condition: Control, 5; 10Gy, 4; 15Gy, 4). 
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4.4 The effect of heterozygous Dock4 deletion on the efficacy of radiotherapy  
Next, I investigated whether Dock4 heterozygous deletion could contribute to the efficacy of 
irradiation. CT2A-luc cells stably expressing luciferase were injected intracranially in wild type (WT) 
and Dock4 heterozygous mice. Mice were randomised based on their IVIS reading just before therapy. 
As the number of male Dock4 mice available for this experiment were not enough two female mice 
were added to the Dock4 het control group as this was the only cohort available at that point of 
breeding (Appendix 4). Further, because SARRP was not available I used a whole brain irradiation using 
RAD X-Ray irradiator. Tumour growth was regularly monitored up to 21 days post intracranial 
implantation using IVIS after subcutaneous injection of luciferin in order to image the growth of 
intracranially injected luciferase labelled CT2A cancer cells using non-invasive IVIS bioluminescence 
imaging (Figure 4A). Figure 4B shows a significant reduction of tumour growth in irradiated WT mice 
compared to WT control mice (p=0.003).  
 
Similarly, tumour growth was significantly reduced in irradiated Dock4 het compared to Dock4 het 
control (p<0.0001). However, there was no significant difference between WT irradiated and Dock4 
irradiated mice (p=0.98). Surprisingly, the growth of tumour in wild type control appeared decreased 
compared to Dock4 het control on day 20 (p=0.005). However, this was due to the use of mixed sex in 
the Dock4 het group, as the female mice had faster tumour growth compared to the male mice (Figure 
4.3B) compared to the male mice at days 17 (p<0.0001) and 20 (p=0.0001) post intracranial injection. 
Overall, while there was significant difference between the growth of control and irradiated mice, 
there was no difference between WT and Dock4 het mice, under control or irradiation conditions in 
this experiment. 
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Figure 4.3 CT2A tumour growth in C57BL/6J wild type and Dock4 heterozygous mice treated with 
an irradiation dose of 15Gy 
CT2A-Luc tumour cells (1x105) were injected intracranially into the striatum of C57BL/6 wild type and 
Dock4 heterozygous mice. Tumour growth was monitored by IVIS and after 9 days radiation (5Gy) was 
delivered for 3 consecutive days using the RAD X-Ray irradiator. 
(A) Schematic diagram of irradiation schedule and time of excision. WT (N=3) and Dock4 het mice 
(N=4) received a total of 15Gy (5Gy/day) whole brain irradiation using RAD X-Ray irradiator. Mice were 
sacrificed at 21 days post intracranial injection following development of neurological symptoms in 
the first mouse. 
(B) Graphs depict tumour growth determined by IVIS bioluminescence photons count. Left-hand graph 
shows the growth of the entire cohort with mixed sex for Dock4 het control: WT control (male), Dock4 
control (2 males and 2 females), WT 15Gy (male) and Dock4 het 15Gy (male).  Right-hand graph shows 
separately the growth of the 2 male and 2 female Dock4 het mice. Note that following imaging, one 
WT control and one WT irradiated mouse were excluded from analysis due to their IVIS reading signal 
remaining low. 
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Having an excellent capability for detecting differences in soft tissue, MRI is widely used for diagnosis 
and the evaluation of the effects of therapy in brain tumours (McKnight 2004). Hence, in addition to 
IVIS imaging mice were scanned using the M7 Compact MRI available in our unit for the detection of 
brain tumours. The results of MR imaging were compared to gross observation and 
immunohistochemical analysis of tumour samples. Since there were some sex dependent effects on 
tumour growth identified by IVIS (Figure 4.3), male mice were chosen for MR scanning on Day 20 post 
tumour implantation. Those mice were subsequently sacrificed by terminal perfusion (Day 21), and 
gross lesions identified were compared with the MR scanned images. The MRI imaging showed that 
control mice (wild type and Dock4 het) had significantly larger tumour volumes compared to irradiated 
mice both by MRI and gross observation of macroscopic lesions (Figure 4.4). These data show clear 
corroboration between MRI and macroscopic findings. When mice were taken down on Day 21 
following tumour implantation 7/8 control mice had developed neurological symptoms. However, 
none of the mice from the irradiated group had shown neurological symptoms at this timepoint 
(Appendix 4). 
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Figure 4.4 MR images of CT2A tumours growing in control and Dock4 heterozygous mice and 
corresponding gross lesions following terminal perfusion 
CT2A-Luc tumour cells (1x105) injected intracranially into the striatum of wild type and Dock4 
heterozygous mice were monitored by IVIS and after 9 days radiation (5Gy) was delivered for 3 
consecutive days using the RAD X-Ray irradiator. Male mice with comparable IVIS readings on Day 9 
were scanned coronally using M7 Compact Magnetic Resonance Imaging (MRI). Aspect imaging 
software was used to capture T2-Weighted MR images. 
(A) Images show MR scans of control and irradiated tumours growing intracranially in wild type (WT) 
or Dock4 heterozygous (het) mice at 20 days post implantation. Presence of tumour is indicated as a 
white mass (dotted red circles).  
(B) Images show gross macroscopic lesions (red arrows) in the same mice following terminal perfusion 
at 21 days post implantation. Note lack of tumour mass in the irradiated Dock4 het by both MRI and 
gross lesion observation.  
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Following tumour growth analysis by IVIS, MRI and gross lesion observation I sought to investigate 
tumour growth at the microscopic level. Tumour sections were compared following H&E staining 
(Figure 4.5). Overall, ionising irradiation reduced tumour volume significantly in accordance with the 
IVIS reading, MRI and macroscopic observation. However, there was no significant difference between 
the tumours growing in wild type and Dock4 heterozygous mice (Figure 4.5). 
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Figure 4.5 Immunohistochemical analysis of CT2A tumours growing in control and Dock4 het mice 
treated with an irradiation dose of 15Gy 
Brain tissue samples from control and irradiated tumours growing in wild type (WT) or Dock4 
heterozygous (het) mice were excised and paraffin embedded, sectioned at 4 µm thickness and H&E 
stained. Images depict two larger representative tumour mass (red dotted circles) from each group. 
Note that tumours shown were grown in male mice except for the control Dock4 het tumours which 
were from one male and one female mouse. Red dotted circles indicate tumour mass in each 
representative sample. 
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4.5 The effect of radiotherapy and heterozygous Dock4 deletion on blood vessel growth and 
lumenisation 
Pilot immunohistochemical analysis of CT2A tumours suggested that the blood vessels of tumours 
growing in the Dock4 het mice may have smaller lumens compared to blood vessels in tumours 
growing in wild type mice. This observation is similar to that previously reported for EO771 intracranial 
tumours, a model of breast cancer brain metastases.  I therefore set out to quantify blood vessel 
lumen size in these tumours as described in Materials and Methods Section 2.3.8. A total of 749 blood 
vessels were analysed in the 4 groups, of which 235 had a confidently detectable lumen (³ 10 µm).  
 
Analysis showed that there was a trend of somewhat reduced number of blood vessels with 
heterozygous Dock4 deletion both in the presence and absence of radiation, although this was not 
statistically significant (Figure 4.6 B&C). The percentage of lumenised vessels was increased in 
response to irradiation from 28.1% and 24.7% to 34.5% and 34.6% in the wild type and Dock4 het 
groups, respectively (Figure 4.7A). Furthermore, analysis showed that there was no difference in 
tumour blood vessel lumen size between tumours growing in wild type (average lumen diameter 
17.7µm) and Dock4 heterozygous mice (average lumen diameter 18.3) as shown in Figure 4.7B. 
Surprisingly, there was a trend for increased lumen size in response to irradiation (average lumen 
diameter 20.19 µm) in tumours growing in wild type mice, which was not statistically significant 
compared to controls (p=0.6). One probable reason for lack of a significant difference between control 
and irradiated groups could be due to the fact that relatively smaller sized tumours were analysed in 
the irradiated mice as they were sacrificed before developing neurological symptoms. This trend was 
reversed with Dock4 heterozygous deletion, as larger diameter lumens (>40 mm) observed in 
irradiated wild type tumours were not observed in the irradiated heterozygous Dock4 deletion group 
(Figure 4.7B).  
 
In summary, 3 out of 4 Dock4 het mice developed tumour following irradiation and 3 out of 5 mice 
had a tumour in WT irradiated mice. It is possible that the high irradiation dose ablates tumour growth 
in both WT and Dock4 het mice and as a result the effect of heterozygous Dock4 deletion were masked 
(Appendix 4). Alternatively, tumour growth inhibition in response to irradiation delivered by the X-
RAD was suboptimal. Hence, I decided to use a sub-curative radiation dose (10Gy) in the next 
experiments delivered by SARRP in order to understand whether Dock4 deletion improves the effect 
of radiotherapy.  
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Figure 4.6 Analysis of blood vessel growth in CT2A tumours growing in control and Dock4 
heterozygous mice treated with irradiation 
Brain tissue samples from control and irradiated tumours growing in wild type (WT) or Dock4 
heterozygous (het) mice were sectioned at 4µm thickness, stained for CD31 and haematoxylin 
counterstained. The slides were scanned and blood vessel growth and lumenisation were quantified 
as described in Materials and Methods. A total of 235 blood vessels with lumen from 17 0.5x0.5mm2 
boxes were analysed (Appendix 2). 
(A) Experimental schedule of intracranial implantation, irradiation and tumour excision. 
(B)  Representative images show increased tumour blood vessel lumen size and number of 
lumenised vessels in WT and Dock4 het mice in absence or presence of ionising radiation. Note more 
lumenised vessels in irradiated tumours compared to control and large lumen size blood vessels in 
irradiated WT mice. 
(C) Graph shows total vessel count per 0.25 mm2 area ± SD, N= number of 0.25 mm2 area (WT 
control,4; Dock4 het control, 4; WT 15Gy, 3; and Dock4 het 15Gy, 3). 
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Figure 4.7 Analysis of blood vessel lumenisation in CT2A tumours growing in control and Dock4 
heterozygous mice treated with irradiation 
Brain tissue samples from control and irradiated tumours growing in wild type (WT) or Dock4 
heterozygous (het) mice were sectioned at 4µm thickness, stained for CD31 and H&E counterstained. 
The slides were scanned and blood vessel growth and lumenisation were quantified as described in 
Materials and Methods. A total of 235 blood vessels with lumen from 17 0.5x0.5mm2 boxes were 
analysed (Appendix 4). 
(A) Graph shows percentage lumenised blood vessels (³ 10 µm) ± SD, N= number of 0.5x0.5mm2 areas 
(WT control, 4; Dock4 het control, 5; WT 15Gy, 3 and Dock4 het 15Gy, 3). 
(B) Graph shows blood vessel lumen size ± SD, N= number of blood vessels with lumen (WT control, 
72; Dock4 het control, 56; WT 15Gy, 59 and Dock4 het 15Gy, 47). 
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4.6 The effect of heterozygous Dock4 deletion on the efficacy of irradiation delivered by SARRP 
Previously an irradiation dose of 10Gy had been shown to reduce but not ablate tumour growth 
(Kegelman et al. 2017 and Zhang et al. 2017). In an irradiation experiment carried out using SARRP a 
total of 52 female mice were injected 1x105 CT2A-luc cells intracranially into the striatum of the right 
hemisphere of the brain. Mice were sacrificed at two different timepoints: early, at 11 days post 
tumour implantation; and late, upon development of neurological symptoms (Figure 4.8A). Tumour 
growth was assessed using bioluminescence IVIS imaging and measurements showed a strong tumour 
growth signal in control mice and weak signal in irradiated mice. In agreement with the IVIS reading 
tumours in control mice showed a bigger tumour volume on MRI scans when compared with 
irradiated mice. Irradiation significantly reduced tumour growth (p<0.0001) in both WT treated and 
Dock4 treated mice compared to control groups (Figure 4.8B). I then looked into the effect of 
irradiation on overall survival and whether combination of heterozygous Dock4 deletion and 
radiotherapy improved survival. Although there was significant increase (p<0.0001) in survival for 
mice that received radiotherapy (Figure 4.8C), there was no significant difference between control WT 
and Dock4 het or between the two irradiated groups. Tumour growth appeared somewhat increased 
in Dock4 het mice compared to WT controls, however, this was not statistically significant. These 
results showed lack of an overall benefit from global heterozygous Dock4 deletion pertaining to 
survival following lower irradiation dose delivered by SARRP. 
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CT2A tumour growth and survival in wild type and Dock4 heterozygous mice treated with an 
irradiation dose of 10Gy delivered by SARRP  
CT2A-Luc tumour cells (1x105) were injected intracranially into the striatum of C57BL/6J wild type and 
Dock4 heterozygous mice. Tumour growth was monitored by IVIS and after 7 days radiation (5Gy) was 
delivered for 2 consecutive days using SARRP. 
 (A) Experimental schedule for early and late excision of CT2A tumours. WT control mice (N=6), Dock4 
het control mice (N=9), WT mice received 10Gy (N=3) and Dock4 het mice received 10Gy (N=9) whole 
brain irradiation using SARRP. Mice were sacrificed at two points: early, Day 11 post tumour 
implantation and late, upon development of neurological symptoms.  
(B) Growth curve - Graphs depict tumour growth determined by IVIS bioluminescence signal intensity 
from late timepoint analysis. N= number of mice (WT control, 6; Dock4 control, 9; WT 15Gy, 3 and 
Dock4 het 15Gy, 9).   
(C) Survival curve – the graph shows number of mice sacrificed following development of 
 neurological symptoms and overall survival were analysed per group. N=number of mice (WT control, 
6; Dock4 control, 9; WT 15Gy, 3 and Dock4 het 15Gy, 9). 
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Figure 4.9 IVIS and MR imaging of CT2A tumours growing in control and Dock4 heterozygous mice 
treated with an irradiation dose of 10Gy delivered by SARRP  
CT2A-Luc tumour cells (1x105) injected intracranially into the striatum of wild type and Dock4 
heterozygous mice were monitored by IVIS and after 7 days radiation (5Gy) was delivered for 2 
consecutive days using SARRP. Three mice/group which had a maximum IVIS reading on Day 18 post 
tumour implantation were scanned coronally using M7 Compact Magnetic Resonance Imaging (MRI). 
Aspect imaging software was used to capture T2-Weighted MR images. 
(A) A total of 52 mice were grouped into 4 groups; 26 mice (13 WT and 13 Dock4 het) received a total 
of 10Gy whole brain irradiation dose over two consecutive days (D7 and D8 post implantation) using 
SARRP and 26 mice (13 WT and 13 Dock4 het) were control. Tumour growth was assessed regularly 
using bioluminescence IVIS imaging following subcutaneous injection of luciferin. 
(B) Images show MR scans of control and irradiated tumours growing intracranially in wild type (WT) 
or Dock4 heterozygous (het) mice at 18 days post implantation. Presence of tumour is indicated as a 
white mass (dotted red circles).  
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4.7 The effect of low dose radiotherapy and heterozygous Dock4 deletion on blood vessel growth 
and lumenisation early after irradiation delivered by SARRP 
I sought to examine the effects of irradiation on the tumour vasculature first at an early timepoint 
following treatment, 3 days after irradiation. For this analysis brain tumours from 12 mice (3 mice per 
group) were excised on D11 following intracranial implantation (Figure 4.10A). Staining of available 
CT2A tumour samples (Appendix 5) with CD31 showed the presence of blood vessels with smaller 
lumen size in irradiated tumours compared to controls (Figure 4.10B). The total number of vessels 
count per 0.25mm2 area significantly increased in WT irradiated tumours compared to WT control  
and decreased in Dock4 het irradiated compared to WT irradiated (Figure 4.10C). Interestingly, 
heterozygous Dock4 deletion significantly decreased the abundance of lumenised blood vessels in the 
presence of irradiation but not in its absence (Figure 4.11A).  Blood vessel lumen size was significantly 
decreased with Dock4 deletion, and further more in the presence of irradiation (Figure 4.11B). Hence, 
combination of radiotherapy and heterozygous Dock4 decreased the overall number of lumenised 
blood vessels and the average lumen size. Altogether, the analysis of the vasculature early after 
irradiation showed effects on the percentage of blood vessels with detectable lumens which was more 
pronounced in tumours with Dock4 heterozygous deletion. However, Dock4 deletion did not affect 
tumour growth either in the absence, or presence of irradiation. Analysis of the late tumour samples, 
by A. Widiyadari, showed a significantly increased lumen size in WT mice following irradiation 
(Appendix 6). These opposing effects of irradiation on the vasculature at earlier and later timepoints 
may account for the absence of measurable differences in overall survival between tumours growing 
in wild type and Dock4 heterozygous mice.  
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Figure 4.10 Analysis of blood vessel growth of CT2A tumours growing in control and Dock4 
heterozygous mice treated with an irradiation dose of 10Gy delivered by SARRP  
Brain tissue samples from control and irradiated tumours growing in wild type (WT) or Dock4 
heterozygous (het) mice were sectioned at 4µm thickness, stained for CD31 and haematoxylin 
counterstained. The slides were scanned and blood vessel growth and lumenisation were quantified 
as described in Materials and Methods. A total of 76 blood vessels with lumen from 32 0.5x0.5mm2 
areas were analysed. 
(A) Experimental schedule of intracranial implantation, irradiation and tumour excision. 
(B) Representative images of sections from excised tumours. 
(C) Graph shows total vessel count per 0.25 mm2 area ± SD, N= number of 0.25 mm2 areas (WT control, 
11; Dock4 het control, 18; WT 15Gy, 6; and Dock4 het 15Gy, 16).  
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Figure 4.11 Analysis of blood vessel lumenisation of CT2A tumours growing in control and Dock4 
heterozygous mice treated with an irradiation dose of 10Gy delivered by SARRP  
Brain tissue samples from control and irradiated tumours growing in wild type (WT) or Dock4 
heterozygous (het) mice were sectioned at 4µm thickness, stained for CD31 and H&E counterstained. 
The slides were scanned and blood vessel growth and lumenisation were quantified as described in 
Materials and Methods. A total of 76 blood vessels with lumen from 32 0.5x0.5mm2 boxes were 
analysed. 
(A) Graph shows percentage lumenised blood vessels (³ 10 µm) ± SD, N= number of 0.5x0.5mm2 areas 
(WT control, 11; Dock4 het control, 18; WT 15Gy, 6 and Dock4 het 15Gy, 16).  
(B) Graph shows blood vessel lumen size ± SD, N= number of blood vessels with lumen (WT control, 
72; Dock4 het control, 56; WT 15Gy, 59 and Dock4 het 15Gy, 47). * p<0.05; ** p<0.01 and ** p<0.001. 
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4.8 Effects of irradiation on blood vessel a-SMA expression 
Following the increased finding of SMA positivity and its direct association with nestin expression in 
patient samples, I investigated whether a-SMA positivity increased in irradiated CT2A tumours 
recapitulating the phenotype of the recurrent patient GBM tumours. Serial sections of CT2A tumours 
were stained for endothelial marker CD31 and the SMC marker a-SMA. Overall, a-SMA failed to stain 
the majority of blood vessels in untreated CT2A tumours, particularly small blood vessels growing in 
either wild type or heterozygous Dock4 mice (Figure 4.12). However, we can clearly see large blood 
vessels, particularly those in the edge region of irradiated tumour tissue, positive for a-SMA (red 
arrows) although this is very low compared to matured blood vessels in normal brain (black arrows). 
This shows that the aberrant blood vessels which showed high a-SMA positivity in recurrent patient 
tumours could, at least partly result from irradiation. In addition to increased SMA positivity in the 
irradiated tumour tissue following irradiation, there was also an increased presence of F4/80 positive 
macrophages/ microglia. Apoptosis and DNA damage markers caspase-3 and g-H2AX, respectively 
were also slightly increased (Appendix 7). 
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Figure 4.12 a-SMA positivity in CT2A tumours 
CT2A tumours were paraffin embedded, sectioned serially (4 µm) and stained using antibodies against 
CD31 and a-SMA. Red arrows point to CD31 positive blood vessels in control and irradiated tumour 
tissues with their respective serial sections showing presence or absence of a-SMA positivity. Black 
arrows point to blood vessels in the normal brain parenchyma showing positivity for both CD31 and 
a-SMA. Scale bar, 100 µm. 
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4.9 Optimisation of deletion of Dock4 f/f using Cre/loxP system and confirmation by tdTomato 
reporter gene 
Initially, in vivo experiments to address the role of Dock4 were performed using mice with global 
heterozygous Dock4 allele knockout as homozygous Dock4 deletion was embryonically lethal beyond 
E7.5. In our work, although the findings showed decreased tumour blood vessel lumen size following 
Dock4 heterozygous deletion there was no overall survival benefit for CT2A tumour bearing mice. 
Then, I hypothesised that deletion of both alleles of Dock4 from ECs could improve the overall survival 
of mice. The use of combined Dock4 conditional knockout and radiotherapy was beyond the remit of 
this thesis. I used a conditional Dock4 knockout mice generated by Ozgene using a Cre/loxP; FLP-FRT 
systems to delete Dock4 in adult mice (Appendix 8A). The VEcad-iCreERT and TdTomato reporter gene 
(both from Beatson Institute of Cancer research) were employed to achieve inducible Dock4 genetic 
deletion  and to confirm the activity of VEcad-iCreERT. Hence, Dock4f/f mice were crossed with the 
line VE-CadiCreERT2-mice in our animal facility and genotyped by Transnetyx. The genotyping results 
confirmed the genotype of each mouse as homozygous or heterozygous or wild type for Dock4, 
TdTomato and Cre genes (Appendix 8B).  
 
Following confirmation of mice genotype, tamoxifen was injected intraperitoneally and CT2A tumour 
cells were injected intracranially. Staining of tumour samples confirmed Cre recombinase activity 
using the TdTomato reporter gene. Using Red Fluorescent Protein (RFP) antibody staining successfully 
detected deletion of the floxed STOP codon of TdTomato allowing its expression upon induction with 
tamoxifen (Figure 4.13A).  Interestingly, in addition to reduced expression of DOCK4 in endothelial 
cells in VEcad-iCre+ve; Dock4f/f  mice compared to VEcad-iCre-ve; Dock4f/f  mice upon induction with 
tamoxifen (Figure 4.13B), there was also reduced DOCK4 expression in CT2A cells  potentially 
indicating a possible role of endothelial Dock4 in the regulation of DOCK4 expression in cancer cells. 
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Figure 4.13 Optimisation of Cre activity using the TdTomato reporter  
(A) Mice were injected with tamoxifen intraperitoneally at a dose of 2mg/mouse/day for 5 consecutive 
days and implanted with CT2A tumour cells intracranially. CT2A brain tumours were excised, sectioned 
and stained for CD31 and TdTomato using an antibody against RFP. 
(B) DOCK4 staining of sections from CT2A tumours growing in VEcad-iCre+ve; Dock4f/f and VEcad-
iCre-ve; Dock4f/f mice. Scale bar, 100 µm.  
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4.10 Pilot analysis of CT2A blood vessels in the conditional Dock4 knockout model in the absence 
of irradiation  
The experiments performed in the Dock4 heterozygous mice showed increased tumour blood vessel 
lumen size following irradiation. On the other hand, it was noticed from both early and late stage 
Dock4 het tumour vasculature analysis that there was a trend of normalisation of tumour vessel lumen 
size with heterozygous Dock4 deletion. In this pilot study I hypothesised that deletion of both alleles 
from endothelial cells could result in further blood vessel normalization improving chemo- and 
radiotherapy. Analysis of tumour blood vessel lumen size was performed at early and late stages post 
tumour implantation, either at 10 days or upon development of neurological symptoms from day 14 
onwards (Figure 4.14A).  
 
For analysis early after intracranial injection a total of 126 blood vessels from 4 Cre negative and 64 
blood vessels from 3 Cre positive mice were analysed. Tumours from Cre positive  and Cre negative 
mice had an average of 36% and 14% lumenised vessels, respectively,  showing that surpisingly, 
endothelial Dock4 deletion increased blood vessel lumenisation (Figure 4.14B). Similarly, the late 
timepoint analysis, when mice were taken down following development of neurological symptoms, 
showed a higher percentage of lumenised blood vessels in tumour samples from Cre positive mice 
20% of a total of 324 blood vessels, compared to Cre negative mice, 12% from a total of 303 vessels 
(Figure 4.14C). However, despite the consistent trend, the differences were not statistically significant  
for either the early and late timepoints. Again, analysis of blood vessel lumen size from Cre positive 
and Cre negative mice showed no significant differences between control tumours and tumours with 
endothelial Dock4 deletion at early  (p=0.34) or late (p=0.35) timepoints (Figure 4.15A, B). 
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Figure 4.14 Analysis of blood vessel lumenisation of CT2A tumours growing in VEcad-iCre; Dock4f/f 
mice  
Brain tissue samples from control from 6 VEcad-iCre positive Dock4f/f and 8 VEcad-iCre negative 
Dock4f/f mice were sectioned at 4µm thickness, stained for CD31 and H&E counterstained. The slides 
were scanned and percentage blood vessel lumenisation was quantified.  A total of 188 and 625 blood 
vessels with lumen (³ 10 µm) from early and late analysis, respectively were analysed.  
(A) Experimental schedule of intracranial implantation and tumour excision at Early and Late 
timepoints. 
(B) Graph shows Early percentage lumenisation of blood vessels ± SD, N= number of tumour samples 
(VEcad-iCre negative Dock4f/f, 4 and VEcad-iCre positive Dock4f/f, 3). 
(C) Graph shows late percentage lumenisation of blood vessels ± SD, N= number of samples (VEcad-
iCre -ve; Dock4f/f, 4 and VEcad-iCre +ve; Dock4f/f, 3). 
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Figure 4.15 Analysis of blood vessel growth of CT2A tumours growing in VEcad-iCre; Dock4f/f mice  
CT2A cells (1x105) were intracranially injected into the striatum of 6 VEcad-iCre positive Dock4f/f and 
8 VEcad-iCre negative Dock4f/f mice and brain tissue samples were sectioned at 4µm thickness, 
stained for CD31 and H&E counterstained. The slides were scanned and blood vessel lumen sizes were 
quantified as described in Materials and Methods.  A total of 188 and 625 blood vessels with lumens 
from Early and Late tumours respectively were analysed.  
(A) Experimental schedule of intracranial implantation and tumour excision at Early and Late 
timepoints. 
(B) Graph shows Early blood vessel lumen size ± SD, N= number of blood vessels with lumen (VEcad-
iCre -ve; Dock4f/f, 18 and VEcad-iCre +ve Dock4f/f, 23). 
(C) Graph shows late blood vessel lumen size ± SD, N= number of blood vessels with lumen (VEcad-
iCre; Dock4f/f negative, 38 and VEcad-iCre; Dock4f/f positive, 78). 
 
 
 
 
 
 129 
4.11 Conclusions 
The dedicator of cytokinesis (DOCK) 4 is a GEF for the small Rho GTPase Rac1, which has been shown 
previously to regulate filopodia formation in organotypic angiogenesis assays, and lumen formation 
in organotypic assays and in the brain in vivo through control of the endothelial actin cytoskeleton. 
Blood vessels play a vital role in tumour growth and understanding the molecular mechanisms by 
which cancer cells manipulate blood vessels to their advantage can provide key approaches to cancer 
therapies. In this part of the study, I first established in the lab and characterised the mouse GBM 
tumour model CT2A for experiments to elucidate the control of tumour vascularisation in GBM. 
Compared to the commonly employed GL261 model, the CT2A tumour model was found to be more 
angiogenic, co-optive and to recapitulate better the invasive cancer cell behaviour seen in human 
GBM tumours. Using the Dock4 heterozygous global deletion model previously developed in our lab I 
grew CT2A tumours orthotopically and assessed changes in tumour vascularisation and growth. 
Analysis showed that there are no significant differences in the vasculature of tumours growing in 
Dock4 het mice compared to tumours growing in wild type controls except at early day analysis where 
there is a significant reduction of lumen size in Dock4 het mice. Consistently, no changes in tumour 
growth were observed in tumours growing in the Dock4 het mice compared to controls. Analysis of 
tumour growth in Dock4 het and litter mate WT mice showed no significant difference as measured 
using IVIS and also confirmed by MRI. 
 
In addition, I optimised a protocol in which initial tumour regression could be observed in response to 
irradiation of CT2A tumours, followed by tumour regrowth (Figure 4.8) recapitulating the response of 
patient GBM tumours to radiotherapy. As most GBM patients receive radiotherapy as part of the 
standard therapy I had hypothesised that radiotherapy may play a role in the changes observed in the 
vasculature of patient recurrent tumours, namely increased vessel size and pericyte coverage. I found 
that in tumours excised early after irradiation there was a significant decrease rather than anticipated 
increase in blood vessel lumen size and percentage lumenisation. However, in the late CT2A tumour 
sample analysis performed by A. Widiyadari in our team, it was found that there is indeed increased 
blood vessel lumen size following irradiation (Appendix 6), although that vascular change was not 
accompanied by a change in tumour growth. 
 
The irradiated tumours growing in Dock4 het mice showed significantly smaller lumen size blood 
vessels compared to irradiated tumours growing in wild type mice in the early timepoint analysis at 3 
days after irradiation.  Further, the increase in lumen size observed in response to irradiation at the 
late timepoint analysis was reversed by Dock4 heterozygous deletion. In addition, as observed in 
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recurrent patient GBM samples, a-SMA positivity appeared increased following treatment of ionizing 
radiation, particularly in larger blood vessels at the late timepoint analysis, but not in the early 
timepoint. Therefore, there are different and sometimes opposing effects of irradiation on the 
vasculature at different timepoints, which may explain the lack of observed differences in tumour 
growth. Dock4 could therefore play a significant role in normalisation of blood vessels following 
radiotherapy by regulating blood vessel lumen size. However, what appeared to be normalisation in 
tumour blood vessel by decreasing lumen size did not affect survival suggesting that either the 
reduction of DOCK4 is not adequate, and/ or longer term growth effects could not be captured in 
these short-term tumour growth experiments. One typical cellular effect of radiotherapy in early 
samples was the increased infiltration of macrophage/microglia which could had accounted for blood 
vessel abnormality at the late timepoint. 
 
Pilot analysis of CT2A tumour blood vessel lumen size in conditional Dock4 knockout mice, where 
Dock4 deletion of both alleles takes place specifically in endothelial cells upon tamoxifen treatment, 
showed no significant difference of tumours with Dock4 deletion compared with control mice, and 
lack of survival benefit.  Further experiments in the future will be necessary to determine the precise 
response, particularly in combination with radiotherapy. 
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Chapter 5 
 
The role of DOCK4 in glioblastoma cancer 
cell invasion 
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5.1 Introduction 
One characteristic feature of GBM is its diffuse infiltrative growth into the normal brain parenchyma 
by destroying the neuronal cells. This results in loss of neurological and cognitive ability and 
subsequently patients’ death. Although the use of radiotherapy to treat such infiltrative cancer is 
widespread some cells remain resistant after such treatments and the cells become more invasive and 
ends up with local or distance recurrence (Edalat et al. 2016 and Wild-Bode et al. 2001). Blood vessels 
in cancer microenvironment play an important role as a scaffold for the invasion of such cancers in 
addition to providing oxygen and nutrients (Cuddapah et al. 2014). The fact that DOCK4, a GEF for 
Rac1, controls both cell-cell adhesion and migration make it both promotor and suppressor of some 
diseases (Gadea and Blangy 2014). For instance, it was reported to have a tumour suppressor property 
and DOCK4 mutations have been observed in some human cancer cell lines (Hiramoto, Negishi, and 
Katoh 2006 and Yajnik et al. 2003). Rac1 also plays a central role in GBM cells growth and progression 
in association with other cell surface receptors (Tajiri et al. 2017; Ueda et al. 2008 and Aoki, Nakamura, 
and Matsuda 2004).  
 
The role of Rac in cell migration and invasion has been controversial and reported to depend on cell 
type. For instance, in rat glioma cells Rac knockdown increased cell migration and this migration was 
even more increased with irradiation (Hwang et al. 2006). Different studies demonstrated increased 
cancer cell invasion following ionising radiation in an in vitro model. For instance, ionising radiation 
increased migration and invasion of neuroblastoma cells in spheroid and Matrigel assays by increasing 
expression of MMP-9, VEGF and uPA (Jadhav and Mohanam 2006). The work of Dong et al. showed 
that ionising radiation increased U87 cells invasion in Matrigel assays by inducing nuclear translocation 
of ß-catenin (Dong et al. 2014). In this part of the study, I set out to investigate the role of DOCK4 in 
glioblastoma invasion and in addition, the effect of the combination of radiotherapy and DOCK4 
knockdown on tumour invasion. I next employed lentiviral shRNA knockdown of DOCK4 in cancer cells 
to investigate the effects in tumour invasion in spheroid assays. Using the U251 glioblastoma cell line, 
which is the most widely used GBM cell line and the patient-derived GBM cells, GBM1, to knockdown 
DOCK4, I investigate the effect of DOCK4 knockdown on GBM cell invasion. In order to recapitulate 
the tumour microenvironment a co-culture experiment using endothelial cells (ECs) and cancer cells 
was used in which tumour invasion was analysed. 
 
5.2 DOCK4 expression in glioblastoma cancer cells  
Previous studies showed that DOCK4 was expressed differently in normal brain and glioblastoma. 
While DOCK4 expression in glioblastoma is significantly higher than that of the neural stem cells, 
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analysis of 547 glioblastoma and 10 normal brain samples from The Cancer Genome Atlas (TCGA) data 
showed no significant differences between normal brain and glioblastoma samples in DOCK4 
expression. However, there is a lack of clarity as to which region of normal brain was used as a 
reference as different brain regions express different levels of DOCK4. For instance, DOCK4 is highly 
expressed in grey matter compared to white matter in a normal brain and within the brain, the highest 
expression of DOCK4 was detected in caudate, hippocampus, and cerebral cortex. In this study double 
immunostaining of normal brain tissue sections for DOCK4/CD31 was conducted. Intriguingly, the 
immunohistochemical staining showed a higher expression of DOCK4 in grey matter, the highest 
expression being in the neurons, and almost none in the white matter (Appendix 9).  Hence, this result 
clearly showed that the neuronal cells are the ones expressing DOCK4 in normal brain. Following this 
finding, I investigated whether DOCK4 expression in GBM was different from normal brain and 
whether there was any variation among different patient GBM tumour samples.  
 
Following optimisation of DOCK4 staining on normal tissue I then investigated the level of DOCK4 
expression in different GBM samples. For this I first determined how to score DOCK4 expression in 
these tumours and adopted DOCK4 expression intensity and fractions of stained cells using different 
GBM tissues based on the Human Protein Atlas (HPA) scoring system (Appendix 10). Accordingly, 4 
different levels of DOCK4 expression were identified depending on intensity and fractions of DOCK4 
expressing cells; None, Low, Moderate and High (Appendix 11). Accordingly, a total of 12 primary 
patient-derived GBM tumour samples and one control normal brain tissues were sectioned and 
stained for DOCK4/CD31 and analysed for DOCK4 medium/high expression level (Figure 5.1). Because 
it is known that cancer cells invade along blood vessels and I also observed a relatively higher DOCK4 
expression around blood vessels, I decided to score DOCK4 expression level around blood vessels. 
 
Overall, a total of 3, 473 tumour blood vessels from 12 primary GBM patient samples were assessed 
for DOCK4 expression of cancer cells around perivascular regions. The result showed a heterogenous 
expression of DOCK4 in different glioblastoma tumour samples (Figure 5.1A) and the most angiogenic 
regions of the tumour had the highest DOCK4 expression and this expression was more common in 
aberrant blood vessel morphologies such as nestin positive and glomeruloid types compared to 
normal-like blood vessels.  
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Figure 5.1 DOCK4 expression levels in patient-derived GBM and its association with survival  
 (A) Histogram shows average % of cancer cells expressing high and medium level of DOCK4 expression 
in patient-derived GBM samples along blood vessels as scored using HPA scoring guideline. Cancer 
cells around blood vessels were scored as low (Score 0 &1) and high (score 2&3) (Appendix 11). Up to 
two layers of cells along each blood vessel were scored for DOCK4 expression. An average of 25 blood 
vessels, minimum 7 and maximum 57, were analysed per box. A total of 12 GBM tumour tissue 
samples were analysed for cancer cell DOCK4 expression level: Values represent average expression 
± SEM; N= Number of 1mm2 areas (Normal Brain, 4; GBM13P, 15; GBM14P, 11; GBM16, 9; GBM20P, 
10; GBM21, 11; GBM25, 13; GBM26, 9; GBM30P, 4; GBM33, 10; GBM36, 9; GBM 37, 12 and GBM39, 
13).   
(B) Graph showing survival curve for patients with high, as defined high DOCK4 expression in > 40% 
cells. N= number of GBM patients (Low, 6 and High, 6). 
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Previously, Debruyne and co-workers found a better survival for GBM patients with high DOCK4 
expression compared to those with low expression using a median cut-off 30% (Debruyne et al. 2018).  
In this study, as the median DOCK4 expression of 12 primary GBM samples was 41% I examined 
whether there is a link between DOCK4 expression and overall patient survival using a cut-off 40% 
(Figure 5.1B). The result showed that although there was a trend of high DOCK4 expression in favour 
of a better overall survival this was not statistically significant (p=0.8). In agreement with this finding 
the analysis of 122 glioblastoma patient samples from Human Protein Atlas data showed lack of 
significant difference between high and low Dock4 mRNA expression and patients’ overall survival 
(Appendix 12). The findings of heterogenous DOCK4 expression in primary patient-derived GBM 
samples prompted me to investigate whether expression level would be increased in recurrences as 
observed in irradiated mouse CT2A tumour samples. Intriguingly, I found that in all four tumours there 
was a tendency of increased DOCK4 expression in recurrent tumours compared to primary tumours 
(Figure 5.2) but not statistically significant. However, the degree of such increment varied. For 
instance, while in GBM13 DOCK4 expression increased from 12% to 21%, in GBM14 it increased from 
61% to 67% as tumour progressed from primary to recurrent.  
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Figure 5.2 DOCK4 expression in primary versus recurrent patient GBM samples 
Four pairs of patients GBM tissue samples were immunostained using DOCK4/CD31 and % 
Medium/High DOCK4 expression of cancer cells along blood vessels were assessed using HPA protein 
expression scoring system (Appendix 10). A total of 1,266 areas were scored around blood vessels 
from primary GBM and 377 areas from recurrent GBM and analysed % DOCK4 expression. N= % of 
medium/high DOCK4 expression per 1mm2 area ± SEM: Number of N for primary tumours as shown 
in Figure 5.1 and for Recurrent (GBM13R, 9; GBM14R, 9; GBM20R, 9 and GBM30R, 5).   
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5.3 DOCK4 knockdown in the U251 cell line inhibits invasion 
Since I found high levels of DOCK4 expression in half of the GBM patient samples analysed while 
DOCK4 has been shown to play a role in invasion and metastasis in lung cancer (Yu et al. 2015), this 
led me to ask whether DOCK4 knockdown in glioblastoma cancer cells would inhibit invasion. In order 
to investigate this, I used the commonly used cell line U251 (Cheng et al., 2015,) (Cockle et al. 2015) 
(Polson, 2018 #180) to assess cancer cell invasion in 3D spheroid assays. Firstly, I tested whether U251 
cancer cells migrate in collagen and I found that they do invade into the surrounding collagen matrix 
(Figure 5.3). Invasion was determined using Migration Index (MI) as previously described by Cockle 
and co-workers (Cockle et al. 2015; see also section 2.1.10 in Materials and Methods). Following 
knockdown of DOCK4 from U251 cells using shRNA a spheroid assay was conducted. There was clear 
reduction of cancer cell invasion into the surrounding collagen matrix when DOCK4 was knocked down 
in U251 cancer cells compared to control U251 cells. In particular, DOCK4 knockdown significantly 
(p<0.01) reduced tumour invasion 3 days after addition of collagen (Figure 5.4). However, 
measurements of cancer cell invasion at later timepoints showed lack of significant differences 
between control in U251 cancer cells and U251 cells with DOCK4 knockdown from day 7 onwards 
(Figure 5.5). A potential reason for loss of the inhibitory effect with longer term culture could be a 
compensatory mechanism by other Dock180 family members in the absence of DOCK4.  
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Figure 5.3 Invasion of U251 cancer cells over time in spheroid assays  
U251 cancer cells (1x103) were seeded in a low adherent and round bottom 96-well plate in 200 µl 
5xDMEM medium. After 3 days when a sphere was formed, supernatants were removed and 100µl 
collagen was added per well at 6.8 : 1 ratio of Collagen to 5xDMEM and neutralised by 0.7% 1M NaOH. 
Finally, 100µl 5xDMEM was added to each well and the plate was incubated at 37o and 5% CO2. Cancer 
cell invasion was measured at Days 0, 3, 7, and 11 following the addition of collagen using EVOS at 4x 
magnification.  
(A) Images depict spheroids formed by cancer cells and their invasion into the surrounding collagen 
matrix. Black dotted circles show area of invasion.  
(B) Dot plot shows invasion area of U251 cells. Mean ± SD, N= number of wells (20 wells).  
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Figure 5.4 Effect of DOCK4 knockdown in U251 cells on invasion in spheroid assays 
U251 cancer cells (2x103) transduced with either empty vector or DOCK4 shRNA were seeded in a low 
adherent round bottom 96-well plate in 200µl neurobasal medium. After 3 days when a sphere was 
formed, supernatants were removed and 100µl collagen was added per well at 6.8 : 1 ratio of collagen 
to 5xDMEM, and neutralised by 0.7% 1M NaOH. Finally, 100 µl 5xDMEM medium was added to each 
well and the plate was incubated at 37o and 5% CO2. Cancer cell invasion was measured at Days 0, 3, 
7, and 11 following the addition of collagen using EVOS at 4x magnification. N= number of wells (EV, 
23; DOCK4 shRNA, 20). EV, Empty vector. 
(A) Images depict spheroids formed by cancer cells transduced with lentiviruses harbouring EV or 
DOCK4 shRNAs. Black dotted circles show area of invasion. 
(B) Bar chart shows invasion area of U251 cells transduced with EV and DOCK4 shRNA measured using 
ImageJ. ** p<0.01. 
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Figure 5.5 Effect of DOCK4 knockdown on U251 cancer cell invasion following transfection in 
spheroid assays  
U251 cancer cells (2x103) transfected with either empty vector or DOCK4 shRNA were seeded in a low 
adherent round bottom 96-well plate in 200µl neurobasal medium. After 3 days when a sphere was 
formed, supernatants were removed and 100µl collagen was added per well at 6.8 : 1 ratio of collagen 
to 5xDMEM, and neutralised by 0.7% 1M NaOH. Finally, 100 µl 5xDMEM medium was added to each 
well and the plate was incubated at 37o and 5% CO2. Cancer cell invasion was measured at Days 0, 3, 
7, and 11 following the addition of collagen using EVOS at 4x magnification. Images depict invasion of 
EV or DOCK4 shRNAs transfected U251 cancer cells into the surrounding collagen matrix on Day 7. N= 
number of wells (EV, 23; DOCK4 shRNA, 20). EV, Empty vector. 
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5.4 DOCK4 knockdown in patient-derived cancer cells inhibits invasion 
Following the observation of reduced invasion in DOCK4 knockdown from U251 cancer cells on Day3 
I sought to check if knockdown of DOCK4 from patient-derived GBM cancer cells also decrease 
invasion. However, before trying to do this experiment I established whether patient-derived cells 
grow in a 3-D sphere model (Appendix 13) as they normally grow in neurobasal medium. The result 
showed that GBM1 cells could grow in neurobasal based medium in a spheroid assay although at a 
slower rate compared to the U251 cancer cell line which grows well in 5x Dulbecco’s Modified Eagle 
Media (5xDMEM). When either empty vector or DOCK4 shRNA transfected GBM1 cancer cells were 
seeded in 96-well plates there was a significant (p<0.05) reduction in cancer cell invasion into the 
surrounding collagen in DOCK4 knockdown GBM1 cells on Day 8 post collagen addition, unlike the 
early effect observed on Day 3 in U251 cells, probably due to the fact that the latter grow faster than 
GBM1 cells (Figure 5.6).  
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Figure 5.6 Effect of DOCK4 knockdown in patient-derived GBM1 cancer cell invasion in spheroid 
assays  
GBM1 cancer cells (2x103) transfected with either empty vector or DOCK4 shRNA were seeded in a 
low adherent round bottom 96-well plate in 200µl neurobasal medium. After 5 days when a sphere 
was formed, supernatants were removed and 100µl collagen was added per well at 6.8 : 1 ratio of 
collagen to 5xDMEM, and neutralised by 0.7% 1M NaOH. Finally, 100 µl neurobasal medium was 
added to each well and the plate was incubated at 37o and 5% CO2. Cancer cell invasion was measured 
at Days 0, 2, 4, and 8 following the addition of collagen using EVOS at 4x magnification. N= number of 
wells (EV, 15; DOCK4 shRNA, 5). EV, Empty vector. 
(A) Images depict spheroids formed by cancer cells infected with lentiviruses harbouring EV or DOCK4 
shRNAs.  
(B) Bar chart shows invasion area of U251 cells transfected with EV and DOCK4 shRNA measured using 
ImageJ.  
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5.5 Establishing collagen based 3-D co-culture assays of glioblastoma cancer cells and HUVEC  
In order to investigate the effect of DOCK4 knockdown in glioblastoma cancer cells under a condition 
which better recapitulates the GBM microenvironment I used a co-culture model of glioblastoma 
cancer cells and ECs instead of the simple monoculture assay. Firstly, I tested the growth and invasion 
of cancer cells in this co-culture model using U251 cell line. When cancer cell invasion into the 
surrounding collagen matrix was assessed under EVOS (Figure 5.7A) there were more invading cells in 
the presence of ECs compared to U251 only cells. Intriguingly, the quantification result showed a 
significant increase in invasion of cancer cells compared to monoculture (Figure 5.7B). Secondly, as 
most U251 cell lines lack both heterogeneity and drug resistance (Patrizii et al. 2018) and do not 
recapitulate the exact nature of patient-derived tumours I decided to use patient-derived GBM cells. 
GBM cells were co-cultured with HUVEC in a 1:1 ratio using neurobasal medium and Human Large 
Vessel Endothelial Cell Basal (HLVEC) medium in a spheroid assay. The result clearly showed a 
significant increase in invasion of cancer cells into the surrounding collagen matrix in the presence of 
ECs (Figure 5.8). Compared to U251 cancer cell line GBM1 cells invaded less, both in the presence and 
absence of ECs. However, comparing the two glioblastoma models the presence of ECs significantly 
increased tumour invasion in GBM1 than in U251 cancer cells.  
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Figure 5.7 Establishment of co-culture of U251 cancer cells and HUVEC in collagen based spheroid 
assays 
U251 cancer cells (2x103), or 2x103 U251 cancer cells mixed with 2x103 HUVEC were seeded in a low 
adherent and round bottom 96-well plates in a 1:1 ratio of 100 µl 5xDMEM and 100µl HLVEC medium. 
After 3 days when a sphere was formed, supernatants were removed and 100µl collagen was added 
per well at 6.8 : 1 ratio of collagen to medium (equal mix of 5xDMEM  and Human Large Vessel 
Endothelial Cell Basal (HLVEC) medium), and neutralised by 0.7% 1M NaOH. Finally, 100 µl of the mix 
medium was added to each well and the plate was incubated at 37o and 5% CO2. Cancer cell invasion 
was measured at Days 0, 2, 4, and 6 following the addition of collagen using EVOS at 4x magnification. 
N= number of wells (U251 cells, 13 and U251 + HUVEC, 11). 
(A) Images depict spheroids formed by cancer cells and HUVEC and their invasion into the surrounding 
collagen matrix. Black dotted circles show area of invasion.  
(B) Bar chart shows invasion area of U251 cancer cells and HUVEC.  
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Figure 5.8 Establishment of co-culture of GBM1 cancer cells and HUVEC in collagen based spheroid 
assays 
GBM1 cancer cells (2x103), or 2x103 GBM1 cancer cells mixed with 2x103 HUVEC were seeded in a low 
adherent and round bottom 96-well plates in a 1:1 ratio of 100 µl neurobasal medium and 100µl 
HLVEC medium. After 5 days when a sphere was formed, supernatants were removed and 100µl 
collagen was added per well at 6.8 : 1 ratio of collagen to medium (equal mix of neurobasal  and HLVEC 
medium), and neutralised by 0.7% 1M NaOH. Finally, 100 µl of the mix medium was added to each 
well and the plate was incubated at 37o and 5% CO2. Cancer cell invasion was measured at Day 0, 2, 4, 
and 8 following the addition of collagen using EVOS at 4x magnification. N=Number of wells (GBM1 
cells, 12 and GBM1 + HUVEC, 16). D=Day.  
(A) Images depict spheroids formed by cancer cells and HUVEC and their invasion into the surrounding 
collagen matrix.  
(B) Bar chart shows invasion area of GBM1 cancer cells in the presence and absence of HUVEC.  
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5.6 Glioblastoma cells but not ECs invade into the surrounding collagen matrix 
Following the increased invasion observed in a co-culture spheroid assay experiment using cancer cells 
and ECs I asked whether this increased invasiveness came from cancer cells or ECs. Hence, in order to 
investigate this, I used green labelled cancer cells with unlabelled ECs and vice-versa. The result 
showed that when green U251 cells were co-cultured with unlabelled ECs the green cancer cells 
invaded into the collagen matrix as observed and measured using the GFP channel of the EVOS (Figure 
5.9, upper panel). On the other hand, when green ECs were co-cultured with unlabelled U251 cancer 
cells the green ECs remained at the centre of the sphere and there was no spreading away of green 
ECs at all. Further, in order to see if there was any spread of the unlabelled cancer cells present in the 
sphere where green labelled ECs remained at the centre of the sphere I used a phase contrast images 
to demonstrate that the invading cells were indeed cancer cells (Figure 5.9, lower panel). A similar 
approach confirmed that the invading cells were cancer cells not ECs using patient-derived GBM1 
cancer cells co-cultured with HUVEC (Figure 5.10). This clearly indicates that cancer cells but not ECs 
are invading into the surrounding normal tissue and ECs play a crucial role in glioblastoma invasion.  
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Figure 5.9 U251 cancer cells but not endothelial cells invade into collagen matrix in spheroid co-
cultures 
Green labelled U251 cancer cells (2x103) and 2x103 unlabelled HUVEC, and vice versa, were seeded in 
a low adherent and round bottom 96-well plates in a 1:1 ratio of 100 µl DMEM and 100µl HLVEC 
medium. After 3 days when a sphere was formed, supernatants were removed and 100µl collagen 
was added per well at 6.8 : 1 ratio of collagen to medium (equal mix of 5xDMEM  and HLVEC medium), 
and neutralised by 0.7% 1M NaOH. Finally, 100 µl of the mix medium was added to each well and the 
plate was incubated at 37o and 5% CO2. Cancer cell invasion was measured at Days 0, 2, 4, and 6 
following the addition of collagen using EVOS at 4x magnification. GFP and phase contrast images 
depict spheroids formed by cancer cells and HUVEC and their invasion into the surrounding collagen 
matrix. N= number of wells (green U251 cells co-cultured with unlabelled HUVEC, 9 and unlabelled 
U251 cancer cells co-cultured with green HUVEC, 13). 
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Figure 5.10 GBM1 cancer cells but not endothelial cells invade into collagen matrix in spheroid co-
cultures 
Green labelled HUVEC (2x103) and 2x103 unlabelled GBM1 cancer cells were seeded in a low adherent 
and round bottom 96-well plates in a 1:1 ratio of 100 µl neurobasal medium and 100µl HLVEC medium. 
After 5 days when a sphere was formed, supernatants were removed and 100µl collagen was added 
per well at 6.8 : 1 ratio of collagen to medium (equal mix of neurobasal  and HLVEC medium), and 
neutralised by 0.7% 1M NaOH. Finally, 100 µl of the mix medium was added to each well and the plate 
was incubated at 37o and 5% CO2. Cancer cell invasion was measured at Days 0, 2, 4, and 8 following 
the addition of collagen using EVOS at 4x magnification. GFP and phase contrast images depict the 
growth and invasion of spheroids into the surrounding collagen matrix. N= number of wells (7 wells). 
 
 
 
 
 
 
 
 
 
 
 
 149 
5.7 The presence of both cancer cell and endothelial cell growth medium is important for invasion  
Following the findings of increased glioblastoma cancer cells invasion in the presence of endothelial 
cells, I asked whether the growth medium in which the cancer cells and ECs were seeded affected 
most the degree of cancer cell invasion. The result of this experiment showed that for glioblastoma 
invasion the presence of both cancer and ECs growth medium were equally important, particularly 
the growth factors and supplements used during seeding the cells. While on average only 3/12 spheres 
(wells) managed to grow and invade into the surrounding collagen matrix when seeded in neurobasal 
medium only, this number increased to over 8 in the presence of both neurobasal and HLVEC medium, 
suggesting that the addition of HLVEC medium doubled the invasion of cancer cells into the 
surrounding collagen matrix in a spheroid assay co-culture (Figure 5.11).  
 
Further, when the medium mixed with collagen or added at the final stage was compared it was 
observed that the medium without supplement didn’t support the formation and growth of spheres 
very well compared to the complete medium with supplement. This implies the important role of 
growth factors such as vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), basic 
fibroblast growth factor (bFGF) and others which are normally added to the medium to grow these 
cancer cells. It was also noticed that rather than the medium used with collagen after sphere 
formation the medium used during the initial seeding stage was more vital for cancer cells to form 
spheres, growth and invasion. Accordingly, while GBM1 and HUVEC co-culture in a 1:1 ratio of 
complete neurobasal medium and HLVEC medium with supplement performed better than those cells 
seeded in neurobasal medium only. In particular, cancer cells invaded better when collagen was added 
with either complete neurobasal medium (Figure 5.11E) or HLVEC medium with supplement (Figure 
5.11G). However, cells which received neurobasal medium without growth factors and supplements 
with collagen to the spheres formed at the bottom of the 96-well plate had the least invasion. This 
leads to a conclusion that it is highly likely that the growth factors, which are normally produced by 
either cancer cells or stroma, play an essential role in cancer cell invasion. 
 
 
 150 
 
 
Figure 5.11 The impact of different growth factors and supplements on cancer cell invasion 
GBM1 cancer cells (2x103) were co-cultured with 2x103 HUVEC cells in a low adherent and round 
bottom 96-well plate in either 200µl neurobasal (NB) medium only (A-D) or in 200µl medium 
containing a 1:1 ratio of neurobasal medium and HLVEC medium (Row E-H). After 5 days when a 
sphere was formed, supernatants were removed and 100µl collagen was added per well at 6.8 : 1 ratio 
of collagen to neurobasal medium only (A&E), neurobasal without supplement (B&F), HLVEC medium 
(C&G) or HLVEC medium without supplement (D&H) and then neutralised by 0.7% 1M NaOH. Finally, 
100µl of NB (A&E), NB without supplement (B&F), HLVEC medium only (C&G) and HLVEC without 
supplement (D&H) were added, respectively and the plate was incubated at 37o and 5% CO2. Cancer 
cell invasion was measured on Days 0, 2, 4 and 8 following the addition of collagen using EVOS at 4x 
magnification. Complete neurobasal medium contains EGF and bFGF growth factors and complete 
HLVEC contains at least VEGF, and Insulin-like growth factor (IGF) or EGF growth factors. N= number 
of wells (A, 3; B, 1; C, 5; D, 4; E, 11; F, 6; G, 10 and H, 6). A-H represents the 96-well plate’s rows. 
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5.8 DOCK4 knockdown in glioblastoma cancer cells does not affect invasion in the presence of 
endothelial cells  
Following the observation of increased cancer cell invasion into the surround collagen matrix in the 
presence of ECs using a spheroid assay, I asked whether knockdown of DOCK4 from such cancer cells 
under co-culture condition could actually reduce or stop their invasiveness. Using U251 cancer cells 
and ECs co-culture in a spheroid assay model I assessed the effect of DOCK4 knockdown from U251 
cancer cells. Surprisingly, despite a slight trend of decrease following DOCK4 knockdown, there was 
no significant difference between empty vector (EV) control and DOCK4 shRNA in invasion of U251 
cancer cells in a co-culture spheroid assay model. Both EV and DOCK4 shRNA U251 cancer cells in a 
co-culture condition invaded greater than U251 cancer cells in a monoculture condition  (Figure 5.12). 
This shows that the significantly reduced effect of cancer cell invasion observed following knockdown 
of DOCK4 from U251 cells under monoculture condition failed to repeat in the presence of ECs, a 
model which better recapitulate the normal tumour microenvironment in patients. 
 
Then, I investigated the effect of DOCK4 knockdown from patient-derived GBM cells on cancer cell 
invasion in the presence of ECs. Unsurprisingly, just like U251 cell line there was no significant 
difference between control GBM1 cells and DOCK4 shRNA GBM1 cells both co-cultured with HUVEC 
(Figure 5.13). However, compared to U251 cell line there was a slightly increased invasion in GBM1 
cancer cells when DOCK4 was deleted compared to control GBM1 implying that deleting DOCK4 could 
have a negative consequence. In conclusion, the use of both glioblastoma cancer cell models showed 
lack of significant difference in cancer cell invasion between DOCK4 knockdown and control in the 
presence of ECs co-culture unlike the significant difference observed in a monoculture scenario.  
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Figure 5.12 Effect of DOCK4 knockdown on U251 cancer cell invasion in the presence of HUVEC 
U251 cancer cells (2x103) as monoculture or a co-culture of EV or DOCK4 knockdown 2x103 U251 
cancer cells with with HUVEC were seeded in a low adherent round bottom 96-well plate in a 1:1 ratio 
of 100 µl 5xDMEM and 100µl HLVEC medium. After 3 days when a sphere was formed, supernatants 
were removed and 100µl collagen was added per well at 6.8 : 1 ratio of collagen to medium (equal 
mix of 5xDMEM  and HLVEC medium), and neutralised by 0.7% 1M NaOH. Finally, 100 µl of the mix 
medium was added to each well and the plate was incubated at 37o and 5% CO2. Cancer cell invasion 
was measured at Days 0, 2, 4, and 6 following the addition of collagen using EVOS at 4x magnification. 
N= number of wells (U251 cells, 13; EV + HUVEC, 11 and DOCK4 shRNA + HUVEC, 9). 
(A) Images depict invasion of cancer cells into collagen matrix, 3 representative images from D6. 
(B) Bar chart shows invasion area of U251 cancer cells and HUVEC. 
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Figure 5.13 Effect of DOCK4 knockdown on GBM1 cancer cell invasion in the presence of HUVEC 
GBM1 cancer cells (2x103)  or 2x103 GBM1 cancer cells with DOCK4 knockdown were seeded in a low 
adherent round bottom 96-well plate in a 1:1 ratio of 100 µl neurobasal medium and 100µl HLVEC 
medium. After 5 days when a sphere was formed, supernatants were removed and 100µl collagen 
was added per well at 6.8 : 1 ratio of collagen to medium (equal mix of neurobasal medium  and HLVEC 
medium), and neutralised by 0.7% 1M NaOH. Finally, 100 µl of the mix medium was added to each 
well and the plate was incubated at 37o and 5% CO2. Cancer cell invasion was measured at Days 0, 2, 
4, and 8 following the addition of collagen using EVOS at 4x magnification. N= number of wells (Empty 
Vector, 17 and DOCK4 shRNA, 9).  
(A) Images depict invasion of cancer cells into collagen matrix. 
(B) Bar chart shows invasion area of U251 cancer cells and HUVEC. 
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5.9 Effect of ionising radiation on cancer cell invasion in the presence of endothelial cells 
Radiotherapy is widely used for treatment of cancer patients. Despite its wide spread use in cancer 
treatment, ionising radiation also cause aggressive invasion in several tumours including breast, brain, 
and lung tissues by increasing production of MMPs from both cancer and the microenvironment 
(Artacho-Cordon et al. 2012).  Many other studies also have shown that the use of ionising radiation 
increased cancer cell invasion in a spheroid assay. Here, following the observation of increased cancer 
cells invasion in a co-culture of cancer cells and ECs, I hypothesised that irradiation could potentially 
decrease such invasion in the absence of ECs and increases invasion in the presence of ECs as ECs 
could potentially play a protective role. In order to investigate this, I used the U251 cancer cell line in 
a spheroid assay with or without HUVEC and treated the cells using irradiation dose of 10Gy. To my 
surprise, I observed an opposite effect of my initial hypothesis. Simply, the U251 cells showed a sign 
of resistance on their own and susceptibility to irradiation when co-cultured with HVEC (Figure 5.14). 
Although there was no significant difference in invasion at any timepoint between control and 
irradiated cancer cells in a monoculture, I observed a significant reduction of cancer cell invasion 
following irradiation at Day 6 post collagen addition to the spheroid assay in the case of cancer cell 
and HUVEC co-culture.  
 
Then I asked whether sensitivity to irradiation is cell type dependent and used the mouse glioblastoma 
CT2A (Appendix 14) and patient-derived GBM20 cancer cells (Appendix 15). When a monoculture of 
CT2A cancer cells were irradiated using either 5Gy or 10Gy doses of ionising irradiation, the spheres 
became smaller in size as opposed to control CT2A spheres which became elongated and expanded 
without invading into the surrounding collagen matrix. However, under co-culture condition, only 
CT2A cells seeded with Human Cerebral Microvascular Endothelial Cells (HCMEC) but not HUVEC 
invaded into the matrix and co-culturing CT2A cancer cells with HUVEC made them sensitive to 
irradiation as observed in the U251 cancer cells. When I tested the effect of irradiation on patient-
derived GBM samples using GBM20, unlike that of U251 cells, I found a total sensitivity of cancer cells 
to irradiation in absence of ECs and a significant increase in cancer cell invasion following irradiation 
doses 5Gy and 10Gy when GBM cancer cells were co-cultured with either HCMEC or HUVEC (Appendix 
15). Further, the patient-derived GBM20 cells failed to grow and spread in the absence of ECs. Overall, 
the results of ionising radiation in a spheroid assay showed how cancer cells’ radioresistance depends 
on both cell type and presence or absence of different cells in the tumour microenvironment like ECs. 
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Figure 5.14 Effect of ionising radiation on U251 cancer cell invasion in the presence or absence of 
HUVEC 
U251 cancer cells (2x103), or 2x103 U251 cancer cells mixed with 2x103 HUVEC were seeded in a low 
adherent and round bottom 96-well plates in a 1:1 ratio of 100 µl 5xDMEM and 100µl HLVEC medium. 
After 3 days when a sphere was formed, supernatants were removed and 100µl collagen was added 
per well at 6.8 : 1 ratio of collagen to medium (equal mix of 5xDMEM  and HLVEC) medium, and 
neutralised by 0.7% 1M NaOH. Finally, 100 µl of the mix medium was added to each well and the plate 
was incubated at 37o and 5% CO2. Next day 10Gy irradiation dose was delivered using RAD 2000 at a 
rate of 2Gy/minute. Cancer cell invasion was measured at Days 0, 2, 4, and 6 following the addition of 
collagen using EVOS at 4x magnification. N= number of wells (U251 control, 13; U251 10Gy, 21; U251 
+ HUVEC Control, 11 and U251 +HUVEC 10Gy, 16 wells). 
(A) Images depict spheroids formed by cancer cells monoculture and co-culture of cancer cells and 
HUVEC, and their consequent invasion into the surrounding collagen matrix.  
(B) Bar chart shows invasion area following irradiation under monoculture and co-culture conditions. 
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5.10 Effect of combined DOCK4 knockdown and irradiation on cancer cell invasion 
Following the demonstration of a slight decrease in U251 cells invasion following irradiation in the 
presence of endothelial cells I hypothesised that a combination of irradiation and DOCK4 knockdown 
in the presence of ECs could lead to further reduction of U251 cancer cells invasion. Unfortunately, 
except the slight trend of decrease observed following irradiation there was no significant difference 
between control and irradiated tumours in the presence of ECs (Figure 5.15).  This could imply that 
DOCK4 knockdown from glioblastoma cells may not significantly decrease or have no synergistic effect 
at least in U251 cancer cell invasion in the presence of endothelial cells, which better recapitulates 
the brain tumour microenvironment. Hence, a combination therapy of DOCK4 knockdown and 
irradiation showed no overall significant benefit in decreasing invasion of glioblastoma cancer cells in 
a spheroid assay. To sum up, although there was no difference between control and irradiated U251 
cells in cancer cells monoculture, U251 cancer cell invasion significantly (p<0.01) reduced in a co-
culture assay with ECs on Day 6 following 10Gy irradiation probably implying that ECs made these 
particular cancer cells susceptible to irradiation although presence of ECs had an opposite effect on 
GBM20 leading to radioresistance. However, combination therapy using both DOCK4 knockdown and 
irradiation failed to reduce cancer cell invasion in the presence of ECs. 
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Figure 5.15 Effect of ionising radiation and DOCK4 deletion on U251 cancer cell invasion in the 
presence of HUVEC 
U251 cancer cells (2x103), or 2x103 U251 cancer cells mixed with 2x103 HUVEC were seeded in a low 
adherent and round bottom 96-well plates in a 1:1 ratio of 100 µl 5xDMEM and 100µl HLVEC medium. 
After 3 days when a sphere was formed, supernatants were removed and 100µl collagen was added 
per well at 6.8 : 1 ratio of collagen to medium (equal mix of 5xDMEM  and HLVEC) medium, and 
neutralised by 0.7% 1M NaOH. Finally, 100 µl of the mix medium was added to each well and the plate 
was incubated at 37o and 5% CO2. Next day, an irradiation dose of 10Gy was delivered using RAD 2000 
at a rate of 2Gy/minute. Cancer cell invasion was measured at Days 0, 2, 4, and 6 following the addition 
of collagen using EVOS at 4x magnification. N= number of wells (DOCK4 shRNA U251 control, 9 and 
DOCK4 shRNA U251 10Gy, 21 wells). 
(A) Images depict spheroids formed by cancer cells monoculture and co-culture of cancer cells and 
HUVEC, and their consequent invasion into the surrounding collagen matrix.  
(B) Bar chart shows invasion area following irradiation under monoculture and co-culture conditions. 
 158 
5.11 Conclusions 
DOCK4 protein is upregulated in normal brain, particularly in grey matter. However, the overall 
analysis of DOCK4 expression in this thesis showed that there is no difference in DOCK4 expression in 
samples from a normal brain and glioblastoma tumour tissue samples. Over the course of this study 
Debruyne and co-workers showed that DOCK4 expressing cells are differentiated cancer cells and had 
low stem cell marker OLIG2 expression and such cells were non-mitotic and such increased DOCK4 
expression in GBM samples had been associated with better patient’s outcome (Debruyne et al. 2018). 
The finding of this thesis showed no significant overall survival benefit between patients with high and 
low DOCK4 expression although there was a trend of association between high DOCK4 expression and 
better overall survival (OS). Nevertheless, there were some patients with low DOCK4 expression but 
had a longer duration of OS.  
 
Knockdown of DOCK4 from both U251 and GBM1 glioblastoma cancer cells significantly reduced 
invasion in a spheroid assay using a monoculture model. However, under a co-culture model of 
glioblastoma cells with ECs cancer cell invasion significantly increased regardless of DOCK4 
knockdown. Hence, unlike the results observed in monoculture model, in a co-culture model knocking 
down DOCK4 did not reduce cancer cell invasion in both U251 and GBM1 cancer cells. Further, the 
investigation as to whether the increased invasion of cancer cells in the presence of ECs was due to 
ECs or cancer cells themselves using both U251 and GBM1 cancer cells clearly demonstrated that 
those invading cells are indeed cancer cells. 
 
Finally, the investigation of the effect of radiotherapy on cancer cell invasion showed that when U251 
cancer cells were cultured with or without HUVEC in a spheroid assay and irradiated using 10Gy 
irradiation dose cancer cells became sensitive to ionising radiation in the presence of ECs. Further, 
there was no overall significant benefit from a combination therapy of DOCK4 knockdown and 
radiotherapy using U251 cancer cells and ECs co-culture in a spheroid assay.  Although the same effect 
was seen using CT2A cancer cells co-cultured with ECs, the use of irradiation in a co-culture of GBM20 
cancer cells and ECs increased cancer cell invasion. This shows that the effect of ionising radiation on 
cancer cell invasion is probably cell type dependent. 
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Discussion 
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6.1 Introduction 
Microvascular proliferation is a hallmark of GBM and plays an important role in the growth and 
progression of these brain tumours. Tumour blood vessels are inherently abnormal and this 
abnormality ranges from large vessel diameter, leakiness and chaotic organisation to glomeruloid 
structures (Carmeliet and Jain 2011). Aberrantly dilated, hyperpermeable and tortuous blood vessels 
in tumours are the result of an imbalance between proangiogenic and anti-angiogenic signaling factors 
leading to temporal and spatial blood flow and oxygenation heterogeneity within a tumour tissue 
(Goel et al. 2011). Vascular endothelial growth factor (VEGF), particularly VEGF-A (Roodink et al. 2006),  
is highly expressed in glioblastoma (Huang et al. 2005) and is primarily responsible for aberrant tumour 
angiogenesis through activation of its receptor VEGFR2 (Xu, Wu, and Zhu 2013). Despite its initial 
promise of increased progression-free survival the anti-VEGF drug Bevacizumab (Avastin) failed to 
improve the overall survival advantage of glioblastoma patients (Wick et al. 2017). The failure of 
Bevacizumab in the clinic for GBM clearly implicate the presence of VEGF independent alternative 
mechanisms in GBM neovascularisation (Kumar and Arbab 2013). Transdifferentiation has been 
described as one of the reasons for the unresponsive nature of GBM to anti-angiogenic drugs (Soda 
et al. 2011). Bergers and co-workers emphasised the presence of mature blood vessels in tumours 
that are refractory to Avastin, also known as Bevacizumab, treatment (Bergers et al. 2003 and Nagy 
et al. 2009). 
 
Therefore, understanding the mechanisms of neovascularisation and nature of blood vessels in GBM 
is vital. Here, I investigated the cellular composition of the perivascular niche in glioblastoma using 
immunohistochemical staining of patient-derived GBM tissue samples and characterised the type and 
prevalence of blood vessel morphologies and their respective lumen sizes in GBM. The result of GBM 
blood vessel characterisation at baseline, following therapy in recurrent patients and in the 
experimental in vivo CT2A model showed an increased prevalence of abnormal morphologies and 
blood vessels with large diameter in recurrent and/or irradiated tumour tissue. Furthermore, global 
heterozygous deletion of Dock4 from stromal cells in mice reduced tumour blood vessel size when 
combined with radiotherapy. However, this was not reflected on the overall survival of mice. 
Furthermore, DOCK4 deletion from GBM cancer cells reduced invasion in a spheroid assays, however, 
when cancer cells were co-cultured with ECs the effect of DOCK4 deletion was not observed, implying 
that DOCK4 may not control cancer cells invasion within the PVN.  
 
6.2 Characterisation of the glioblastoma vasculature 
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Glioblastoma is characterised by aberrant blood vessels, the diagnostic and prognostic value of which 
has not yet been fully exploited due to several limiting factors. Although most previous studies 
characterised GBM blood vessels using microvascular density (MVD), this approach had a number of 
drawbacks. For instance, researchers used different types of characterisation methods and cell 
markers (Korkolopoulou et al. 2002 and Chen et al. 2015). Furthermore, the inherent problems of 
intratumoural variation (Kalkan 2015; Schiffer et al. 2015 and Takeuchi et al. 2010) and inter-observer 
variability (Preusser et al. 2006) enormously affected its reliability. This current study also clearly 
showed that there is a significant difference between the MVD of primary and recurrent tumours as 
the number of blood vessels (MVD) dramatically decreased in recurrences. 
 
Using positivity of GBM blood vessels for the stem cell marker Nestin (Suzuki et al. 2010) this study 
identified 5 different types of GBM blood vessel morphologies by immunohistochemistry staining: 
Single perivascular, Multi perivascular, Nestin +ve, Glomeruloid Nestin –ve and Glomeruloid Nestin 
+ve morphologies. While the first two morphologies are referred to as ‘normal-like’ as they are also 
found in normal brain tissue, the latter three morphologies are abnormal and only found in GBM 
tumour tissue samples. The analysis of blood vessel morphologies in primary GBM tumour tissue 
samples from both Leeds and Imperial College samples showed that patients present with 
heterogeneous blood vessel morphologies. This finding is in accordance with that of Chen et al who 
also reported 4 different types of microvascular patterns in primary GBM samples using 
immunofluorescence staining. In their study they identified microvascular sprouting (MS), vascular 
cluster (VC), vascular garland (VG) and glomeruloid vascular proliferation (GVP), and reported that the 
level of CD34, CD133 and Nestin expression was significantly higher in VG and GVP (Chen et al. 2017). 
Earlier, Briner et al had examined vascular patterns in 114 primary glioblastomas and had first 
described the presence of unevenly distributed ‘glomeruloid/ garland-like/clustered vascular 
formations’ and evenly distributed ‘capillary-like vessels’, the latter potentially arising at least partly 
from classic angiogenesis based on expression of the neoangiogenic markers CD105 and Id-1 (Birner 
et al. 2003). Patients with high proportion of aberrant blood vessels, particularly Nestin positive 
Glomeruloids showed a trend for poorer overall survival compared to patients with higher proportion 
of normal-like blood vessels although this was not statistically significant, presumably due to the 
relatively small number of patient samples. 
 
Analysis of paired samples from two independent data sets from Leeds and Imperial College 
demonstrated that recurrent tumours had more aberrant blood vessel morphologies compared to 
primary tumours. Out of a total of 15 paired primary and recurrent GBM samples analysed 80% had a 
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decrease in normal-like tumour blood vessel morphologies, and an accompanied increase in abnormal 
morphologies upon recurrence. The identification of more normal-like blood vessels in primary 
tumours compared to recurrent tumours in this study showed that normal-like blood vessels may 
indicate an earlier stage of progression within the glioblastoma diagnosis. On the other hand, the 
increased abundance of Nestin positive and glomeruloid networks of aberrant blood vessel 
morphologies in recurrent tumours could be an indication of either progression or the effects of 
therapy.  
 
A novel approach of this study is the use of Nestin positivity to define the boundary between cancer 
cells and stroma. One characteristic feature of the Nestin positive cells lining the glioblastoma blood 
vessel channels was their shape. Generally, unlike the spindle shaped ECs in normal brain vasculature 
the ECs lining the GBM vasculature were found to be round and plump just like some cancer cells.  
Hence, these cells were observed in some tumours and seemed to be ‘replacement’ of normal 
endothelial cells by cancer-like Nestin positive cells. Chang (Chang et al. 2000) and Tomaso (di Tomaso 
et al. 2005) and their co-workers had previously reported the presence of mosaic type of blood vessels 
in tumours where round and plump shaped cells lined tumour blood vessels. However, in this current 
study I found intact CD31 positivity in all blood vessels analysed in GBM from a total of 26 primary and 
15 paired GBM patients and therefore it can be concluded that normal ECs line the GBM blood vessels. 
Although some GBM blood vessels stained positive for both stem cell marker Nestin and endothelial 
cell marker CD31 using Nestin/ CD31 double immunostaining, IF staining clearly showed that Nestin 
positive cells are distinct from CD31 positive cells although the Nestin positive cells were located in 
close association with the CD31 positive ECs.  
 
The identity of Nestin positive cells forming or surrounding GBM blood vessels has been controversial 
and has led to different theories by which glioblastoma tumours derive their blood supply. The 
detection of CD31 and Nestin positive cells in GBM blood vessels prompted me to further investigate 
their identity and whether these cells could be cancer cells, astrocytes, immune cells or 
pericytes/SMCs. Some previous studies have indicated that vascular abnormalities in tumours could 
be due to other cells forming blood vessels. For instance, the work of Ricci-Vitiani and colleagues 
(Ricci-Vitiani et al. 2010) and Soda and co-workers (Soda et al. 2011) suggested that cancer stem cells 
transdifferentiated into ECs and form the blood vessel lumen lining of the glioblastoma. However, this 
raised controversy and other studies argued that ECs positivity for mutant IDH1 and EGFR 
amplification in GBM blood vessels is a truly rare event, and if there at all it accounts for less than 1% 
of the lining of blood vessels in samples (Rodriguez et al. 2012) as opposed to 60% GSCs to EC 
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transdifferentiation claimed by Ricci-Vitiani and colleagues (Ricci-Vitiani et al. 2010). Furthermore, El 
Halluin and co-workers also found that only a small fraction of ECs expressed EGFR amplification in 
GBM tissue samples and in in vitro experiment cancer cells only became positive for EC marker in the 
presence of co-culture of cancer cells and ECs (El Hallani et al. 2014). However, the analysis of De 
Pascalis and colleagues showed more CD31 positive ECs showing a EGFR/CEP7 amplification in 
recurrent tumours compared to primary GBM tumours (De Pascalis et al. 2018). 
 
When stem cell marker SOX2 and OLIG2 staining was performed in  this study none of the blood 
vessels in primary and recurrent GBM tumours stained positive, again arguing against nestin positive 
perivascular cells being cancer cell derived. The astrocytes and differentiated cancer cell marker GFAP, 
and immune cell markers CD45 and CD68 were also negative in the Nestin positive cells. However, 
using IHC, 68.2% of these Nestin positive cells were positive for pericyte/SMCs markers α-SMA and 
PDGFRb. This was confirmed using IF showing that Nestin positive cells co-expressed α-SMA and 
PDGFRβ markers but not cancer cell, astrocyte and immune cell markers. Jain described these 
perivascular pericytes as morphologically abnormal and have a weak contact with both ECs and the 
matrix (Jain 2003). Bergers and Benjamin associated increased tumour blood vessel lumen size with 
increased proliferation of blood vessel wall (Bergers and Benjamin 2003) and lack of pericytes 
consequently leading to vessel enlargement, leakage, and tumour metastasis (Carmeliet and Jain 
2011). However, large calibre blood vessels identified in this study by means of nestin positivity were 
mature blood vessels lined by PDGFRb and a-SMA perivascular cells. 
 
In future studies it will be interesting to find out whether the a-SMA/Nestin positive perivascular cells 
are resident stem cells or bone-marrow derived mesenchymal stem cells. In an in vivo experiment 
using Nestin-GFP transgenic mice Klein and colleagues showed that Nestin positive cells around 
melanoma tumour blood vessels originated from resident cells, but not from the bone-marrow (Klein 
et al. 2014). On the other hand, in an in vitro study, bone-marrow derived human mesenchymal stem 
cells (hMSCs) which had been cultured in tumour conditioned medium became positive for Nestin, α-
SMA, NG2, CD151 and desmin but not for vWF and smooth myosin indicating that they are pericyte-
like cells but not ECs or SMCs (Birnbaum et al. 2011). Furthermore, pericytes themselves have a 
mesenchymal stem cell (MSC) potential (Appaix et al. 2014).  
 
This study showed that Nestin/a-SMA positive aberrant blood vessels are commonly located near 
areas of necrosis and near regions of tumour hypoxia compared to the peripheral region of a tumour 
tissue where more of normal-like blood vessel morphologies are commonly located.  This probably 
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implies that hypoxia could potentially be a contributing factor to the formation of these aberrant 
blood vessels in GBM. In recurrent tumours Nestin positive and glomeruloid Nestin positive blood 
vessels supported lower hypoxia levels compared to blood vessels with normal-like morphology 
and/or occluded blood vessels which were associated with the highest hypoxia levels. Using a 
glioblastoma xenograft ear model Sundberg found that glomeruloid blood vessels form at the very 
late stage of tumour development following necrosis and hypoxia (Sundberg et al. 2001). Importantly, 
the presence of blood vessels with large lumen size and Nestin positive aberrant morphologies in 
recurrent GBM could be a consequence of radiotherapy and/or chemotherapy normally administered 
post-surgery. Radiotherapy causes destruction of immature blood vessels leading to hypoxia (Barker 
et al. 2015). Hence, it is highly likely that the increased changes in blood vessel morphology, Nestin 
positivity and functionality in GBM following recurrence could represent a therapy induced 
phenotype. 
 
6.3 The role of DOCK4 in blood vessel growth and tumour progression in GBM  
Tumour blood vessels are inherently aberrant and have a larger lumen size. Mostly, uneven 
and abnormal blood vessel lumen diameter follows compression of immature blood vessels 
by tumour mass (Jain 2003) and normalising them through the restoration of the pro- and 
anti-angiogenic cytokines can make solid tumours more sensitive to both chemo- and 
radiotherapy (Jain 2003 and Carmeliet and Jain 2011). Following establishment and 
characterisation of the experimental CT2A model I investigated whether Dock4 deletion 
would normalise the aberrant tumour blood vessels using mice with Dock4 heterozygous 
deletion, as homozygous Dock4 deletion is embryonically lethal (Abraham et al. 2015).  The 
CT2A tumour model appeared to recapitulate the invasive and co-optive nature of patient 
GBM than the GL261 tumour model. Furthermore, a previous study also showed that just like 
patient-derived GBM samples murine glioblastoma tumour model CT2A express a stem cell 
markers nestin, CD133, OCT4 and is proliferative and invasive both in in vitro and in vivo 
(Binello et al. 2012). DOCK4 is a GEF for a small GTPase Rac1 which plays an important role in 
sprouting angiogenesis (Abraham et al. 2015). Nohata and co-workers demonstrated the 
importance of Rac1 for angiogenesis and blood vessel integrity in postnatal vascular network 
and vessel sprouting in retinal angiogenesis (Nohata et al. 2016). Our lab also showed that 
Dock4 regulates blood vessel lumen size in EO771 breast cancer brain met model when 
injected intracranially into Dock4 heterozygous mice (Abraham et al. 2015). Here, the effects 
of heterozygous Dock4 deletion were assessed in the presence or absence of irradiation. 
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The main effect of ionising radiation on tumour vasculature includes increased EC 
permeability, detachment from basement membrane and apoptosis (Heckmann et al. 1998). 
For instance, the use of a total dose of 40Gy (8Gy/ fraction) increased BBB permeability 5 days 
following irradiation in rats orthotopically injected with C6 glioma (Zawaski et al. 2012). 
Radiation treatment has acute, subacute or late effects on brain tissue with major injuries to 
blood vessels characterised by vasodilation, oedema and vascular lesion, respectively (Walker 
et al. 2014). Early effects of radiation therapy include DNA damage, recruitment of 
inflammatory cells and death of ECs, while late effects include collagen deposition (fibrosis), 
hypoxia and atherosclerosis (Barker et al. 2015). Hence, radiation appears to have different 
effects on the tumour microenvironment at different time points. In this study using two 
different doses (10Gy or 15Gy) and sources (SARRP or X-RAD) radiation significantly 
decreased tumour growth with a better response at 10Gy delivered by SARRP leading to 
tumour regression followed by regrowth, thus mimicking patient GBM response to 
radiotherapy. In order to assess the effect of global heterozygous Dock4 deletion on CT2A 
blood vessels in the presence of irradiation I performed analysis at early (3 days) and late 
(over 21 days on presentation of neurological symptoms) time points post irradiation. Early 
analysis showed a trend of decreased lumenisation with irradiation, which was further 
enhanced by Dock4 heterozygous deletion leading to a significant decrease in vessel size with 
combination of radiotherapy and DOCK4 reduction. At later time point (21 days post 
irradiation) there was a significant increase in blood vessel size which was reversed by 
heterozygous Dock4 deletion. 
 
Immunohistochemical staining of early CT2A tumour samples showed increased expression 
of apoptosis marker Caspase-3, DNA double-strand break marker gH2Ax and immune cell 
marker F4/80 following irradiation. The finding of high expression of F4/80, although not 
quantified, agrees with previous findings. Morganti and co-workers showed that a single 
fraction of 10Gy irradiation dose increased the infiltration of F4/80+ peripheral macrophages 
into the brain without affecting the integrity of the BBB (Morganti et al. 2014). Furthermore, 
in an orthotopic in vivo experiment using GBM cell line and murine glioblastoma cells, Kioi 
and co-workers found an increased recruitment of bone marrow-derived cells (BMDCs) 
following irradiation through secretion of HIF-1 (Kioi et al. 2010). Overall, radiotherapy 
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increases M2-like macrophages in GBM which are more radioresistant than M1-like 
macrophages and the non-polarised M0 macrophages (Leblond et al. 2017). Hence, secretes 
of macrophages and the angiogenic factors (Martin 2013) could be involved in late response 
to irradiation of blood vessel growth. 
 
Previous studies used radiotherapy in combination with other treatments such as anti-
angiogenic and chemotherapy to normalise blood vessels through reduction of 
hyperpermeability, increased pericyte coverage, normalised basement membrane and 
reduced hypoxia which eventually contributed to efficacy of therapy and improved patient 
survival (Goel et al. 2011).  In future studies it will be interesting to determine the effects of 
Dock4 deletion on pericyte coverage, permeability, basement membrane characteristics and 
tumour hypoxia. As seen in the recurrent GBM patient tumour tissue samples, preliminary 
analysis showed that there was increased a-SMA expression in irradiated CT2A tumours. This 
may suggest that these cells play an important role in the progression of GBM post 
radiotherapy. Hosono and co-workers who reported desmin positive pericytes in rat RG2 
glioma model using immunohistochemical staining showed that pericytes contribute to 
increased tumour angiogenesis through formation of basement membrane (Hosono et al. 
2017).  
 
6.4. The role of DOCK4 in glioblastoma cancer cell invasion  
The current standard of therapy in glioblastoma failed to stop the infiltrative cancer stem cells 
which are the underlying cause of tumour recurrence, resistance and poor patients’ outcome. 
Hence, targeting the molecular mechanisms behind the advancement of such cells is crucial.  
Invading glioblastoma cells highly express Rac1 and Cdc42 at the leading edge (Hirata et al. 
2012), and while Rac1 regulates lamellipodia, Cdc42 regulates filopodia (Etienne-Manneville 
and Hall 2002). DOCK4 is a GEF which transforms a small Rho GTPase molecule Rac1 from 
inactive state to active state. In breast cancer cell line MDA-MB-231 the C-terminal proline-
rich region of DOCK4 interacts with SH3YL1 region of Rac1 and increase cancer cell migration 
(Kobayashi et al. 2014). Westbrook et al. reported a higher DOCK4 expression in bone homing 
MDA-MB-231 compared to parental control and high DOCK4 was found to be a risk factor for 
bone metastasis (Westbrook et al. 2018). Furthermore, Yu and colleagues also showed that 
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high DOCK4 in lung ADC increases tumour cell extravasation and metastasis through TGF-
b/Smad signaling pathway (Yu et al. 2015).  
 
Using immunohistochemical staining of 12 primary patient derived GBM samples for DOCK4 
this study found a heterogeneous level of DOCK4 expression in patient-derived GBM tumour 
tissue samples. High DOCK4 expression was detected along blood vessels, particularly along 
the nestin positive and glomeruloid aberrant blood vessel morphologies. Although there was 
no significant correlation between patients’ OS and the level of DOCK4 expression from this 
small sample size it was observed that there was a trend of association between high DOCK4 
expression and better patients’ outcome. This is in agreement with the findings of Debruyne 
and colleagues who showed high Dock4 expression in GBM with better patients’ outcome 
(Debruyne et al. 2018). The analysis of TCGA data also showed that patients with high DOCK 
expression had a trend of better outcome compared to those with low DOCK4 expression.   
 
Therefore, in order to understand the role of DOCK4 in cancer cell invasion U251 cell line, 
which fundamentally lacks heterogeneity and drug resistance (Patrizii et al. 2018) and patient 
derived GBM1 were used. Knockdown of DOCK4 protein from these glioblastoma cancer cells 
initially reduced cancer cell invasion in a spheroid assays on Day 3 and Day 8 post collagen 
addition, respectively. Nonetheless, this difference gradually disappeared at a later time 
points. Then, using a co-culture model which  better recapitulates the tumour 
microenvironment in patients I observed a significantly increased invasion of cancer cells in 
the presence of ECs in both U251 and GBM1. Calabrese and co-workers showed that 
endothelial cells play an important role in the tumour environment. For instance, brain 
tumour ECs serve as self-renewal and maintenance of glioma stem cells and their depletion 
stopped tumour growth in in vivo experiment using mice (Calabrese et al. 2007).  
 
Unsurprisingly, under such co-culture model knockdown of DOCK4 from both U251 and 
GBM1 failed to decrease cancer cell invasion in the presence of ECs. The fact that deleting 
DOCK4 from cancer cells in this experiment failed to decrease the overall cancer cell invasion 
in the presence of ECs in co-culture spheroid assays probably indicate that DOCK4 plays a 
cancer suppressor role. In a recent study, silencing DOCK4 from differentiated glioblastoma 
cancer cells using siRNA showed suppression of the nuclear translocation of b-catenin and 
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consequent tumour growth. Subsequently, over expression of DOCK4 increased nuclear 
translocation of b-catenin and decreased GBM cancer cell stemness and proliferation in 
differentiated GBM cancer cells implying the importance of DOCK4 in cancer cells (Debruyne 
et al. 2018). This shows that DOCK4 plays contradicting roles in different cell types. Therefore, 
ECs in co-culture assays play an important role in tumour growth and aggressiveness. When 
Yan et al co-cultured U251 cells with HUVEC the level of CD133 positivity and invasiveness 
increased in a co-culture model compared to U251 cells only (Yan et al. 2014).  
 
Radiotherapy induces DNA double strand breaks and stops tumour growth, however, the 
development of radioresistance is very common (Lim et al. 2018). Both in vitro and in vivo 
studies showed that ionising radiation increase VEGF secretion by cancer cells which in turn 
leads to invasion of cancer cells and radioresistance (Scaringi, Enrici, and Minniti 2013). 
Borovski et al showed that the tumour ECs play an important role in maintaining cancer cell 
proliferation and protection of such cancer cells from chemotherapy and  radiotherapy 
probably through regulation of MGMT gene (Borovski et al. 2013). Here, in a co-culture of 
cancer cells and HUVEC a single dose of 10Gy ionising radiation significantly reduced invasion 
of U251 cancer cells into the surrounding collagen matrix on Day 6, implying that the presence 
of ECs probably made U251 cancer cells susceptible to radiation. However, when murine 
model CT2A and patient-derived GBM cancer cells were irradiated in the presence of ECs their 
invasion increased showing variation in cell types. Although combination therapy using 
irradiation and Rac1 inhibition reduced radioresistance in breast cancer cell lines MCF-7 and 
T47D in in vitro assay (Hein et al. 2016) such combination therapy failed to reduce invasion in 
glioblastoma cell line U251 when DOCK4 deletion and a single dose of 10Gy ionising radiation 
were concurrently used.  
 
6.5 Concluding remarks 
Characterisation of patient derived GBM samples using Nestin/CD31 double immunostaining 
showed that GBM patients present with heterogenous blood vessel morphologies as well as 
blood vessel lumen size. There is a strong indication that high nestin positivity of GBM blood 
vessels, particularly glomeruloid morphology, is associated with poor patients’ outcome. 
Analysis of these nestin positive blood vessels showed that they are less likely to be cancer 
cells as previously thought but the fact that they are positive for pericyte and SMC markers 
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indicate that stroma cells could be their ancestral origin. Furthermore, these nestin positivity 
significantly increased in recurrent tumour samples which are more hypoxic than primary 
tumours implying that hypoxia could be a factor for the formation of such aberrant blood 
vessels. In addition to nestin, different patient derived GBM tumours also expressed DOCK4 
and there is a strong correlation between the level of DOCK4 and Nestin expression. Overall, 
this study concludes that there is an inverse correlation between DOCK4 between expression of 
hypoxia and Dock4 in most GBM patient samples and low DOCK4 expression was associated with a 
poor overall survival. 
 
DOCK4, a GEF for Rac1, regulates blood vessel morphogenesis and lumen size through actin 
cytoskeleton (Abraham et al. 2015). An orthotopic implantation of CT2A cancer cells in mice 
with Dock4 heterozygous global deletion showed a reduced blood vessel lumen size in Dock4 
heterozygous compared to control mice. When tumour blood vessel lumen size was analysed 
following irradiation the blood vessel lumen size was increased in irradiated WT mice 
compared to control mice. However, a combination of radiotherapy and Dock4 heterozygous 
deletion reduced such large blood vessels implying normalisation of glioblastoma blood 
vessels. Nonetheless, such combination did not reflect on the overall survival of mice.  
 
Using a spheroid assay I demonstrated that cancer cell invasion into the surrounding collagen 
matrix was reduced in both U251 and GBM1 cancer cells. However, when such cancer cells 
were co-cultured with endothelial cells there was no significant difference between DOCK4 
knockdown and control glioblastoma cancer cells. Furthermore, while radiotherapy reduced 
cancer cell invasion in a co-culture of U251 cancer cells and HUVEC there was no significant 
difference between irradiated and control U251 cells in the absence of ECs. However, a 
combination of DOCK4 knockout and radiotherapy did not reduce tumour invasion at least in 
U251 cancer cells in a spheroid assay. To sum up, the analysis of both patient GBM tissue 
samples and in vivo experiment showed increased tumour blood vessel lumen size and SMA 
positivity in recurrent/irradiated samples. The fact that deletion of DOCK4 from stroma and 
cancer cells increased tumour growth and invasion, respectively, might imply that DOCK4 
molecule could rather play an important tumour suppressor role in GBM and may not be 
directly responsible for the increased aberrant blood vessels in GBM. 
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Appendix 1  
 
 
 
 
Leeds Teaching Hospitals NHS Trust clinical data 
GBM tissue samples were collected from Leeds Teaching Hospital (LTH) theatre through a research 
nurse from patients who were admitted to Leeds General Infirmary Hospital for brain tumour surgery 
and consented for their samples to be used for research. In addition, ethical approval was obtained 
from the University of Leeds Ethical Committee in order to use patient samples and their clinical data 
in anonymized way. The samples were fixed in 4% PFA and paraffin embedded following collection. 
Out of a total of 64 patients diagnosed with GBM over a period of 5 years 52 FFPE blocks were available 
for analysis. After excluding samples with inadequate amount of material 21 FFPE blocks (16 primary 
and 5 recurrent) were available and presented in this table with their clinical data. 
 
 
 
 
 
 
 
Gender Age Surgery RT Chemotherapy post surgery
GBM 13 Female 79 GBM IV Left frontal lobe 13.10.12 6.1.14 Yes Yes 2012 Not detected No Proneural 31.8.14 22
GBM 14 Male 58 Giant cell GBM IV
Right cerebral 
lobe 29.3.11  28.1.13 Yes Yes 2011 Temozolomide Moderate No
Proneural 
(Mesenchymal) 16.5.14 39
GBM 16 Female 63 GBM IV Left posterior parietal lobe 4.4.13 Yes post surgery n/a No 2.7.13 3
GBM 20 Male 50 GBM IV Right temporal region 28.8.12 22.7.13 Yes
Sep -Nov 
2012
Temozolomide  
and IMA950 
post primary 
surgery. PCV 
post second 
surgery
Not detected No Proneural (Mesenchymal)  14.1.14 17
GBM 21 Male 72 GBM IV Left temporal lobe 19.08.13 Yes Post surgery Methylated No 3.2.14 5
GBM 25 Female 38
GBM IV 
(60%) arising 
in a 
background 
of diffuse 
astrocytoma.
Left frontal 
craniotomy 30.9.13 17.7.18 Yes Post surgery Temozolamide Methylated Detected 25.10.18 58
GBM26 Male 63 GBM IV Right temporal craniotomy 21.10.13 Yes Post surgery Temozolamide Not detected No  7.4.14 5.5
GBM 30 Female 50 GBM IV Right frontal lobe 3.2.14 15.1.16 Yes Post surgery
Temozolamide,        
PCV and  
Avastin 
Not detected No Classical  20.4.16 26
GBM 33 Male 42 GBM IV Right hemisphere 25.4.14 Yes Temozolamide No 4.1.15 9
GBM 36 Male 64 GBM IV Left parieto-occipital lobe 2.6.14 Yes Post surgery
Temozolomide 
+ Lomustine No 7.12.17 42
GBM 37 Female 61 GBM IV Right frontal lobe 6.6.14
13.5.17/ 
14.8.17/ 
20.4.18
Yes Post surgery Temozolamide No 12.8.18 49
GBM 39 Male 47 GBM IV Right frontal lobe 8.7.14 Yes post surgery Temozolamide Not detected No 20.1.15 6
GBM 46 Male 66 GBM IV Right parietal lobe 6.3.15 Yes Post surgery No 11.1.16 10
GBM47 Male 52 GBM IV Left frontal lobe 13.3.15 Yes Post surgery Temozolamide No 2.12.16 21
GBM52 Male 56 GBM IV Right occipital lobe 15.5.15 Yes Post surgery Temozolamide No Classical 21.2.16 9
GBM63 Male 57 GBM IV Left Parietal lobe 11.1.16 11.11.16 Yes Post surgery
Temozolamide, 
PCV, and 
Avastin
No Classical 2.4.17 15
OSID
1st 
operation 
date
GBM Grade Location Recurre-nce date
MGMT 
Methylation
Date of 
death
1DH1/2 
mutation
Patient Treatment
Molecular 
subtype
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Imperial College Healthcare NHS Trust clinical data 
Imperial College GBM FFPE blocks were obtained following application to Brain UK. Imperial College 
patient data was incomplete hence analysis of overall survival was not possible. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Laboratory 
nomenclature Gender Age GBM Grade Surgery
GBM1 F 53 GBM IV Debulking Right parietal Right parietal
GBM2 F 59 GBM IV Debulking Right frontal Right frontal
GBM3 M 52 GBM IV Debulking
Right temporo-
parietal
Right temporo-
parietal
GBM4 F 43 GBM IV Biopsy Right parietal Right parietal
GBM5 M 48 GBM IV Debulking Left frontal Left frontal
GBM6 M 47 GBM IV debulking Left parietal Left frontal
GBM7 F 70 GBM IV Debulking
Right fronto-
temporal
Right fronto-
temporal
GBM8 M 50 GBM IV Debulking Right parietal Right parietal
GBM9 F 49 GBM IV Debulking Right frontal Right frontal
GBM10 F 38 GBM IV Debulking Left parietal Left parietal
Tumour Location
Imperial College GBM patients' data
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Total number of areas and blood vessels scored in Leeds and Imperial patient samples 
Table shows number of 1mm2 areas (boxes) analysed per patient sample. Boxes were placed on viable 
parts of the GBM tissue samples excluding necrotic zones.  
 
 
 
 
 
  
Normal brain/ 
GBM
No. of boxes 
analysed
No. of blood vessels 
characterised GBM
No. of 
boxes 
No. of blood vessels 
characterised
Normal brain 4 147 GBM1 7 183
GBM13P 16 670 GBM1R 8 71
GBM13R 9 61 GBM2 10 252
GBM14P 10 150 GBM2R 9 160
GBM14R 9 43 GBM3 8 216
GBM20P 10 152 GBM3R 10 139
GBM20R 9 46 GBM4 8 145
GBM30P 3 91 GBM4R 9 112
GBM30R 5 32 GBM5 10 761
GBM63P 2 34 GBM5R 7 221
GBM63R 2 118 GBM6 8 144
GBM16 9 177 GBM6R 6 39
GBM21 11 73 GBM7 8 150
GBM25 13 324 GBM7R 8 92
GBM26 6 151 GBM8 9 349
GBM33 6 89 GBM8R 10 87
GBM36 9 255 GBM9 9 282
GBM37 11 129 GBM9R 8 151
GBM39 13 254 GBM10 8 131
GBM46 2 28 GBM10R 8 126
GBM47 7 131
GBM52 7 120
Total            
(Excluding normal 
brain)
169 3128 Total 168 3811
Leeds samples Imperial samples
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Number of mice, symptoms, lesions, staining and areas examined in the RAD-irradiator 
experiment 
A total of 17 mice were intracranially injected 1x105 CT2A-Luc cancer cells into the striatum of right 
brain hemisphere. Following injection mice were monitored for tumour growth using IVIS imaging and 
randomised into four treatment groups as shown in the table above. A total of 15Gy ionising radiation 
was delivered using RAD X-Ray irradiator for 3 consecutive days starting from Day 9–11 post tumour 
implantation. Mice were taken down on Day 21 post tumour implantation by terminal perfusion upon 
development of neurological symptoms in one mouse. Tumour tissue samples were collected, fixed 
in 4% PFA, paraffin embedded, sectioned at 4 µm and stained using EC marker CD31 antibody, and 
counterstained using haematoxylin. The stained tissue slides were scanned and 0.5mm x 0.5mm boxes 
were placed over different tumour tissue regions and blood vessels lumen size ³10 µm were analysed 
using ImageScope.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
WT control Dock4 Het control WT 15Gy Dock4 Het 15Gy
No. of mice injected 4 4 5 4
No. of mice with symptoms 3 4 0 0
No. of mice with gross lesion 3 4 2 1
Microscopic lesion 3 4 3 3
No. of tumours used for IHC 2 3 3 3
No. of areas analysed 4 5 4 4
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Number of mice, levels and vessels analysed in early irradiation effects analysis 
A total of 52 mice intracranially injected 1x105 CT2A-Luc cancer cells into the striatum of right brain 
hemisphere. Mice were monitored for tumour growth and randomised into 4 different treatment 
groups based on their IVIS reading signal the day before radiotherapy. Mice which were in the 
treatment group received 2 consecutive doses of 5Gy ionising radiation using SARRP on Day 7 and Day 
8. In order to see the early effect of radiation on tumour vasculature 3 mice/group were taken down 
by terminal perfusion on Day 11 following tumour implantation. One WT control and one Dock4 Het 
control did not develop tumour and both were excluded from analysis. However, one normal brain 
was included for reference. Tumour tissue samples were collected, fixed in 4% PFA, paraffin 
embedded, sectioned at 4 µm thickness at different levels and stained using EC marker CD31 antibody, 
and counterstained using haematoxylin. The stained tissue slides were scanned and a 0.5mm x 0.5mm 
boxes were placed over different tumour tissue regions and blood vessels lumen size ³10 µm were 
analysed using ImageScope.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Normal brain WT control Dock4 het control WT 10Gy Dock4 het 10Gy
No. of mice 1 3 3 3 3
No. of tumour samples available 1 2 2 3 3
No. of levels analysed 2 5 6 8 8
No. of vessels with lumen (10) µm 4 36 65 23 14
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Analysis of CT2A samples at late timepoints following irradiation (performed by A. Widyadari) 
(A) Schematic diagram depicting CT2A tumour implantation, irradiation and late excision upon 
development of neurological symptoms. Mice were taken down from D18 onwards by terminal 
perfusion.  
(B) CT2A tumour tissue samples were paraffin embedded, sectioned and stained using EC marker 
CD31. Representative images from different groups show differences in blood vessel lumen size. Scale 
bar 100, µm.  
(C) Quantification of lumen size. Boxes (0.5x0.5mm2) were placed on scanned CT2A tumour tissue 
samples and blood vessels with lumens were analysed using ImageScope. N= number of blood vessels 
with detectable lumen (³10 µm); WT control, 34; Dock4 het control, 57; WT irradiated, 46; Dock4 het 
irradiated, 46). ** p<0.01 and ** p<0.001. D, Day 
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Staining of irradiated tumour samples for markers of immune cells, apoptosis and DNA damage  
The images show a marked increase in F4/80 immune cells following irradiation, and a modest 
increase in apoptosis was also observed through staining for Caspase 3. The gH2AX staining show the 
expected effects of irradiation on DNA damage 3 days following irradiation. Mice received irradiation 
using SARRP 7 days after intracranial injection of CT2A cells as described in Figure 4.8.  
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Conditional Dock4 knockout model generated by Ozgene (A) and typical genotyping (B) 
(A) Dock4 conditional knockout model generated by Ozgene. Dock4f/f mice were crossed 
with VE-cadERT2-CreTd tomato gene carrying mice. In order to confirm how well Cre delete the stop 
codon and allow Td to be expressed iVE-Cre;Rosa26Td mice were first injected tamoxifen 
intraperitoneally followed by intracranial injection of CT2A tumours. Upon development of 
neurological symptoms mice were taken down and tumour tissue samples were stained using RFP 
antibody which appeared red in the presence of Cre gene as shown in Figure 4.13. 
Both Cre and FLP recombinase enzymes were used in order to recognise and delete Dock4 gene 
specifically from ECs with the help of LoxP and FRT sites, respectively. Litters with 
TdVEcadCre+;Dock4f/f genes or control litter mates with TdVEcadCre-;Dock4f/f genotype were 
injected tamoxifen intraperitoneally before intracranial injection of CT2A cancer cells.  
(B) Typical example of genotyping of ear biopsies performed by Transnetyx. 
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DOCK4 expression level of white matter and grey matter in a normal brain 
Normal brain tissue sample was formalin fixed, paraffin embedded and sectioned at 4 µm. Double 
immunostaining of DOCK4 and CD31 primary antibodies on normal brain tissue were followed by 
secondary antibodies and counterstained using DAB. Low or no DOCK4 expression in white matter 
(left) and increased DOCK4 positivity in neurons (arrow) in grey matter (right). Scale bar, 100 µm. 
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Quantification of protein expression level by different cells was scored based on The Human 
Protein Atlas (HPA) method 
For quantification of the level of protein expression in different cell types used in this thesis the 
combination of both Staining Intensity (Appendix 11) and Fraction of Stained Cells were used based 
on the Human Protein Atlas (HPA) scoring method.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Staining Intensity Fraction of Stained Cells Combination of the Two
Negative (-) Not detected
<25% weak
Weak 25-75% or 75% low Low
<25% moderate
Moderate 25-75% or 75% medium Medium
<25% strong
Strong 25-75% or 75% high High
HPA Scoring Method
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Scoring DOCK4 expression level in patient GBM samples 
GBM tissues samples were paraffin embedded, sectioned at 4 µm and stained using DOCK4/CD31 
primary antibodies followed by secondary antibodies and counterstained using DAB. GBM patient 
samples were classified into four groups based on their DOCK4 expression intensity and fraction of 
stained cells (Appendix 10): ‘negative’ DOCK4 expression (0); ‘weak’ expression (1), ‘moderate’ 
expression (2) and ‘strong’ expression (3). Scale bar, 100 µm. 
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High and low DOCK4 mRNA expression in patient glioblastoma samples and their overall survival  
A total of 122 patient glioblastoma samples from The Cancer Genome Atlas (TCGA) was analysed for 
DOCK high and low expression using fragments per kilobase of transcript per million reads (FPKM) 
mRNA. Using an average cut-off 5.9 FPKM as high and low DOCK4 mRNA expression there was no 
significant difference in patient’s overall survival between the two groups. N = Number of patients  ± 
SD (Low, 56 and High, 66 samples).  
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Optimisation of patient derived GBM cancer cells in collagen based spheroid assay 
GBM1 cancer cells (1x103) were seeded in a low adherent and round bottom 96-well plates in 200 µl 
neurobasal medium. After 5 days when a sphere was formed, supernatants were removed and 100µl 
collagen was added per well at 6.8 : 1 ratio of collagen to neurobasal medium and neutralised by 0.7% 
1M NaOH. Finally, 100 µl of neurobasal medium was added to each well and the plate was incubated 
at 37o and 5% CO2. Cancer cell invasion was measured at Day 0, 3, 6 and 10 following the addition of 
collagen using EVOS at 4x magnification. N=Number of wells = 6 wells. 
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Effect of ionising radiation on CT2A cancer cell invasion in a spheroid assay in the presence and 
absence of endothelial cells 
CT2A cancer cells (2x103), or 2x103 CT2A cancer cells mixed with 2x103 HUVEC or HCMEC were seeded 
in a low adherent and round bottom 96-well plates in a 1:1 ratio of 100 µl neurobasal medium and 
100µl HLVEC medium. After 5 days when a sphere was formed, supernatants were removed and 100µl 
collagen was added per well at 6.8 : 1 ratio of collagen to medium (equal mix of neurobasal  and HLVEC 
medium), and neutralised by 0.7% 1M NaOH. Finally, 100 µl of the mix medium was added to each 
well and the plate was incubated at 37o and 5% CO2. In a treatment groups either 5Gy or 10Gy 
irradiation doses were applied at a rate of 2Gy/minute using RAD irradiator. Cancer cell invasion was 
measured at Day 0, 3, 6, 10 and 14 following the addition of collagen using EVOS at 4x magnification. 
N=Number of wells (Control CT2A, 15; Control CT2A + HUVEC, 14; Control CT2A + HCMEC, 12; 5Gy & 
10Gy CT2A, 16; 5Gy & 10Gy CT2A + UVEC, 8; and 5Gy & 10Gy CT2A + HCMEC, 8 wells). D=Day; HCMEC, 
Human Cerebral Microvascular Endothelial Cells  
(A) Images depict spheroids formed by cancer cells or their co-culture with HUVEC or HCMEC and their 
invasion into the surrounding collagen matrix .  
(B) Bar chart shows invasion area of CT2A cancer cells in the presence and absence of HUVEC or 
HCMEC. 
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Effect of ionising radiation on GBM20 cancer cell invasion in a spheroid assay in the presence and 
absence of endothelial cells 
GBM20 cancer cells (2x103), or 2x103 GBM20 cancer cells mixed with 2x103 HUVEC or HCMEC were 
seeded in a low adherent and round bottom 96-well plates in a 1:1 ratio of 100 µl neurobasal medium 
and 100µl HLVEC medium. After 5 days when a sphere was formed, supernatants were removed and 
100µl collagen was added per well at 6.8 : 1 ratio of collagen to medium (equal mix of neurobasal  and 
HLVEC medium), and neutralised by 0.7% 1M NaOH. Finally, 100 µl of the mix medium was added to 
each well and the plate was incubated at 37o and 5% CO2. In a treatment groups either 5Gy or 10Gy 
irradiation doses were applied at a rate of 2Gy/minute using RAD irradiator. Cancer cell invasion was 
measured at Day 0, 3, 6, 10 and 14 following the addition of collagen using EVOS at 4x magnification. 
N=Number of wells (Control GBM20, 14; Control GBM20 + HUVEC, 16; Control GBM20 + HCMEC, 15; 
5Gy & 10Gy GBM20, 16; 5Gy & 10Gy GBM20 + HUVEC, 13; 5Gy GBM20 + HCMEC, 13 and 10Gy GBM20 
+ HCMEC , 15). D=Day; HCMEC, Human Cerebral Microvascular Endothelial Cells  
(A) Images depict spheroids formed by cancer cells or their co-culture with HUVEC or HCMEC and their 
invasion into the surrounding collagen matrix.  
(B) Bar chart shows invasion area of GBM20 cancer cells in the presence and absence of HUVEC or 
HCMEC.  
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